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N-methyl-D-aspartate receptors (NMDARs) are ligand-gated ion channels found at nearly 
all vertebrate excitatory synapses that contribute to a multitude of nervous system functions. 
Unique biophysical properties, including high Ca2+ permeability, voltage-dependent Mg2+ block, 
and slow gating kinetics, allow NMDARs to control the magnitude and timing of Ca2+ influx 
following synaptic events. Ca2+ influx through NMDARs drives an array of signaling pathways that 
regulate critical neuronal functions such as synaptic plasticity and cell survival. Abnormal NMDAR 
activity is involved in a remarkable range of nervous system disorders including schizophrenia, 
major depressive disorder, stroke, neuropathic pain, and neurodegenerative diseases. 
Specifically, NMDAR overactivation can lead to accumulation of toxic levels of Ca2+ that initate 
cell death signaling pathways. Because of the core involvement of NMDARs in normal brain 
physiology as well as brain pathologies, NMDARs are attractive targets for neurotherapeutic 
drugs. The NMDAR channel blocker memantine, a clinically approved treatment for Alzheimer’s 
disease, displays a combination of clinical utility and tolerability unique amongst NMDAR 
antagonists. We recently discovered that memantine enhances NMDAR desensitization by 
stabilizing a Ca2+-dependent desensitized receptor state. Stabilization of a Ca2+-dependent state 
by memantine offers a rational mechanism by which memantine can target specific NMDAR 
subpopulations involved in disease: preferential inhibition of NMDARs in neurons experiencing 
long durations of high Ca2+ influx. Therefore, we systematically investigated the relation between 
channel blocker potency, intracellular Ca2+ concentration ([Ca2+]i, and NMDAR desensitization. 
We found that while potency of memantine depended on [Ca2+]i, the potency of another clinically 
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useful channel blocker, ketamine, was [Ca2+]i-independent. Utilizing this discrepancy, we 
compared the memantine and ketamine binding sites and identified a residue in the NMDAR 
transmembrane domain that strongly contributes to NMDAR desensitization and memantine 
potency. Lastly, we characterized novel NMDAR channel blockers and discovered that potency 
of a memantine derivative was also dependent on [Ca2+]i. The data presented in this dissertation 
provide key insight into how [Ca2+]i affects channel blocker activity and NMDAR desensitization, 
and ultimately improve our understanding of the structural and functional mechanisms underlying 
the effects of channel blocking drugs on NMDAR function. 
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1.0 GENERAL INTRODUCTION 
Armed with only a limited vocabulary, neurons can generate an effectively infinite number 
of specific, meaningful messages to elicit an astoundingly diverse array of thoughts, behaviors, 
and experiences. While we possess a superficial grasp of neuronal vernacular, enough to 
recognize and even translate certain phrases, our understanding of basic construction of these 
remarkably complex messages is still limited. Understanding how to combine symbols to form 
words and phrases, and how these words and phrases can be combined to express complex 
statements, is critical to achieving literacy in a new language. Like letters to written English, ion 
channel signals are the constitutive units of the neuronal language – meaningless in isolation, but 
immensely powerful when organized.  
Ion channels are proteins that allow ions to flow across cell membranes and are necessary 
for the transmission of information between nervous system cells. Neurons, the cells responsible 
for the majority of signaling in the nervous system, transmit information to and receive information 
from other neurons through specialized structures called synapses. Synaptic transmission 
involves the release of molecules known as neurotransmitters from a presynaptic neuron onto the 
cell membrane of a postsynaptic neuron, where receptor proteins bind the neurotransmitter. 
These neurotransmitter receptors then convert the chemical signal from the presynaptic neuron 
into a physiological response in the postsynaptic neuron. The transduction of chemical signals 
into electrical responses is performed by ligand-gated ion channels, neurotransmitter receptors 
that activate in response to agonist binding and permit ion flux across cellular membranes. The 
cumulative opening of many ligand-gated ion channels alters the concentrations of intracellular 
ions and the membrane voltage of the postsynaptic neuron, which both have profound 




concomitant synaptic inputs either electrically excites or inhibits the cell, determining whether the 
signal will be propagated to other downstream neurons. Ligand-gated ion channel activity can 
also alter the concentrations of intracellular ions in the postsynaptic neuron, which can lead to the 
strengthening or weakening of specific synaptic inputs and regulate gene expression. Through 
these mechanisms, ion channels govern the activity of individual neurons and, in turn, shape the 
neuronal ensembles that drive higher-level nervous system function. 
Ionotropic glutamate receptors (iGluRs), a family of ligand-gated ion channels activated 
by the amino acid glutamate, are the primary mediators of fast excitatory transmission in the 
central nervous system. Among iGluRs, N-methyl-D-aspartate receptors (NMDARs) are 
particularly important for both the electrical and chemical components of signal transduction. 
NMDARs are expressed in nearly all nervous system cells and normal NMDAR activity is vital 
both to basic neuronal physiology and higher-level brain function. Likewise, NMDAR dysfunction 
is a central feature of many nervous system disorders, making NMDARs attractive 
pharmacological targets for treatment of various neurological and psychiatric disorders. 
Unfortunately, modulating NMDAR activity with therapeutic drugs has proven to be excruciatingly 
complicated due to the near-ubiquitous involvement of NMDARs in normal brain function. 
Compounds that inhibit NMDARs by binding in and blocking ion flux through the NMDAR channel, 
known as channel blockers, are currently the most clinically efficacious NMDAR-targeting 
neurotherapeutic drugs. While the mechanism of inhibition employed by channel blockers seems 
quite simple, channel blockers exert additional, more nuanced effects on ion channel function that 
may contribute to their clinical profiles. The work presented in this dissertation details the ability 
of NMDAR channel blockers, with a primary focus on the clinically useful NMDAR channel blocker 





This introduction aims to accomplish four main tasks. First, I will discuss ion channel gating 
and the relation between channel gating and channel block. Second, I will review the basic 
characteristics of NMDARs, the receptor at the center of this dissertation research, and the 
inherent complexity of their pharmacology. Next, I will detail the effects of channel blockers on 
NMDAR state transitions to illustrate how channel blockers can act as powerful tools for the study 
of NMDAR channel function. I will then introduce the concept of state-specific antagonism and 
describe a strategy for targeting of specific NMDAR states with channel blockers.  
1.1  ION CHANNEL GATING 
(Adapted from Appendix A (Phillips et al., 2020)) 
Neuronal information processing depends on the distribution and properties of the ion 
channels found in neuronal membranes. Channel gating, perhaps the most basic characteristic 
of ion channels alongside ion permeation, refers to the ability of ion channels to either open and 
allow transmembrane ion flux or to close and prevent ion flux. The gating mechanisms employed 
by ligand-gated ion channels are divided into three general categories: activation, deactivation, 
and desensitization. Activation refers to the transition of ion channels from closed to open states 
following application of agonist. Deactivation refers to the transition of channels from open to 
closed states following removal of agonist. Desensitization is canonically defined as a decrease 
in the fraction of channels that are in the open state (termed open probability, or Popen) in the 
maintained presence of agonist (Katz & Thesleff, 1957). Desensitization is typically a direct 
consequence of agonist binding. A fourth gating mechanism that resembles desensitization but 
is not driven by agonist binding has been referred to both as desensitization and inactivation 




inactivation is a term typically used to describe a different mechanism employed by voltage-gated 
channels (Hille, 2001). While driven by different underlying mechanisms, both desensitization and 
inactivation ultimately describe nonconducting channel states that do not respond to typical 
activating stimuli (Katz & Thesleff, 1957; Hille, 2001). Gating mechanisms of ion channels are 
finely tuned and are essential to normal nervous system function, with even minor aberrations of 
channel gating often resulting in disease. While most known channelopathies involve dysfunction 
of voltage-gated channels, naturally occurring genetic variants that alter the gating of ligand-gated 
ion channels are increasingly associated with neurological disorders, including epilepsy, 
intellectual disability, and autism (Yuan et al., 2015). 
Studies of drugs that inhibit channel function provide valuable insight into ion channel 
gating mechanisms. Channel blockers, antagonists that bind in and prevent ion flux through ion 
channels, have been successfully used to probe both the structure of ion channel pores and the 
kinetics of channel gating. Channel gating requires conformational changes in or near the channel 
pore (i.e., the transmembrane ion conduction pathway), and channel blockers are known to 
interact differentially with channels in open, closed, inactivated, and desensitized states 
(Heidmann & Changeux, 1986; Benveniste & Mayer, 1995; Blanpied et al., 2005; Purohit & 
Grosman, 2006; Glasgow et al., 2017). Thus, channel blockers are exceptionally well-positioned, 
both figuratively and literally, for use as analytic probes in studies of channel gating.  
1.1.1 Reciprocal interactions between channel block and channel gating 
Channel gating can profoundly influence channel block, and channel block can profoundly 
influence channel gating. The initial binding of channel blockers often depends on gating state. 
Most blockers of ligand-gated ion channels can only enter and bind to the channel while agonist 




open channel blockers and are the focus of this dissertation. In some cases, open channel 
blockers are also termed “use-dependent” (Courtney, 1975). A blocker is termed use-dependent 
if inhibition by the blocker (1) requires activation of the channel, and (2) increases with duration 
of channel activation until an equilibrium between blocker binding and unbinding is reached 
(Figure 1A). The actions of almost all known ligand-gated ion channel blockers have been found 
to be at least partially dependent on channel opening, binding either exclusively or with much 
faster kinetics when the channel is open.  
Channel blocker unbinding also depends on gating transitions. If closure of the channel 
gate and agonist unbinding can occur while the blocker is bound, the blocker may become 
“trapped” in the channel (Figure 1C,D), unable to unbind until agonist is reapplied. Interestingly, 
some trapping blockers display the ability to escape from a fraction of blocked channels even 
after removal of agonist, a phenomenon termed “partial trapping” that is not fully understood 
(Blanpied et al., 1997; Sobolevsky & Yelshansky, 2000; Mealing et al., 2001; Bolshakov et al., 
2003; Kotermanski et al., 2009). On the other hand, sequential or “foot-in-door” channel blockers 
physically occlude closure of the channel gate (Figure 1E).  
The depth of the blocking site, size of the channel blocker, location of the channel gate, 
and gating-associated conformational changes all contribute to whether channels can close while 
the blocker is bound. These features dictate the structural interactions between channel blockers 
and the receptor’s gating machinery, which in turn determine the influence that the channel 
blocker can reciprocally exert on gating transitions.  
Bound channel blockers can affect gating transitions in three general ways. Blockers can:  
1. Alter agonist binding and/or unbinding kinetics; 
2. Stabilize channel open states; 




For example, the binding of large sequential blockers to open channels prevents both 
transition of channels into closed states (Figure 1E) and agonist unbinding (Armstrong, 1971; 
Ruff, 1977; Neher & Steinbach, 1978; Benveniste & Mayer, 1995; Sobolevsky et al., 1999). In 
contrast, smaller trapping blockers can interact with either open or closed channel states and can 
therefore have many possible effects on channel gating (Figure 1D). For example, trapping 
blockers can stabilize open or closed channels and/or facilitate entry into or recovery from 
desensitized states (Blanpied et al., 2005; Glasgow et al., 2017; Song et al., 2018). The inherent 
intertwining of channel gating and block allows channel blockers to be leveraged as powerful tools 






Figure 1. Interplay between channel gating and open channel block.   
A, Schematic depicting inhibition of current (black line) by a prototypical open channel blocker. Three 
agonist applications (green bars) are shown. The first agonist application in the absence of blocker shows 
the control response. The second agonist application, which follows the application and removal of a blocker 
(red bar), shows that the blocker cannot access its binding site when the channel is closed. The third agonist 
application, which is made in the presence of a blocker, shows that the blocker can access its binding site 
and inhibit agonist-activated current when the channel is in the open state. Entry of a blocker into open 
channels accelerates the apparent decay of the response and decreases the steady state response. 




application in the presence of the blocker may be unaffected, as shown here. However, if blocker binding 
is fast relative to current activation kinetics, the peak response may be reduced. B, Ion channels can 
transition between open, ion permeable states and closed, impermeable states. kc is transition rate into 
closed state and ko is transition rate into open state. C–E, The size of channel blocking compounds (red) 
and depth of the blocking site affects blocker interactions with the channel gate. C, Small channel blockers, 
such as inorganic cations, can block open channels without preventing channel closure or affecting gating 
transitions. kon is blocker binding rate and koff is blocker unbinding rate. When the channel is blocked by a 
blocker that does not interact with the gate, channel closing rate is k’c and channel opening rate is k’o. D, 
Small-to-intermediate-sized organic channel blockers can block open channels without preventing channel 
closure, but nevertheless can interact with the channel gate, either accelerating or decelerating gating 
transitions. When the channel is blocked by a blocker that interacts with the gate, channel closing rate is 
k’’c and channel opening rate is k’’o. E, Large, organic, sequential/foot-in-door blockers can block open 
channels and prevent channel closure. k’’’c is channel closing rate when the channel is blocked by a 





1.2 IONOTROPIC GLUTAMATE RECEPTORS 
iGluRs are members of the pore loop superfamily of ion channels, integral membrane 
proteins that mediate the majority of ion flux across neuronal membranes (Hille, 2001; Traynelis 
et al., 2010). Fast excitatory synaptic transmission in the central nervous system is primarily 
mediated by iGluRs, and proper functioning of iGluRs is vital to synaptogenesis, synaptic 
plasticity, signal integration, and information transfer between neurons (Traynelis et al., 2010; 
Paoletti et al., 2013). Due to the integral roles iGluRs play in neuronal function and their ubiquitous 
expression, aberrant iGluR activity contributes to a wide variety of neuronal dysfunctions that can 
drive nervous system disorders (Zorumski & Olney, 1993; Javitt, 2004; Lau & Zukin, 2007; Bowie, 
2008; Burnashev & Szepetowski, 2015; Lee et al., 2015; Yuan et al., 2015; Salpietro et al., 2019). 
iGluRs are divided into three main classes by structure: α-amino-3-hydroxyl-5-methyl-4-
isoxazole-propionate receptors (AMPARs), kainate receptors (KARs), and the aforementioned 
NMDARs. A fourth division of the iGluR family, δ receptors, shares substantial sequence 
homology with other iGluRs. Surprisingly, despite forming functional ion channels (Ady et al., 
2014; Benamer et al., 2018; Gantz et al., 2020), δ receptors show no ligand-gated ion channel 
function (Yamazaki et al., 1992; Araki et al., 1993; Lomeli et al., 1993; Orth et al., 2013). All iGluRs 
assemble as complexes of four membrane-spanning subunits that form a central pore. Each 
iGluR subunit contributes exclusively to one subtype of iGluR: GluA1–4 form AMPARs, GluN1, 
GluN2A-D, and GluN3A-B form NMDARs, and GluK1–5 form KARs. Despite this wide diversity, 
all iGluR subunits possess a similar general structure (shown in Figure 2A using an NMDAR as 
an example) consisting of four discrete, semiautonomous domains, namely, an extracellular 
amino-terminal domain (ATD), an extracellular ligand-binding domain (LBD), a transmembrane 
domain (TMD), and an intracellular carboxy-terminal domain (CTD, which was deleted from the 




the LBD. The four TMDs of iGluRs form the pore, and thus the site of channel blocker binding 
(Figure 2B). Within the TMD lies the glutamine (Q) – arginine (R) – asparagine (N) (QRN) site, a 
site found at the tip of the re-entrant loop (M2 loop) in the iGluR pore (Figure 2C) that helps form 
the selectivity filter and plays a crucial role in the differential cation selectivity and channel block 
of the three iGluR classes (Hume et al., 1991; Sommer et al., 1991; Burnashev, Monyer, et al., 
1992; Burnashev, Schoepfer, et al., 1992; Premkumar & Auerbach, 1996). Recent mid- and high-
resolution structures of AMPAR (Twomey et al., 2017, 2018; Twomey & Sobolevsky, 2018; 
Nakagawa, 2019) and NMDAR (Song et al., 2018; Chou et al., 2020) TMDs provided great insight 
into iGluR gating transitions and channel block. 
1.3  NMDA RECEPTORS 
NMDARs display numerous biophysical properties unique amongst the iGluR family, 
including high Ca2+ permeability, slow gating kinetics, dependence on co-agonism for gating, and 
voltage-dependent block by magnesium (Mg2+) ions (Mayer et al., 1984, 1987; Nowak et al., 1984; 
Johnson & Ascher, 1987; Vicini et al., 1998; Wyllie et al., 1998; Traynelis et al., 2010). These 
characteristics allow NMDARs to control Ca2+ influx during synaptic activity and therefore play a 
pivotal role in synaptic development and plasticity (Sheng et al., 1994; Malenka & Bear, 2004; 
Akgül & McBain, 2016). NMDARs are obligate heterotetramers, typically composed of two GluN1 
subunits (eight splice variants), which bind glycine or d-serine, and two GluN2 subunits (GluN2A–
GluN2D), which bind glutamate. A third group of subunits, GluN3A-B, also bind glycine/d-serine 
(although d-serine acts only as a partial agonist (Grand et al., 2018)) and can assemble with 
GluN1 and GluN2 subunits to form NMDARs activated by glutamate and glycine/d-serine. 




NMDARs activated solely by glycine/d-serine. However, these GluN1/3 receptors only pass weak 
currents in physiological conditions, so their role in neuronal function is largely unknown, though 
recent work has begun to shed light on their contribution to learning mechanisms (Grand et al., 
2018; Otsu et al., 2019). Conventional NMDARs consisting of two GluN1 subunits and two GluN2 
subunits rely on the binding of both glutamate and glycine/d-serine for activation (Johnson & 
Ascher, 1987; Mothet et al., 2000) and, unlike AMPARs and KARs, require all four agonist binding 
domains to be occupied for the channel to transition to the open state (Benveniste & Mayer, 1991; 
Clements & Westbrook, 1991; Schorge et al., 2005). Additionally, conventional NMDARs possess 
a conserved asparagine at the QRN site of each subunit (Figure 2C) that confers sensitivity to 
block by Mg2+ and high Ca2+ permeability, even relative to Ca2+-permeable AMPAR and KARs 






Figure 2. General NMDAR structure and putative blocking site. 
A, Recently published structure of an NMDAR in an “active” state showing domain topology shared by all 
iGluR subtypes (ATD, amino-terminal domain; LBD, ligand-binding domain; TMD, transmembrane domain; 
Protein Data Bank (PDB) code 6WHT; (Chou et al., 2020)). GluN1 subunit is depicted in dark blue and 
GluN2B in cyan. Horizontal lines show the approximate locations of the outer and inner surfaces of the 
membrane. B, Blow-up of NMDAR TMD (boxes in A) with docked channel blocker memantine (space-filling; 
carbons are red, nitrogen is orange) displaying typical site of channel block. Most channel blocking 




entrant M2 loops of each subunit (opaque; M1, M3, and M4 transmembrane helices are transparent for 
visualization of blocking site). C, Magnified view of memantine coordination by the QRN site asparagine 
residues GluN1 N616 and GluN2B N615 (shown in stick format), which are critically involved in NMDAR 
channel blocker binding (Mori et al., 1992; Ferrer-Montiel et al., 1998; Lemke et al., 2014; Mesbahi-Vasey 
et al., 2017; Fedele et al., 2018). Autodock Vina was used for molecular docking of memantine to PDB 
6WHT, and structural images were prepared using the program Visual Molecular Dynamics (VMD) 




1.3.1 Diversity of NMDAR subunits 
NMDAR subtype is defined by the identity of the subunits that compose a receptor. The 
subunit composition of NMDARs, primarily the identity of the glutamate-binding GluN2 subunits, 
dictates their functional characteristics. Many key biophysical properties of NMDARs are 
governed by the GluN2 subunit. There is a clear dichotomy between the GluN2A-B subunits and 
the GluN2C-D subunits in terms of gating kinetics, channel conductance, ion permeability, and 
channel block. GluN1/2A and GluN1/2B diheteromers display far faster activation and 
desensitization kinetics, higher permeability to Ca2+, greater single channel conductance, and 
stronger voltage-dependent channel block by Mg2+ than GluN1/2C and GluN1/2D diheteromers 
(Monyer et al., 1992, 1994; Burnashev et al., 1995; Kuner & Schoepfer, 1996; Qian et al., 2005; 
Gielen et al., 2009; Traynelis et al., 2010; Siegler Retchless et al., 2012; Wyllie et al., 2013; 
Paoletti et al., 2013; Glasgow et al., 2015). Of particular importance to the work presented in this 
dissertation, desensitization of NMDARs substantially differs by subtype. While desensitization of 
GluN1/2C and GluN1/2D receptors is extremely weak, GluN1/2A and GluN1/2B receptors both 
display multiple forms of desensitization (Monyer et al., 1994; Krupp et al., 1996, 1998). The 
biophysical differences between NMDAR subtypes contribute to their role neuronal function, 
primarily by shaping the duration of the synaptic response, and thus have great influence on 
neuronal function and plasticity (Nevian & Sakmann, 2004, 2006; Urakubo et al., 2008; Carter & 
Jahr, 2016). GluN2 subunit expression also differs greatly by subcellular localization, brain region, 
and over the course of development (Monyer et al., 1992, 1994; Watanabe et al., 1992; Ishii et 
al., 1993; Akazawa et al., 1994; Zhong et al., 1995; Misra et al., 2000; Brickley et al., 2003; Dunah 
& Standaert, 2003; Martel et al., 2012; Kellermayer et al., 2018), further enhancing the impressive 




Most characterization of the functional differences found between NMDAR subtypes has 
been performed on diheteromeric receptors, which are comprised of two GluN1 subunits and two 
identical GluN2 subunits, expressed in heterologous cells. However, nearly all neurons express 
multiple different GluN2 subunits, which can co-assemble to form triheteromeric receptors 
comprised of two GluN1 subunits and two different types of GluN2 subunits. Multiple studies have 
reported evidence of GluN1/2A/2B, GluN1/2A/2C, and GluN1/2B/2D receptors in neurons (Sheng 
et al., 1994; Chazot et al., 1994; Luo et al., 1997; Chazot & Stephenson, 1997; Dunah et al., 1998; 
Tovar & Westbrook, 1999; Misra et al., 2000; Piña-Crespo & Gibb, 2002; Brickley et al., 2003; 
Dunah & Standaert, 2003; Lu et al., 2006; Brothwell et al., 2008; Rauner & Köhr, 2011; Gray et 
al., 2011; Tovar et al., 2013; Huang & Gibb, 2014; Bhattacharya et al., 2018; Swanger et al., 
2018). Furthermore, GluN1/2A/2B receptors are likely to be the most prevalent form of NMDAR 
expressed in the neocortex and hippocampus (Sheng et al., 1994; Luo et al., 1997; Gray et al., 
2011; Rauner & Köhr, 2011; Paoletti et al., 2013; Tovar et al., 2013; Stroebel et al., 2018). Though 
triheteromeric receptors are difficult to study in isolation, recent advances have allowed for 
functional isolation or expression of modified isolated triheteromeric NMDARs in heterologous 
cells (Hansen et al., 2014; Stroebel et al., 2014; Yi et al., 2017). Triheteromeric NMDARs display 
distinct biophysical characteristics relative to their diheteromeric counterparts. For example, 
GluN1/2A/2B receptors exhibit agonist affinity, maximal Popen, and gating kinetics intermediate to 
GluN1/2A and GluN1/2B diheteromers. Interestingly, the intermediate properties of triheteromers 
are not simply the average of the properties expressed by their related diheteromers but instead 
may be shifted toward one of the GluN2 subunits (Hansen et al., 2014; Stroebel et al., 2014, 2018; 
Sun et al., 2017; Bhattacharya et al., 2018), generating a sort of “dominance” by one of the two 
GluN2 subunits. In all, the 360 possible combinations of GluN1 splice variants and GluN2 subunits 




1.3.2 NMDAR-mediated Ca2+ influx – a double-edged sword 
NMDARs are involved in nearly all aspects of synaptic function and play a critical role in 
synaptic plasticity (Malenka & Bear, 2004; Lüscher & Malenka, 2012). The unique combination of 
slow gating kinetics, voltage-dependent channel block by Mg2+, and high Ca2+ permeability 
possessed by NMDARs allows them to dictate the timing and magnitude of Ca2+ influx following 
synaptic activity. These features also allow NMDARs to act as coincidence detectors. For 
example, if one weak synaptic input releases glutamate onto a postsynaptic neuron, NMDARs 
will open, but will not pass substantial current due to Mg2+ block. However, if that same weak 
synaptic input releases glutamate while the postsynaptic cell is depolarized due to other strong 
synaptic inputs, Mg2+ will unblock from the NMDARs at the weak synapse and Ca2+ will flow into 
the postsynaptic compartment. Ca2+ acts as a powerful second messenger and initiates an 
extensive array of signaling cascades that can either weaken or strengthen synaptic connections. 
Intracellular Ca2+ concentration ([Ca2+]i) regulates the expression of synaptic plasticity, with brief 
bouts of high [Ca2+]i pushing the synapse toward potentiation while sustained, small increases in 
[Ca2+]i push synapses toward depression. Interestingly, recent studies have also reported that 
glutamate binding to the GluN2 subunit can elicit NMDAR-mediated synaptic depression without 
the need for Ca2+ influx (Nabavi et al., 2013; Babiec et al., 2014; Stein et al., 2015). However, this 
non-ionotropic mechanism of NMDAR signaling still requires the maintenance of resting levels of 
[Ca2+]i (Nabavi et al., 2013), illustrating the importance of tightly regulated [Ca2+]i to synaptic 
plasticity. 
NMDAR-mediated Ca2+ influx is also heavily involved in neuronal survival. Physiological 
levels of NMDAR signaling promote activity of the cAMP response element binding protein 
(CREB), which is critical for both neuronal survival and plasticity, and the PI3K-Akt signaling 




Bading, 2010). However, excessive NMDAR activity leads to buildup of abnormally high [Ca2+]i 
and subsequent activation of cell death signaling pathways (Choi, 1987, 1992; Tymianski et al., 
1993; Lau & Tymianski, 2010), a process known as excitotoxicity. Excitotoxicity is heavily involved 
in many neuropathologies and is a key feature of cell death following ischemia, Huntington’s 
disease, Alzheimer’s disease, and Alzheimer’s disease-related dementias (Zorumski & Olney, 
1993; Lipton, 1999, 2004; Hynd et al., 2004; Koutsilieri & Riederer, 2007; Dong et al., 2009; 
Olivares et al., 2012; Mota et al., 2014; Gardoni & Di Luca, 2015; Wang & Reddy, 2017). Some 
studies have suggested that subcellular localization or NMDAR subtype plays a role in 
determining whether NMDAR activity drives a cell toward survival rather than death, with GluN2A-
containing synaptic receptors signaling for cell survival and GluN2B-containing extrasynaptic 
receptors eliciting cell death (Hardingham et al., 2002; Léveillé et al., 2008; Papadia et al., 2008; 
Okamoto et al., 2009; Kaufman et al., 2012; Martel et al., 2012; Yan et al., 2020). However, other 
reports argue against such a clear dichotomy and show that synaptic, GluN2A-containing 
NMDARs are involved, perhaps even necessary and sufficient, for eliciting excitotoxicity (von 
Engelhardt et al., 2007; Papouin et al., 2012; Wroge et al., 2012; Zhou et al., 2013). Despite this 
debate, it is clear that NMDAR-mediated Ca2+ influx must be tightly regulated for maintenance of 
proper neuronal function. 
1.4  NMDA RECEPTOR CHANNEL BLOCK 
Due to their many roles in normal and pathological brain function, NMDARs are attractive 
targets for development of neurotherapeutics. NMDAR channel blockers are currently the most 
clinically useful NMDAR-targeting drugs and show great promise in the treatment of multiple 




neuron death following ischemia (Krystal et al., 1994; Parsons, Danysz, & Quack, 1999; Parsons 
et al., 2007; Zhou et al., 2011; Danysz & Parsons, 2012; Persson, 2013; Kafi et al., 2014; Abdallah 
et al., 2015; Kong et al., 2017; Nair & Sahoo, 2019). NMDAR channel blockers display a strikingly 
diverse array of clinical effects, despite sharing overlapping binding sites and a similar general 
mechanism of inhibition ((Ferrer-Montiel et al., 1998; Kashiwagi et al., 2002); the putative blocking 
site for memantine is shown in Figure 2B,C). For example, the clinically relevant blockers 
memantine and ketamine share similar chemical properties and binding kinetics but possess 
vastly different effects on brain function. Ketamine is a drug of abuse and poorly tolerated, but 
possesses impressive efficacy in treating neuropathic pain and major depressive disorder 
(Noppers et al., 2010; Zhou et al., 2011; Persson, 2013; Miller et al., 2014; Abdallah et al., 2015). 
On the other hand, memantine possesses weaker efficacy in treatment of neuropathic pain and 
little to no effect on major depressive disorder, but is well-tolerated with few side effects and 
shows efficacy in the treatment of neurodegenerative disorders such as Alzheimer’s disease 
(Parsons, Danysz, & Quack, 1999; Parsons et al., 2007; Lipton, 2004; Chen & Lipton, 2006; 
Olivares et al., 2012; Gideons et al., 2014; Kafi et al., 2014; Amidfar et al., 2018). 
Despite the clinical relevance of organic NMDAR channel blockers, the most important 
NMDAR channel blocker is undoubtably the inorganic cation Mg2+. In 1984, Linda Nowak and the 
Ascher lab reported that the peculiar voltage sensitivity displayed by NMDARs was a 
consequence of channel block by endogenous extracellular Mg2+ ions (Nowak et al., 1984), a 
discovery soon replicated by another research group (Mayer et al., 1984). Channel block by Mg2+ 
is perhaps the most distinctive feature of NMDARs and has extreme impact on normal brain 
function. Mg2+ blocks NMDARs at resting membrane potentials and unbinds as the cell becomes 
depolarized. The voltage-dependence of Mg2+ block enables NMDARs to act as coincidence 
detectors that sense postsynaptic depolarization near-simultaneously with presynaptic glutamate 




as well as learning and memory (Malenka, 1994; Rudhard et al., 2003; Chen, Errington, et al., 
2009; Lüscher & Malenka, 2012).  Mg2+ block is also critical for proper excitation-inhibition balance 
and autonomic nervous system function, as deficiencies in Mg2+ block can lead to severe 
pathological phenotypes and death (Single et al., 2000; Rudhard et al., 2003; Chen, Errington, et 
al., 2009; Lemke et al., 2014). 
Likely due to its vast physiological and clinical relevance, the biophysical underpinnings 
of NMDAR channel block have been extensively studied. Most, if not all, well-characterized 
NMDAR channel blockers with slow kinetics display some degree of use dependence and 
voltage-dependent binding. Most NMDAR channel blockers are monovalent or divalent cations 
and display far greater inhibition at negative than at positive membrane potentials (MacDonald et 
al., 1991; Parsons et al., 1995; Antonov & Johnson, 1996; Blanpied et al., 1997; Sobolevsky et 
al., 1999; Sobolevsky & Yelshansky, 2000; Bolshakov et al., 2003; Gilling et al., 2009). Nearly all 
known NMDAR channel blockers show some effect on channel gating (Johnson & Qian, 2002) 
and channel blockers are found to modulate nearly every aspect of gating (Wright & Nowak, 1992; 
Vorobjev & Sharonova, 1994; Costa & Albuquerque, 1994; Antonov et al., 1995; Benveniste & 
Mayer, 1995; Antonov & Johnson, 1996; Li-Smerin & Johnson, 1996; Blanpied et al., 1997, 2005; 
Chen & Lipton, 1997; Sobolevsky et al., 1998, 1999; Sobolevsky & Yelshansky, 2000; 
Sobolevsky, 2000; Glasgow et al., 2017). The striking diversity in the clinical effects of NMDAR 
channel blockers may in part arise from their diverse effects on channel gating.  
1.4.1 Sequential blockers of NMDARs prevent channel closure and agonist dissociation 
The sequential/foot-in-door blockers 9-aminoacridine (Table 1), tetrapentylammonium, 
and the amantadine derivative IEM-1857 are thought to force NMDARs to remain in open states 




Koshelev & Khodorov, 1995; Antonov & Johnson, 1996; Sobolevsky et al., 1999; Sobolevsky, 
2000). Importantly, occupancy of the channel by IEM-1857, tetrapentylammonium, or 9-
aminoacridine also prevents agonist dissociation and channel desensitization (Benveniste & 
Mayer, 1995; Antonov & Johnson, 1996; Sobolevsky et al., 1999), suggesting that blocker 
unbinding and subsequent channel closure are required for agonist dissociation. This finding is 
consistent with models of sequential channel block of nAChRs proposed by (Adams, 1975, 1976; 
Ruff, 1977; Neher & Steinbach, 1978). An experimental procedure used to test whether a channel 
blocker prevents channel closure and agonist dissociation is to determine if the blocker induces 
“tail currents”. A tail current is a transient increase in receptor-mediated current observed upon 
rapid and simultaneous removal of blocker and agonist from the extracellular solution. If a blocker 
prevents channel closure, channels pass through the open, unblocked state following blocker 
unbinding, resulting in a tail current. However, any antagonist that unblocks more quickly than 
agonists unbind can induce tail currents; thus, observation of tail currents does not provide 
unambiguous evidence that a blocker acts via a sequential mechanism. More powerful evidence 
that a blocker prevents channel closure can be provided by (1) observation that a blocker chops 
single-channel currents into “bursts” of brief openings, and that the total channel open time during 
bursts is independent of blocker concentration (Neher & Steinbach, 1978), and (2) observation 
that the blocker concentration that inhibits responses by 50% (the IC50) is inversely proportional 
to the receptor’s Popen, a prediction that can be tested, e.g., by recording the IC50 of a blocker over 
a range of agonist concentrations (Johnson & Qian, 2002). The finding that channel occupation 
by sequential blockers prevents agonist unbinding as well as channel closing provided 
fundamental information on state transitions of ligand-gated ion channels. 
Organic channel blocking compounds were remarkably useful in determining the location 
of the channel gate itself. The size of a blocking molecule is a key determinant of whether the 




comparing block by IEM-1857 and the similar but smaller blocker IEM-1754 (Table 1) found that 
while binding of IEM-1857 prevented channel closure independent of voltage, IEM-1754 only 
prevented channel closure at relatively depolarized membrane potentials. At more hyperpolarized 
potentials, IEM-1754 is “pulled” by the membrane electric field deeper into the channel where it 
no longer prevents channel closure, instead acting as a trapping channel blocker (Antonov & 
Johnson, 1996). The voltage dependence of IEM-1754 block, as well as its interactions with 
permeant ions, demonstrated that IEM-1754 has two blocking modes, one in which the blocker 
associates with a shallower site and places the bulk of the molecule in the way of the gate, and a 
second in which the blocker associates with a deeper site and permits closure of the gate 
(Antonov & Johnson, 1996; Antonov et al., 1998; Qian & Johnson, 2002). This finding strongly 
supported the idea that the NMDAR channel gate lies at the extracellular entrance to the channel, 
an idea that was recently validated by crystal and cryo-EM structures of ligand-bound NMDARs 
(Tajima et al., 2016; Chou et al., 2020). 
1.4.2 Channel block by Mg2+ does not appear to affect NMDAR state transitions 
The majority of NMDAR channel blockers affect gating, but at least one blocker exists as 
an exception to this rule: Mg2+ (Table 1). Binding of Mg2+ to the NMDAR channel does not prevent 
gate closure, agonist dissociation, or desensitization (Nowak et al., 1984; Ascher & Nowak, 1988; 
Benveniste & Mayer, 1995; Sobolevsky & Yelshansky, 2000). Further evidence that Mg2+ has no 
effect on channel gating is provided by the relation between its equilibrium dissociation constant 
(Kd) and IC50. The relation between Kd and IC50 directly depends on how a channel blocker affects 
channel transitions after binding. Kd ≈ IC50 suggests that a blocker has no effect on gating, Kd > 
IC50 implies that a blocker stabilizes channel closed states, and Kd < IC50 implies that a blocker 




effectively as Popen decreases (IC50 = Kd/Popen; (Hille, 2001; Johnson & Qian, 2002)). Mg2+ boasts 
nearly equivalent Kd and IC50 (Qian et al., 2002), suggesting that Mg2+ occupancy of the channel 
has no effect on state transitions.  
The unusual ability of Mg2+ to block without altering gating could be due to its small size. 
A large conformational change in the extracellular region of the NMDAR channel is associated 
with gating, a conclusion supported by structural studies [(Chou et al., 2020) and the observation 
that large organic blockers prevent channel closure. Although smaller organic blockers generally 
permit channel closure, stabilizing or destabilizing interactions with channel residues may alter 
channel gating kinetics. It is possible that the small size of Mg2+ (which is likely to be mostly 
dehydrated when blocking the channel (Mesbahi-Vasey et al., 2017)), coupled with its limited 
interactions with channel residues outside of the ion selectivity filter (Mesbahi-Vasey et al., 2017), 
allows binding in the NMDAR channel without affecting gating machinery. Also, in contrast to most 
organic blockers, Mg2+ has not been directly shown to act as a use-dependent open channel 
blocker or as a trapping blocker. Mg2+ displays extremely rapid binding and unbinding kinetics 
(Nowak et al., 1984; Ascher & Nowak, 1988; Sobolevsky & Yelshansky, 2000), preventing 
accurate determination in whole-cell recordings of the rapid component of block or unblock, 
measurements required for demonstration of use dependence and trapping. Kinetic modeling 
studies, however, suggested that Mg2+ does indeed act as an open channel blocker (Sobolevsky 
& Yelshansky, 2000).  
Despite the lack of effects of Mg2+ block on NMDAR gating, depolarization-induced Mg2+ 
unblock clearly depends on gating. Mg2+ unblock from GluN1/2A and GluN2B receptors displays 
a slow component as well as an extremely rapid component (Spruston et al., 1995; Vargas-
Caballero & Robinson, 2003; Kampa et al., 2004; Clarke & Johnson, 2006, 2008; Clarke et al., 
2013). Although kinetic models in which Mg2+ block affects gating transitions and/or agonist 




2004), substantial experimental evidence demonstrated that Mg2+ does not affect NMDAR state 
transitions (Nowak et al., 1984; Ascher & Nowak, 1988; Benveniste & Mayer, 1995; Sobolevsky 
& Yelshansky, 2000). This disagreement was reconciled by the discovery of the inherent (i.e., 
Mg2+-independent) voltage-sensitivity of NMDAR gating, which underlies the slow component of 
Mg2+ unblock (Clarke & Johnson, 2008; Clarke et al., 2013). Thus, the interplay between Mg2+ 
block and NMDAR gating is unidirectional, whereas Mg2+ block depends on NMDAR gating, but 
NMDAR gating is unaffected by Mg2+ block. 
1.4.3 Trapping channel blockers modulate NMDAR state transitions 
Trapping channel blockers display more subtle effects on gating than sequential blockers. 
Early studies using a combination of patch-clamp electrophysiology and kinetic modeling 
concluded that the amino-adamantane derivatives memantine and amantadine and the 
phencyclidine derivative NEFA have clear effects on channel gating (Blanpied et al., 1997; Chen 
& Lipton, 1997; Dilmore & Johnson, 1998; Sobolevsky et al., 1998). Initial proposals for the effects 
of amino-adamantane derivatives on NMDAR gating were wide-ranging, including models that 
suggested memantine and amantadine could stabilize open receptor states, as well as models 
that suggested memantine may stabilize closed receptor states (Blanpied et al., 1997; Chen & 
Lipton, 1997; Sobolevsky et al., 1998). It is possible that these discrepancies arose from the 
abilities of amino-adamantane derivatives to escape from some blocked channels after agonist 
removal (partial trapping), and to inhibit NMDARs via association with a site accessible in the 
absence of agonist (Blanpied et al., 1997; Chen & Lipton, 1997; Sobolevsky et al., 1998; 
Kotermanski et al., 2009; Glasgow et al., 2018).  
Thorough evidence that amino-adamantane derivatives affect closed-state transitions 




Amantadine’s Kd (110 μM) is considerably greater than its IC50 (~35 μM; (Sobolevsky & Koshelev, 
1998; Sobolevsky et al., 1998; Bolshakov et al., 2003; Blanpied et al., 2005)). Kd > IC50 implies 
that a blocker’s mechanism of inhibition likely involves stabilization of channel closed states, either 
through decreasing the rate of channel opening, increasing the rate of channel closure, or both. 
Such blockers therefore have two inhibitory actions: (1) blocking current flow through open 
channels and (2) stabilization of closed channels. Amantadine is an example of such a dual-
mechanism channel inhibitor. Investigation of amantadine block of single-channel and whole-cell 
NMDAR current revealed that binding of amantadine not only accelerates channel closure, but 
that this acceleration of channel closure is actually the predominant mechanism of inhibition by 
amantadine at concentrations lower than 100 μM (Blanpied et al., 2005). 
Recent studies reported additional drug-specific and NMDAR subtype-specific effects of 
channel blockers on gating transitions. Investigation of mechanisms by which memantine and 
ketamine preferentially target distinct populations of NMDARs led to the discovery that memantine 
and ketamine have differential, subtype-specific effects on NMDAR desensitization (Glasgow et 
al., 2017). While ketamine accelerated recovery from desensitization of GluN1/2B receptors, 
memantine binding profoundly slowed recovery from desensitization of GluN1/2A receptors. The 
effect of memantine on GluN1/2A receptor desensitization was not observed in low-Ca2+ 
conditions, suggesting that memantine stabilizes a Ca2+-dependent desensitized state of 
GluN1/2A receptors. A comparison of IC50 values measured in low and high Ca2+ conditions with 
Kd values predicted by a kinetic model found that in high Ca2+, Kd > IC50, whereas in low Ca2+, Kd 
≈ IC50, suggesting that memantine only alters GluN1/2A gating when Ca2+-dependent 
desensitization can occur (Glasgow et al., 2017).  
Visualization of NMDARs bound to trapping channel blockers was provided by recent 
structural studies. Song et al. crystalized the closed GluN1/2B channel in complex with the high 




mechanism of block by MK-801 and memantine (Song et al., 2018). Both blockers were found to 
bind within the central cavity of the ion channel and promote closure of the channel gate, perhaps 
via a mechanism similar to amantadine (Blanpied et al., 2005). Although this result may seem to 
contrast with the previous finding that memantine did not affect GluN1/2B receptor desensitization 
(Glasgow et al., 2017), it is important to note that (1) memantine could affect GluN1/2B channel 
closure without affecting desensitization, and (2) the crystalized MK-801-NMDAR construct 
lacked both the ATD and CTD, which play key roles in gating and desensitization (Ehlers et al., 
1996; Krupp et al., 1996, 1998, 2002; Villarroel et al., 1998; Vissel et al., 2002; Maki et al., 2012; 
Chou et al., 2020). Stabilization of closed channels by NMDAR channel blockers could have 
profound physiological implications by effectively increasing the potency of blockers under 







Table 1. NMDAR channel blockers and their effects on gating.  
Magnesium is depicted coordinating six water molecules (waters are replaced with the critical Asn residues 
when Mg2+ is blocking the channel), and all organic blockers are depicted in bond-line format. Blockers 
structures are scaled to depict approximate relative sizes. 
Compound Structure Type of Blocker Effects on Gating 
Magnesium 
 
Unclear - due to fast unblocking 
kinetics, trapping of Mg2+ has not 
been directly demonstrated. 
None (Nowak et al., 1984; 
Ascher & Nowak, 1988; 
Sobolevsky & Yelshansky, 





Sequential (Benveniste & Mayer, 
1995; Koshelev & Khodorov, 1995).  
Stabilizes open state, 
prevents agonist dissociation 
(Benveniste & Mayer, 1995; 
Koshelev & Khodorov, 1995). 
IEM-1754 
 
Depolarized potentials: sequential. 
Strongly negative potentials: 
trapping (Antonov & Johnson, 
1996). 
Depolarized potentials: 
Stabilizes open state 
(Antonov & Johnson, 1996). 
Amantadine 
 
Partial trapping (Blanpied et al., 
1997; Sobolevsky & Yelshansky, 
2000). 
Accelerates channel closure 
of native NMDARs and 
GluN1/2B receptors 
(Blanpied et al., 2005). 
Memantine 
 
Partial trapping (Blanpied et al., 
1997; Chen & Lipton, 1997; 
Mealing et al., 1999; Kotermanski & 
Johnson, 2009; Kotermanski et al., 
2009). 
Slows GluN1/2A receptor 
recovery from Ca2+-
dependent desensitization 
(Glasgow et al., 2017). 
Ketamine 
 
Trapping (MacDonald et al., 1987; 
Mealing et al., 1999). 
Accelerates GluN1/2B 
receptor recovery from 





1.5 PHARMACOLOGICAL TARGETING OF SPECIFIC NMDARS STATES 
Many NMDAR channel blockers, including amantadine and memantine, act by blocking 
and stabilizing NMDAR closed states (Blanpied et al., 2005; Glasgow et al., 2017). Stabilization 
of closed states by a channel blocker effectively enhances the potency of the blocker (Section 
1.4.3). The ability to both block and modulate the gating of NMDAR receptors could lend additional 
specificity to channel blockers. Desensitized states are closed channel states the occupancy of 
which can vary by NMDAR subtype and physiological context (Benveniste et al., 1990; Krupp et 
al., 1996, 1998; Villarroel et al., 1998; Glasgow et al., 2017). Therefore, targeting specific receptor 
desensitized states could allow for preferential inhibition of select populations of NMDARs based 
on NMDAR subtype, physiological context, or both. This concept, known as state-specific or 
context-specific antagonism, is a rational strategy for the design of improved neurotherapeutic 
agents with reduced off-target and negative side effects. In this section, I will provide background 
on a context and subtype specific form of NMDAR desensitization, Ca2+-dependent 
desensitization, and discuss the rationale behind the targeting of Ca2+-dependent desensitized 
receptor states for neurotherapeutic purpose. 
1.5.1 Targeting NMDA receptor desensitization  
There are multiple distinct NMDAR desensitization processes, including glycine-
dependent desensitization, Ca2+-dependent desensitization, and glycine-and-Ca2+-independent 
desensitization (Mayer et al., 1989; Benveniste et al., 1990; Lerma et al., 1990; Lester et al., 1990; 
Sather et al., 1990; Legendre et al., 1993; McBain & Mayer, 1994). Glycine-dependent 
desensitization can only occur in subsaturating glycine concentrations, and results from negative 




glutamate to the GluN2 subunit decreases the affinity of glycine to the GluN1 subunit. This 
reduction in affinity encourages glycine to unbind from the GluN1 subunit, which results in channel 
closure (Benveniste et al., 1990; Lester et al., 1993). Since the decay in the NMDAR response is 
a direct consequence of agonist unbinding, there is some debate as to whether glycine-dependent 
desensitization is a form of “true” desensitization (McBain & Mayer, 1994), as desensitization is 
canonically defined as a decrease in receptor POpen while agonist is still bound  (Katz & Thesleff, 
1957). Mechanisms of glycine-and-Ca2+-independent desensitization (Sather et al., 1990) are less 
clear, but most evidence suggests that glycine-and-Ca2+-independent desensitization is mediated 
through the extracellular NTD regions of GluN2 subunits in a subtype-dependent manner (Krupp 
et al., 1998; Villarroel et al., 1998). 
Ca2+-dependent desensitization results from an increase in [Ca2+]i, due either to NMDAR-
mediated Ca2+ influx or Ca2+ from other sources (Legendre et al., 1993; Vyklický, 1993; Medina et 
al., 1994). The terms used to refer to desensitization processes that are Ca2+-dependent has been 
inconsistent and include glycine-independent desensitization and the commonly-used Ca2+-
dependent inactivation (Legendre et al., 1993; Tong & Jahr, 1994; Tong et al., 1995; Krupp et al., 
2002; Iacobucci & Popescu, 2020). Regardless of name, all share the common features of (1) 
decreasing NMDAR POpen while agonist is still bound and (2) dependence on elevation of [Ca2+]i. 
Therefore, unless otherwise stated, I will be referring to all desensitization processes regulated 
by [Ca2+]i as Ca2+-dependent desensitization (CDD) in this dissertation.  
The mechanisms underlying CDD involve a combination of molecular interactions that are 
not yet fully understood, but the Ca2+-binding/Ca2+-activated proteins calmodulin (CaM), α-actinin, 
and calcineurin have all been implicated in CDD. CDD is certainly mediated, at least in part, 
through the binding of Ca2+-bound CaM to the GluN1 C-terminal domain (CTD; (Ehlers et al., 
1996; Zhang et al., 1998; Krupp et al., 1999; Rycroft & Gibb, 2002)). α-actinin binds to the GluN1 




1997; Krupp et al., 1999). The interplay between CaM and α-actinin is complex, with evidence 
suggesting that Ca2+-bound CaM displaces α-actinin from its binding site on the GluN1 CTD, 
promoting desensitization (Wyszynski et al., 1997; Krupp et al., 1999; Merrill et al., 2007). 
Calcineurin has been suggested to interact with the GluN2A CTD and promote CDD through 
interaction with CaM (Tong et al., 1995; Krupp et al., 2002; Rycroft & Gibb, 2004). NMDAR CDD 
also depends on NMDAR subtype, but the mechanism underlying CDD in each subtype is 
unclear. CDD has been reported in GluN1/2A, GluN1/2B, and GluN1/2D receptors, but not 
GluN1/2C receptors (Krupp et al., 1996; Medina et al., 1996; Iacobucci & Popescu, 2020). 
GluN1/2A receptors are the only subtype to show CDD in all studies concerning NMDAR CDD, 
while studies of GluN1/2B receptor and GluN1/2D receptors have provided less consistent 
findings. Regardless of the underlying mechanisms, CDD is a key part of an endogenous 
negative-feedback loop that reduces Ca2+ influx through NMDARs in response to increases in 
[Ca2+]i and thus protects neurons from excessive buildup of [Ca2+]i.  
Dependence on context (i.e., increased [Ca2+]i) and NMDAR subtype make CDD an 
attractive target for pharmacological modulation. Indeed, previous data from our lab revealed that 
memantine stabilizes a Ca2+-dependent desensitized state of GluN1/2A receptors (Glasgow et 
al., 2017). Enhancement of CDD by memantine suggests a logical mechanism for 
neuroprotection: preferential inhibition of NMDARs in cellular populations subjected to 
pathological levels of Ca2+ influx, i.e., NMDARs likely to mediate excitotoxic cell death (Zorumski 
& Olney, 1993; Rothman & Olney, 1995; Okamoto et al., 2009). In turn, characterization of the 
memantine-NMDAR complex may give insight into the structural underpinnings and mechanisms 
of CDD. The goals of the research presented in this dissertation are: 
1. To characterize the relation between NMDAR CDD and channel block by memantine.  









2.0 CA2+-DEPENDENT DESENSITIZATION REGULATES SUBTYPE-SPECIFIC BLOCK OF 
NMDA RECEPTORS BY MEMANTINE 
2.1 OVERVIEW 
N-methyl-D-aspartate receptors (NMDARs) are key mediators of neuronal Ca2+ influx. 
NMDAR-mediated Ca2+ influx plays a central role in synaptogenesis, synaptic plasticity, dendritic 
integration, and neuronal survival. However, excessive NMDAR activity can lead to buildup of 
pathological levels of Ca2+ inside neurons, which initiates cellular signaling pathways that result 
in neuronal death. Thus, drugs targeting NMDARs are of great clinical interest. The NMDAR 
channel blocker memantine is a well-tolerated Alzheimer’s disease medication that also shows 
promise in treatment of other neurological disorders. Interestingly, memantine enhances 
desensitization of NMDARs in a subtype- and Ca2+-dependent manner. Furthermore, memantine 
inhibits NMDARs more effectively in conditions that allow for increased Ca2+ influx and buildup, 
which suggests that memantine could preferentially target overactive NMDAR subpopulations. 
However, the direct effect of intracellular Ca2+ on NMDAR inhibition by memantine has not been 
systematically examined. Utilizing specially designed Ca2+-buffering solutions and whole-cell 
patch-clamp recordings, we demonstrated that NMDAR channel block by memantine is directly 
related to intracellular Ca2+ concentration. We discovered that memantine potency increases 
alongside increasing intracellular Ca2+, and that the effect of intracellular Ca2+ on memantine 
action depends on NMDAR subtype. These results present a previously unexamined form of 
state-specific antagonism, Ca2+-dependent NMDAR channel block, that could have a profound 





NMDA receptors (NMDARs) are ionotropic glutamate receptors that possess a unique set 
of biophysical properties, including dependence of gating on co-agonism, voltage-dependent 
block by Mg2+, high permeability to Ca2+, and slow gating kinetics (Mayer et al., 1984, 1987; 
Nowak et al., 1984; Johnson & Ascher, 1987; Vicini et al., 1998; Wyllie et al., 1998; Traynelis et 
al., 2010). This unique combination of properties allows NMDARs to control the magnitude and 
timing of Ca2+ influx during synaptic activity. Ca2+ influx due to NMDAR activity is vital to many 
aspects of neuronal function, including neuronal survival, synaptic development, and synaptic 
plasticity (Sheng et al., 1994; Malenka & Bear, 2004; Hardingham, 2006; Akgül & McBain, 2016).  
The magnitude of NMDAR-mediated Ca2+ influx is a crucial determinant of the signaling 
pathways elicited by NMDAR activity.  Low levels of NMDAR activity sustain small, prolonged 
increases of intracellular Ca2+ concentration ([Ca2+]i), which supports signaling cascades involved 
in synaptic depression. In contrast, intense, transient NMDAR activation leads to brief bouts of 
high [Ca2+]i, which activates signaling cascades that drive synaptic potentiation (Lisman et al., 
2002; Lüscher & Malenka, 2012). Sustained high [Ca2+]i, however, initiates signaling cascades 
that result in neuronal death (Choi, 1987, 1992; Tymianski et al., 1993; Lau & Tymianski, 2010). 
Cell death elicited by NMDAR overactivation, known as excitotoxicity, is a key feature of many 
nervous system disorders including Alzheimer’s disease, Alzheimer’s disease-related dementias, 
Huntington’s disease, and cell death following stroke or ischemia (Zorumski & Olney, 1993; 
Lipton, 1999, 2004; Hynd et al., 2004; Koutsilieri & Riederer, 2007; Dong et al., 2009; Olivares et 
al., 2012; Mota et al., 2014; Gardoni & Di Luca, 2015; Wang & Reddy, 2017). Thus, NMDAR-
mediated Ca2+ influx must be tightly regulated for proper nervous system function. 
Although NMDARs are attractive targets for modulation by neurotherapeutic drugs, 




of NMDARs in normal neuronal function, arbitrary inhibition of NMDARs generates unacceptable 
side effects (Olney et al., 1989; Zorumski & Olney, 1993; Krystal et al., 1994; Muir, 2006). The 
specific inhibition of select subpopulations of NMDARs involved in disease may provide an 
avenue around the detrimental side effects of broad-scale NMDAR inhibition. A potential strategy 
for targeting specific NMDAR subpopulations is to target NMDARs based on subunit composition. 
NMDAR subunits are encoded by seven genes: a single GRIN1 gene encodes the GluN1 subunit, 
four GRIN2 genes encode GluN2A-GluN2D subunits, and two GRIN3 genes encode GluN3A-
GluN3B subunits. To add to this broad subunit diversity, the GluN1 subunit also has 8 distinct 
splice variants (Traynelis et al., 2010). NMDARs are heterotetrameric complexes typically 
assembled from two obligatory GluN1 subunits and two GluN2 subunits (Karakas & Furukawa, 
2014; Lee et al., 2014). The specific combination of GluN1 splice variants and GluN2 subunits 
governs many NMDAR characteristics including subcellular localization, intracellular signaling 
partners, and biophysical features such as agonist affinity, gating kinetics, channel block, and 
pharmacology (Hardingham & Bading, 2010; Siegler Retchless et al., 2012; Paoletti et al., 2013; 
Hansen et al., 2014; Glasgow et al., 2015; Stroebel et al., 2018; Yi et al., 2018).  
Most attempts to selectively target NMDAR subpopulations have focused on developing 
drugs that can distinguish between NMDARs that contain different GluN2 subunits. In addition, 
most characterization of subtype-selective inhibitors of NMDAR has been performed on 
diheteromeric receptors composed of two GluN1 subunits and two identical GluN2 subunits. 
However, neurons can also co-express multiple different GluN2 subunits that can co-assemble to 
form complex triheteromeric receptors (Tovar et al., 2013; Bhattacharya et al., 2018; Stroebel et 
al., 2018; Yi et al., 2018), the pharmacology of which is poorly understood. Perhaps due to this 
vast subtype diversity, subtype-selective antagonism has not yet produced clinically useful drugs, 




The most clinically successful NMDAR antagonists are channel blockers. Open channel 
blockers are drugs that bind in and prevent ion flux through open ion channels. However, most 
open channel blockers can elicit powerful and dangerous side effects, likely due to indiscriminate 
inhibition of large populations of NMDARs (Olney et al., 1989; Zorumski & Olney, 1993; Krystal 
et al., 1994). In stark contrast to other moderate and high-affinity NMDAR channel blockers, the 
adamantane derivative memantine is remarkably well-tolerated (Parsons, Danysz, & Quack, 
1999; Chen & Lipton, 2006). Memantine is a clinically approved treatment for Alzheimer’s disease 
(Witt et al., 2004; Mecocci et al., 2009; Danysz & Parsons, 2012) and shows promise in treating 
many other disorders including Parkinson’s disease, Alzheimer’s disease-related dementias, 
post-stroke cell death and dementia, schizophrenia, and disorders associated with rare de novo 
mutations of NMDAR subunits (Sonkusare et al., 2005; Lipton, 2006; Parsons et al., 2007; 
Berthier et al., 2009; Olivares et al., 2012; Pierson et al., 2014; Johnson et al., 2015; Di Iorio et 
al., 2017; Zheng et al., 2018). A leading hypothesis regarding the clinical safety of memantine is 
that memantine may preferentially inhibit subpopulations of NMDARs involved in disease (Zhao 
et al., 2006; Léveillé et al., 2008; Okamoto et al., 2009; Xia et al., 2010), which may arise from 
the ability of memantine to modulate NMDAR gating.  
Memantine acts not only by blocking ion flux through NMDARs, but also by stabilizing a 
desensitized state of the NMDAR channel. Desensitized states are closed, agonist-bound states 
the occupancy of which can vary significantly by NMDAR subtype and physiological context 
(Benveniste et al., 1990; Krupp et al., 1996, 1998; Villarroel et al., 1998; Glasgow et al., 2017). 
We recently reported that memantine enhances NMDAR desensitization in a subtype- and 
context-specific manner (Glasgow et al., 2017). Memantine profoundly slows recovery of 
GluN1/2A receptors, but not GluN1/2B receptors, from desensitization. The effect of memantine 
on desensitization was absent in low extracellular Ca2+, and memantine inhibition of GluN1/2A 




(Glasgow et al., 2017). These data suggest that memantine stabilizes a Ca2+-dependent 
desensitized state of the GluN1/2A receptor. Ca2+-dependent desensitization (CDD; also termed 
Ca2+-dependent inactivation) is elicited by increases in [Ca2+]i (Legendre et al., 1993; Rozov & 
Burnashev, 2016; Iacobucci & Popescu, 2017, 2020) and acts as an endogenous negative-
feedback loop by reducing NMDAR-mediated Ca2+ influx in response to increasing [Ca2+]i.  
Stabilization of a Ca2+-dependent state by memantine offers a rational mechanism by which 
memantine can target specific NMDAR subpopulations involved in disease: preferential inhibition 
of NMDARs in neurons experiencing long durations of high Ca2+ influx, i.e. subpopulations of 
NMDARs involved in excitotoxicity. Selective inhibition of overactive NMDARs is an ideal property 
of a neuroprotective drug, and the elucidation of the mechanistic underpinnings of Ca2+-
dependent inhibition of NMDARs by memantine may aid in the design of more efficacious 
neuroprotectants.  
Here we further investigated the relation between NMDAR CDD and the mechanism of 
action of memantine. Through electrophysiological recordings and manipulation of [Ca2+]i, we 
found that memantine inhibition of GluN2A-containing NMDARs is directly dependent on [Ca2+]i. 
This [Ca2+]i dependence of memantine action is also dependent on the ability of the receptor to 
access a Ca2+-dependent desensitized state. We found that although both GluN1/2A and 
GluN1/2A receptors exhibit CDD, [Ca2+]i-dependent inhibition by memantine is a GluN2A-specific 
phenomenon, suggesting that the relation between CDD and memantine inhibition is subtype-
specific. Together, these results strongly support the hypothesis that memantine stabilizes a Ca2+-
dependent desensitized state of GluN2A-containing NMDARs and present a previously 





2.3 MATERIALS AND METHODS 
2.3.1 Cell culture and transfection 
Experiments were performed in tsA201 cell cultures (European Collection of Authenticated 
Cell Cultures) or primary cortical neuron cultures. tsA201 cells were maintained as previously 
described (Glasgow & Johnson, 2014) in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum and 1% GlutaMAX (Thermo Fisher Scientific). Cells 
were plated at a density of 105 cells/dish in 35 mm petri dishes on 15 mm glass coverslips treated 
with poly D-lysine (0.1 mg/mL) and rat-tail collagen (0.1 mg/mL). 18-24 hours after plating, the 
cells were transfected using FuGENE 6 (Promega) with complementary DNA (cDNA) coding for 
enhanced green fluorescent protein (EGFP; Genbank ACS32473 in pCI-neo or pIRES) to identify 
transfected cells, WT rat GluN1-1a (GluN1; GenBank X63255 in pcDNA3.1 or U08261 in pCI-
neo), and either GluN2A (GenBank M91561 in pcDNA1 or D13211 in pIRES), GluN2B (GenBank 
M91562 in pcDNA1), GluN2C (GenBank M91562 in pcDNA1), or GluN2D (GenBank L31611 in 
pcDNA1). EGFP was expressed using one of two plasmids: pCI-neo:EGFP:GluN1-1a or 
EGFP:pIRES:GluN2A, both kind gifts from Dr. Kasper Hansen.  pCI-neo:EGFP:GluN1-1a was 
constructed by inserting cDNA encoding EGFP in pCI-neo under transcriptional control of the 
CMV promoter, between the CMV promoter and the GluN1 open reading frame (Yi et al., 2018). 
EGFP:pIRES:GluN2A was constructed by inserting cDNA encoding EGFP between the CMV 
promoter and the GluN2A open reading frame in pIRES, with the internal ribosome entry site (i.e., 
the IRES) between the EGFP and GluN2A open reading frames. Both plasmids allow for co-
expression of independent EGFP and NMDAR subunit proteins.  For experiments with GluN1/2A 
receptors, cells were transfected with cDNA ratios of 1 GluN1: 1 GluN2. Cells were transfected 




GluN1/2C, and GluN1/2D receptors. 200 μM of the competitive NMDAR antagonist dl-APV was 
added to medium at the time of transfection to prevent NMDAR-mediated cell death. 
Primary cortical cultures (provided by Karen Harnett-Scott and Dr. Elias Aizenman of the 
University of Pittsburgh) were prepared from embryonic day 16 rats of both sexes. Pregnant rats 
(Charles River Laboratories) were sacrificed via CO2 inhalation. Brains of embryonic rats were 
dissected, and cortices were dissociated with trypsin. Dissociated neurons were then plated at a 
density of 6.6 *105 to 7.0 * 105 cells/well on 15 mm glass coverslips in 6-well plates. Coverslips 
were acid-etched and treated with either poly-L-ornithine or poly-D-lysine prior to plating. Neurons 
were maintained in D10FC medium during days in vitro (DIV) 1-18. Non-neuronal cell proliferation 
inhibited on DIV 15 by adding 1-2 μM cytosine arabinosine (AraC) to D10FC. AraC and D10FC 
were removed on DIV18 and cells were maintained in D2C medium from DIV18 onward. 
2.3.2 Electrophysiology  
Patch-clamp electrophysiological experiments were performed in the whole-cell voltage-
clamp configuration. Recordings from tsA201 cells were performed 18-30 hours after transfection. 
Recordings from cultured neurons were performed after DIV 15 to allow for adequate GluN2A 
subunit expression, which occurs after roughly two weeks in vitro (Zhong et al., 1994; Li et al., 
1998; Sinor et al., 2000). Pipettes were fabricated from borosilicate capillary tubing (outer 
diameter = 1.5 mm, inner diameter = 0.86 mm) using a Flaming Brown P-97 electrode puller 
(Sutter Instruments) and fire-polished to a resistance of 3.0 – 4.5 MΩ for tsA201 cell recordings 
or 3.5 – 5.0 MΩ for neuronal recordings. Whole-cell currents were amplified with Axopatch 1D or 
Axopatch 200A amplifiers and digitized using a Digidata 1440A digitizer (Molecular Devices). 
Current signals were low-pass filtered at 5 kHz and sampled at 20 kHz using pCIamp10.7 




and data from cells with series resistance > 20 ΜΩ was excluded from analysis. In all experiments, 
an empirically determined liquid junction potential of -6 mV between the internal and external 
solutions was corrected. For experiments in Figures 4 – 7 and 10, data was collected 5 – 10 min 
after break-in. 
Control bath solution (referred to as external solution) for tsA201 cell experiments 
contained (in mM): 140 NaCl, 2.8 KCl, 10 HEPES, 0.01 EDTA, 0.1 glycine, and either 0.1 or 1 
CaCl2. For all neuronal experiments, external solution contained 140 NaCl, 2.8 KCl, 10 HEPES, 
0.01 EDTA, 0.01 glycine (lowered from tsA201 cell experiments to prevent activation of inhibitory 
glycine receptors), and 0.1 CaCl2, with 0.2 μM tetrodotoxin (TTX) added to prevent synaptic 
events or action potential escape. Agonists and antagonists were added to external solutions on 
day of experiments. 1 mM glutamate (diluted from 1 M stock) was used for tsA201 cell 
experiments, and 10 μM NMDA (diluted from 10 mM stock) for neuronal experiments. Various 
concentrations of memantine and ketamine (both diluted from 10 mM stocks in dH2O) were used 
for both tsA201 cell and neuronal experiments. For IC50 measurements, antagonist solutions were 
prepared via serial dilution. Control, agonist, and antagonist solutions were delivered to the 
patched cell via ten polyimide barrels using our in-house fabricated rapid-switching fast perfusion 
system (Glasgow & Johnson, 2014). Switches between solutions were performed by moving the 
barrel position relative to the patched cell with a voice-coil motor controlled by a custom program 
(Blanpied et al., 1997). Solution flow rate was maintained at 1 – 2 mL/min for all experiments. 
2.3.3 Intracellular solution preparation and determination of free [Ca2+] 
All intracellular (pipette) solutions contained 120 – 130 mM CsCl, 10 mM HEPES, and 4 
mM MgATP and were pH balanced to 7.2 ± 0.05 with CsOH. To allow for study of the effects of 




concentrations of CaCl2 and empirically determined concentrations of BAPTA, HEDTA, or NTA to 
buffer Ca2+ to desired concentrations. Because estimation of free Ca2+ concentrations ([Ca2+]F) in 
buffered solutions are subject to multiple sources of error (McGuigan et al., 2016), we utilized the 
Ligand Optimization Method (LOM (McGuigan et al., 1991, 2006)) to (1) aid in the design of 
intracellular solutions containing known concentrations of buffered [Ca2+]F and (2) empirically 
determine [Ca2+]F following solution preparation. The LOM is a multi-step process that obtains the 
best fit of the Nicolsky-Eisenman equation (Nicolsky et al., 1967) to data measured with a Ca2+-
selective electrode by optimizing four parameters vital to accurate determination of [Ca2+]F: the 
slope of the electrode at [Ca2+] < 10 μM (s), the lumped interference constant (Σ) describing the 
nonlinearity of the electrode at low [Ca2+]F, the total concentration of the Ca2+-binding buffer ([B]T), 
and the Kd of the buffer.  
All solutions used for the LOM were prepared from a background solution containing 120 
mM CsCl and 10 mM HEPES and balanced to pH 7.2 with CsOH. Ionic content of the background 
solution was designed to mimic our typical intracellular solutions. Seven calibration solutions, 
necessary for determination of s, were prepared by adding CaCl2 to background solution to 
produce total [Ca2+] ([Ca2+]T) ranging from 0.5 - 10 mM. 10 Ca2+-buffer solutions containing 10 
mM of the calcium chelators BAPTA, HEDTA, or NTA (measured by weight) and known 
concentrations of [Ca2+]T were prepared from background solution using the ratiometric method 
(McGuigan et al., 2014). All measurements of [Ca2+]F were made at 25o C using a Ca2+-selective 
combination electrode that converts effective concentrations of free Ca2+ ions into electrical 
potentials according to the Nernst equation (Orion 9720BNWP, ThermoFisher) and a pH meter in 
mV mode (Accument AR15, ThermoFisher). To obtain values for fitting of the Nicolsky-Eisenman 
equation, electrical potentials of the calibration solutions were first measured in order of 
descending [Ca2+]T, followed by measurement of electrical potentials of the Ca2+-buffer solutions 




each solution by subtracting the potential measured in the [Ca2+]T = 10 mM calibration solution. 
The relative potentials were then fit using the program CaSALE, a custom R script written 
specifically for use with the LOM (kindly provided by Dr. James Kay; (McGuigan et al., 2014)) that 
automizes the iterative optimization of s, Σ, [B]T, and Kd. Values of optimized parameters are listed 
in Table 2. 
After LOM curves were obtained for each Ca2+ buffer (Figure 3), [Ca2+]Ts required to give 
desired [Ca2+]F in our intracellular solutions were calculated using the optimized [B]T, and Kd 
values with Equation 1: 
Buffers with Kd closest to the target [Ca2+]F were used for each solution: BAPTA (Kd = 144 
nM) for [Ca2+]F < 1 μM, HEDTA (Kd = 2.24 μM) for [Ca2+]F 1 – 10 μM, and NTA (Kd = 81.5 μM) for 
[Ca2+]F > 10 μM. The calculated [Ca2+]T was added to background solution containing the specified 
buffer and 4 mM MgATP and the solution was pH balanced with CsOH. ΔE was then recorded 
for the prepared solution and was used, along with the optimized s and Σ values, to confirm the 
final [Ca2+]F with Equation 2: 
where E0 represents the intrinsic potential of the recording system, a parameter determined by 
CaSALE calculations. Final [Ca2+]F were confirmed to vary from the value predicted by the LOM 
curve by less than 2% on average (Table 3). All Ca2+-buffer solutions were prepared using the 
LOM except for the [Ca2+]F = 5 μM solution, which was prepared using the program 
MAXCHELATOR (Bers et al., 2010) and later measured using the LOM. The original intention 
was to prepare a [Ca2+]F = 10 μM solution using MAXCHELATOR estimates, but MAXCHELATOR 
does not account for buffer purity or the effect of background solution composition on buffer Kd 
[Ca2+]F =  10
ΔE − Eo
s  –  Σ 
[Ca2+]T =
([Ca2+]F )([B]T + [Ca
2+]F +  Kd)





values (McGuigan et al., 2016; Tran et al., 2018). The HEDTA Kd value utilized by 
MAXCHELATOR is substantially higher than most measurements in solutions of similar 
composition to our intracellular solution (Tran et al., 2018) as well as our LOM measurements 
(MAXCHELATOR Kd = 7.2 μM; LOM Kd = 2.24 μM) which resulted in preparation of a solution 
with substantially lower [Ca2+]F than predicted (MAXCHELATOR predicted [Ca2+]F = 10 μM; LOM 
measured [Ca2+]F = 4.87 μM), illustrating the importance for precise measurement of [Ca2+]F in 
buffered solutions. 
2.3.4 Analysis 
All electrophysiology data were analyzed with Clampfit 10.7 (Molecular Devices) and 
Prism 7-9 (Graphpad). Baseline current was subtracted from all current measurements. 
Concentration-inhibition relations for channel blockers were measured using the protocol shown 
in Figure 4A. Agonist was applied until current reached steady-state (ISS), then sequentially 
increasing concentrations of antagonist were applied in the presence of constant [agonist]. Each 
antagonist solution was applied until a steady level of inhibition was reached (10 – 20 s for 
GluN1/2A receptors, 20 – 30 s for GluN1/2B GluN1/2C, and GluN1/2D receptors and in neuronal 
experiments). Antagonists were then removed and agonist alone was reapplied to allow recovery 
from channel block. Cells in which current did not recover to at least 85% of the steady-state 
current elicited by the initial agonist application were excluded from analysis. IC50 values were 













where IDrug represents the mean ISS over the final 1 s of drug application at a particular [Drug], IGlu 
is the average of the mean ISS over the final 1 s of the agonist application preceding drug 
application and the mean ISS over the final 1 s of the agonist application following recovery from 
inhibition, and nH is the Hill coefficient. IC50 and nH were free parameters during fitting. The effect 
of [Ca2+]i on memantine potency was quantified with a modified version of the Hill equation,  
Equation 4:  
where IC50 represents the memantine IC50 measured at each [Ca2+]i, maxIC50 represents the 
maximal IC50 (the IC50 recorded at [Ca2+]i < 1 nM), minIC50 represents the minimal IC50  value, 
CaEC50 represents the [Ca2+]i that elicits a half maximal effect on memantine potency, and nH is 
the Hill coefficient. CaEC50 and nH were free parameters during fitting.  
The time course of recovery from desensitization (RfD) for GluN1/2A receptors was 
measured using the protocol shown in Figure 5. Patched cells were subjected to repeated 
glutamate applications in the absence of antagonist or the presence of the indicated antagonist 
concentration following inter-application intervals of 1, 2, 5, 10, 20, 50, 100, and 200 s in random 
order or in order of increasing or decreasing duration. Figure 5 shows an example experiment 
using inter-application intervals of increasing length. Peak currents (IPeak) following each inter-
application interval were measured as the mean current over a 30 ms window centered around 
the peak absolute current. Ipeaks were then normalized to the IPeak following the 200 s inter-
application interval to account for current rundown or changes in recording parameters. Cells 
where normalized IPeak for any inter-application interval exceeded 1.2 were excluded from 
analysis. Plot of normalized IPeaks as a function of inter-application interval were fit with either 
single or double exponential functions to determine time constants for RfD. To allow for 












comparison with single exponential time constants (τ), double exponential time constants were 
converted to a weighted time constant (τw) using Equation 5:  
where τfast, Afast, τslow, and Aslow represent the time constant and amplitude of the fast component 
and the time constant and amplitude of the slow component, respectively.  
For experiments measuring the effect of [Ca2+]i on desensitization, desensitization was 
quantified as a ratio of Iss to IPeak. Iss was measured as in IC50 experiments. IPeak was measured as 
in RfD experiments.  
 
  
τw =  
(τfast ∗ Afast)  + (τslow ∗ Aslow)









Optimized Parameter BAPTA HEDTA NTA 
s (mV/decade Ca2+) 28.7 28.8 28.3 
Σ 8.47 * 10-9 7.64 * 10-18 1.79 * 10-16 
[B]T (M) 9.49 * 10-3 9.04 * 10-3 8.71 * 10-3 
Kd (M) 1.44 * 10-7 2.24 * 10-6 8.15* 10-5 





Figure 3. Ligand Optimization Method.  
A-C, Ligand Optimization Method for BAPTA (A), HEDTA (B), and NTA (C). Line represents best fit of the 
Nicolsky-Eisenmann equation to ΔE values after final optimization of [B]T, Kd, s, and Σ. Points represent 





Table 3. Measured [Ca2+]F values  Ca2+-Buffer solutions. 
#5 μM solution prepared using MAXCHELATOR predictions, with [Ca2+]F measured under the assumption 
that  [B]T did not substantially vary between solutions. All other solutions prepared using LOM predictions. 
All [Ca2+]F values measured using LOM after final solution preparation. 
Target [Ca2+]F 
(M) 







1 * 10-8 BAPTA 6.16 * 10-4 -164.58 -164.6 9.98 * 10-9 
1 * 10-7 BAPTA 3.89 * 10-3 -142.51 -142.5 1.00 * 10-7 
1 * 10-6 HEDTA 2.79 * 10-3 -115.07 -115.1 9.98 * 10-7 
#5 * 10-6 HEDTA 6.20 * 10-3 NA -95.3 4.87 * 10-6 
1 * 10-5 HEDTA 7.39 * 10-3 -86.30 -86.3 1.00 * 10-5 







2.4.1 Ca2+-dependent block of GluN1/2A receptors by memantine 
Memantine augments desensitization of GluN1/2A receptors by slowing recovery from, 
and therefore increasing occupancy of, a Ca2+-dependent desensitized receptor state (Glasgow 
et al. 2017). To further parse the relation between memantine block and CDD, we used whole cell 
patch-clamp recordings to measure memantine potency while “clamping” [Ca2+]i with Ca2+-
buffering pipette solutions containing known [Ca2+]F and high concentrations of Ca2+ buffer. 
Estimation of [Ca2+]F in buffered solutions is often performed using freely available software 
(Schoenmakers et al., 1992; McGuigan et al., 2006; Bers et al., 2010) and requires the Ca2+-
binding affinity (Kd) and the purity of the buffer ([B]T) to be known. However, reported Kd values 
for commonly used Ca2+ buffers vary considerably and the purity of many Ca2+ buffers is reduced 
by binding to H2O while in solid form (McGuigan et al., 2016). Thus, accurate estimation of [Ca2+]F 
in buffered solutions difficult. To avoid misestimation of [Ca2+]F in our pipette solutions, we utilized 
the Ligand Optimization Method ((Luthi et al., 1997; McGuigan et al., 2006, 2007, 2016); see 
Methods section for details) to obtain accurate Kd and [B]T values for each buffer used and 
empirically measure the [Ca2+]F in our pipette solutions (Table 3). Furthermore, we performed 
recordings in low extracellular [Ca2+] ([Ca2+]e = 0.1 mM) to minimize the impact of Ca2+ influx on 
[Ca2+]i and limit any confounding effects of [Ca2+]e on NMDAR channel function (Ascher and 
Nowak 1988, Maki and Popescu 2014). Thus, we were able to isolate and examine the effect of 
[Ca2+]i on memantine potency.  
Recordings from transfected tsA201 cells expressing GluN1/2A diheteromers revealed a 
clear dependence of memantine potency on [Ca2+]i (Figure 4A-D). Memantine inhibition was 




culminating in a striking ~4-fold difference in potency between the lowest and highest [Ca2+]i 
conditions (Figure 4C; [Ca2+]i < 1 nM IC50 = 2.76 ± 0.27; [Ca2+]i = 50 μM IC50 = 0.70 ± 0.06 μM, n 
= 5). This effect appeared to saturate at roughly [Ca2+]i = 5 μM (Figure 4C,D). Memantine inhibition 
was sensitive not only to levels of [Ca2+]i consistent with active signaling (1 μM) and pathological 
conditions (5 – 50 μM) in neurons, but also low [Ca2+]i’s at (100 nM) or even below (10 nM) resting 
levels, indicating that memantine potency is sensitive to [Ca2+]i across a physiologically important 
range. To quantify the effect of [Ca2+]i on inhibition by Mem, we fit the memantine IC50 data as a 
function of [Ca2+]i using a modified version of the Hill equation (Equation 4). The relatively linear 
middle portion of the [Ca2+]i-Memantine IC50 curve spans the entire range of physiological [Ca2+]i 
observed in neurons, with the half maximal effect of [Ca2+]i reached at [Ca2+]i = 54 nM (Figure 4D). 
These results suggest that memantine inhibition of GluN1/2A receptors is dynamically regulated 
by physiological fluctuations in [Ca2+]i.  
Although it is likely that the primary effect of [Ca2+]i on NMDARs in our experiments is 
modulation of CDD, manipulating [Ca2+]i may alter other NMDAR channel properties that broadly 
affect channel block (Lan et al., 2001; Skeberdis et al., 2006; Murphy et al., 2014). To determine 
whether the effect of [Ca2+]i on memantine IC50 could be attributed to a general effect of [Ca2+]i on 
channel block, we measured the effect of [Ca2+]i on the IC50s of the prototypical NMDAR channel 
blocker Mg2+ and of another clinically important organic channel blocker, ketamine. Neither Mg2+ 
IC50 (Figure 4E,F) nor ketamine IC50 (Figure 4G,H) showed any dependence on [Ca2+]i, 
suggesting that [Ca2+]i has no broad effects on channel block. The [Ca2+]i-independent nature of 
ketamine potency is consistent with our previous findings that ketamine has no effect on CDD 
(Glasgow et al., 2017), supporting the idea that the [Ca2+]i dependence of memantine IC50 is 







Figure 4. Ca2+-dependent block of GluN1/2A receptors by memantine. 
 A, Overlay of WT GluN1/2A receptor currents used to measure memantine (Mem) concentration-inhibition 
curves during application of glutamate (Glu; black bar) and memantine (red bars) For visualization of 
differences in inhibition, only traces in conditions of [Ca2+]i < 1 nM (grey), [Ca2+]i = 1 μM (teal), and [Ca2+]i = 
10 μM (blue) are shown. [Ca2+]e = 0.1 mM to prevent Ca2+ influx from altering [Ca2+]i. Currents are 
normalized to steady state current measured in 0 memantine. B, Memantine concentration-inhibition curves 
for [Ca2+]i = 10 μM (blue), 1 μM (teal), 100 nM (light blue), 10 nM (gold), and < 1 nM (grey). Lines depict fit 
of Hill equation (Equation 3) to data. C, Summary of memantine IC50 values measured at the indicated 
[Ca2+]i (< 1 nM Ca2+i: IC50 = 2.76 ± 0.27 μM, n = 9; 10 nM Ca2+i: IC50 = 1.93 ± 0.07 μM, n = 6; 100 nM Ca2+i: 
IC50 = 1.76 ± 0.12 μM, n = 5; 1 μM Ca2+i: IC50 = 1.07 ± 0.04 μM, n = 4; 5 μM Ca2+i: IC50 = 0.69 ± 0.06 μM, n 
= 5 10 μM Ca2+i: IC50 = 0.69 ± 0.05 μM, n = 5; 50 μM Ca2+i: IC50 = 0.70 ± 0.06 μM, n = 5). ANOVA with 
Sidak’s post hoc test. *p < 0.05, **p < 0.01, ****p < 0.0001. D, Curve describing the effect of [Ca2+]i on 
memantine IC50. Line depicts fit of Equation 4 to data. Memantine becomes more potent (i.e. IC50 
decreases) as [Ca2+]i increases. Dashed line at memantine IC50 = 0.69 μM depicts minimum IC50. Dotted 
lines and open circle show the [Ca2+]i required to induce a half-maximal effect on memantine IC50 ([Ca2+]i = 
54 nM). E, Mg2+ concentration-inhibition curves for [Ca2+]i < 1 nM (grey) and [Ca2+]i = 10 μM (blue). Lines 




= 39.9 ± 3.3 nM, n = 6) and 10 μM (blue; IC50 = 38.3 ± 2.7 nM, n = 7). 2-tailed Student t-test, p = 0.72. G, 
Ketamine concentration-inhibition curves for [Ca2+]i < 1 nM (grey) and [Ca2+]i = 10 μM (blue). Lines depict 
fit of Hill equation to data. H, Summary of ketamine IC50 values measured at [Ca2+]i of < 1 nM (grey; IC50 = 
0.82 ± 0.04, n = 6) and 10 μM (blue; IC50 = 0.78 ± 0.03 μM, n = 7). 2-tailed Student t-test, p = 0.46. For C, 
F, and H, points represent individual values, bars and error bars depict mean ± SEM. For B, D, E, and G, 
data are depicted as mean ± SEM and some error bars are smaller than symbols. Intracellular Ca2+-
buffering conditions for each internal solution used (i.e. [Ca2+]T and buffer) are given in Table 3, and [B]T for 




2.4.2 Ca2+-dependent desensitization is required for Ca2+-dependent block of GluN1/2A 
receptors by memantine  
To determine whether memantine enhances GluN1/2A receptor desensitization by 
stabilizing a Ca2+-dependent desensitized receptor state, we assessed the involvement of the 
GluN1 C-terminal domain (CTD) in two key phenomena: the effect of memantine on recovery of 
GluN1/2A receptors from desensitization, and the effect of [Ca2+]i on memantine potency. The C0 
region of the GluN1 CTD, a short sequence located ~30 amino acid resides after the 
transmembrane domain, is included in all GluN1 splice variants and is the primary structural 
mediator of NMDAR CDD via its interactions with calmodulin (Ehlers et al., 1996; Zhang et al., 
1998; Krupp et al., 1999). Truncation of the GluN1 subunit proximal to C0 (GluN1ΔCTD) 
eliminates CDD (Ehlers et al., 1996; Zhang et al., 1998; Krupp et al., 1999) without affecting other 
desensitization mechanisms (Krupp et al., 1998), allowing us to examine whether entry into a 
Ca2+-dependent desensitized state is required for the effects of [Ca2+]i on memantine action.  
We measured the time course of recovery from desensitization (RfD) of GluN1/2A WT and 
GluN1ΔCTD/2A mutant receptors in the presence and absence of 3 μM memantine to assess 
whether the GluN1 CTD is involved in memantine’s ability to stabilize a Ca2+-dependent 
desensitized state. Consistent with previous results (Glasgow et al., 2017), memantine greatly 
slowed RfD of WT GluN1/2A receptors in [Ca2+]e = 1 mM (Figure 5A,B,E,G) but showed no effect 
on RfD in [Ca2+]e = 0.1 mM (data not shown). The effect of memantine on RfD in [Ca2+]e = 1 mM 
was ablated by truncation of the GluN1 CTD (Figure 5C,D,F,G). RfD of GluN1ΔCTD/2A mutant 
receptors showed no sensitivity to memantine and did not significantly differ from RfD of WT 
receptors in the absence of memantine (Figure 5G), confirming that the effect of memantine on 




We then compared memantine IC50 values in [Ca2+]e = 0.1 mM for WT and GluN1ΔCTD 
mutant receptors in conditions of low ([Ca2+]i <1 nM) and high ([Ca2+]i = 5 μM) intracellular Ca2+. 
WT receptors again displayed robust [Ca2+]i-dependence of block by memantine. However, [Ca2+]i 
had no effect on block of GluN1ΔCTD/2A receptors (Figure 6). Additionally, GluN1ΔCTD mutant 
IC50 values in both conditions did not significantly differ from the WT value in the low [Ca2+]i 
condition (Figure 6C), revealing that the sensitivity of memantine IC50 to [Ca2+]i is entirely 
dependent on the GluN1 CTD. Consistent with our hypothesis, truncation of the GluN1 CTD also 
ablated CDD (Figure 6 D,E). Together, our results provide powerful evidence that the slowing of 
GluN1/2A receptor RfD by memantine and the [Ca2+]i dependence of memantine inhibition both 







Figure 5. The GluN1 C-terminal domain is required for enhancement of GluN1/2A receptor 
Ca2+-dependent desensitization by memantine. 
A-D, Representative current traces of WT GluN1/2A (A, B) and GluN1ΔCTD/2A receptor responses to 1 
mM Glu (black bars) after inter-application intervals of decreasing duration in the absence (A, C) and 
presence (B, D) of 3 μM memantine (red bars). Dotted line placed at IPeak after the 200 s inter-application 
interval to allow for visualization of differences between peaks. E, F, Exponential fits to time course of RfD 
data. Symbols depict normalized IPeak values (see Section 2.3.4) for WT receptors (E) or GluN1ΔCTD/2A 
receptors (F). Data are depicted as mean ± SEM and some error bars are smaller than symbols. G, 
Summary and comparison of time constant of RfD values (WT Control τ = 4.66 ± 0.95 s, n = 8; WT Mem τw 
= 44.56 ± 3.46 s; GluN1ΔCTD Control τ = 2.58 ± 0.32 s; n = 4; GluN1ΔCTD Mem τ = 2.58 ± 0.32 s; n = 4). 
ANOVA with Tukey’s post hoc test; ****p < 0.0001. Points represent individual values, bars and error bars 





Figure 6. Ca2+dependent block by memantine requires the GluN1 C-terminal domain. 
A, Representative GluN1ΔCTD/2A receptor currents used to measure memantine concentration-inhibition 
relations in conditions of [Ca2+]i = <1 nM (grey) and 5 μM (blue) in 0.1 mM Ca2+e. B, Concentration-inhibition 
curve for memantine at [Ca2+]i = <1 nM and 5 μM. Points represent mean; error bars smaller than points. 
C, Summary of memantine IC50 values for WT GluN1/2A and GluN1ΔCTD/2A receptors in conditions of 
[Ca2+]i  <1 nM and [Ca2+]i = 5 μM. GluN1 CTD truncation ablates the effect of [Ca2+]I on memantine IC50 (for 
GluN1ΔCTD/2A receptors, [Ca2+]i < 1 nM: 2.13 ± 0.27 μM, n = 4; [Ca2+]i = 5 μM: 2.18 ± 0.34 μM, n = 4). 2-
way ANOVA (interaction p < 0.001) with Tukey post hoc test for multiple comparisons (***p < 0.001, ****p 
< 0.0001). Points represent individual values, bars and error bars show mean ± SEM. D, Overlay of 
GluN1ΔCTD/2A receptor currents used to measure desensitization with [Ca2+]i = <1 nM (grey) and 5 μM 
(blue) in 0.1 mM Ca2+e. Currents are normalized to IPeak. E, Comparison of ISS/IPeak values across conditions 
of [Ca2+]i  <1 and [Ca2+]i = 5 μM. No difference in desensitization was observed (Student t-test). Intracellular 
Ca2+-buffering conditions for each internal solution used (i.e. [Ca2+]T and buffer) are given in Table 3, and 




2.4.3  [Ca2+]i-dependent block by memantine depends on receptor subtype 
NMDARs display great diversity in subunit composition. The GluN2 subunit strongly 
influences many biophysical properties of NMDARs, including channel block and desensitization 
(Krupp et al., 1996, 1998; Siegler Retchless et al., 2012; Glasgow et al., 2015, 2017). However, 
the dependence of CDD on GluN2 subunit identity, and therefore the dependence of [Ca2+]i-
dependent block by memantine on GluN2 subunit identity, is still ambiguous. CDD has been 
reported in GluN1/2A, GluN1/2B, and GluN1/2D receptors, but not GluN1/2C receptors (Krupp et 
al., 1996; Iacobucci & Popescu, 2020). However, while GluN1/2A CDD is well-characterized 
(Ehlers et al., 1996; Krupp et al., 1996, 1999, 2002; Zhang et al., 1998; Iacobucci & Popescu, 
2017, 2020), our understanding of GluN1/2B and GluN1/2D CDD is far less clear. GluN1/2A 
receptors display obvious CDD across a broad array of experimental conditions (Ehlers et al., 
1996; Krupp et al., 1996; Iacobucci & Popescu, 2017, 2020). On the other hand, studies of CDD 
in GluN1/2B receptors have drawn inconsistent conclusions. GluN1/2B receptors were originally 
reported not to display CDD (Krupp et al., 1996), but recent studies have detailed that CDD of 
GluN1/2B receptors can be achieved in conditions of very high [Ca2+]i (Iacobucci & Popescu, 
2020). Furthermore, we have previously shown that memantine enhances CDD of GluN1/2A 
receptors but has no effect on GluN1/2B receptor desensitization(Glasgow et al., 2017), 
suggesting that either GluN1/2A and GluN1/2B receptors are differentially sensitive to Ca2+ or that 
distinct mechanisms underlie CDD of GluN1/2A and of GluN1/2B receptors. Furthermore, CDD 
of GluN1/2D receptors has only been investigated using experiments manipulating [Ca2+]e (Krupp 
et al., 1996; Iacobucci & Popescu, 2020). Therefore, we sought to further elucidate the link 
between CDD and [Ca2+]i-dependent block by memantine by investigating the effect of [Ca2+]i on 




We performed recordings from transfected tsA201 cells expressing GluN1/2A, GluN1/2B, 
GluN1/2C, or GluN1/2D receptors to measure desensitization and memantine potency in 
conditions of [Ca2+]i <1 nM and [Ca2+]i = 10 μM. As expected, GluN1/2A receptors exhibited both 
robust [Ca2+]i dependence of block by memantine (Figure 7A,E,I)  and strong CDD, showing 
substantially larger steady-state current/peak current ratios (Iss/IP) with [Ca2+]i <1 nM than with 
[Ca2+]i = 10 μM (Figure 7A,M). In contrast, GluN1/2B receptors displayed weak CDD (Figure 
7B,N), but inhibition by memantine was entirely insensitive to [Ca2+]i (Figure 7B,F,J). The lack of 
[Ca2+]i dependence of memantine block of GluN1/2B receptors is consistent with our previous 
observations that memantine has no effect on GluN1/2B receptor RfD (Glasgow et al., 2017). 
[Ca2+]i had no effect on either desensitization or memantine inhibition of GluN1/2C (Figure 
7C,G,K,O) or GluN1/2D receptors (Figure 7D,H,L,P). Interestingly, the GluN1/2A memantine IC50 
for cells with [Ca2+]i = 10 μM is nearly identical to the IC50 values in all other subtypes regardless 
of condition. Furthermore, inhibition of GluN1/2A receptors in cells with [Ca2+]i < 1 nM was 
substantially weaker than memantine inhibition of any other NMDAR subtype tested, regardless 
of condition (Figure 7I-L). These finding suggests two intriguing possibilities. First, Ca2+i may drive 
the memantine binding site in the GluN1/2A channel into a conformation that resembles the 
binding site in the other NMDAR subtypes. Second, the GluN1/2A receptor may access a 
conformation in conditions of low [Ca2+]i that is inaccessible by the other subtypes and exhibits 
weaker affinity for memantine. The accessibility of an additional state with weaker memantine 
affinity by GluN1/2A receptors may explain the discrepancies between memantine IC50 for 
GluN1/2A receptors and other GluN1/2 diheteromers reported previously (Parsons, Danysz, 







Figure 7. GluN2 subunit identity determines the effect of [Ca2+]i on memantine potency and 
NMDAR desensitization. 
A-D, Overlay of current traces used to measure memantine concentration-inhibition curves for indicated 
NMDAR subtype in cells with [Ca2+]i < 1 nM (grey) and [Ca2+]i = 10 μM (blue). [Ca2+]e = 0.1 mM. Traces are 
normalized to ISS before application of memantine to facilitate comparison of inhibition between [Ca2+]i 
conditions. Black bar depicts Glu application; red bars depict memantine applications. Insets depict overlay 
of response (normalized to IPeak) to 1 mM Glu in the absence of memantine used to measure ISS/IPeak. E-H, 




± SEM. Some error bars are smaller than points. I-L, Summary of IC50 values for indicated receptor subtype 
and [Ca2+]i. Inhibition of GluN1/2A receptors by memantine depends on [Ca2+]i. GluN1/2B, GluN1/2C, and 
GluN1/2D receptor inhibition is unaffected by [Ca2+]i. M-P, Summary of ISS/IPeak values for indicated receptor 
subtype and [Ca2+]i. GluN1/2A and GluN1/N2B receptors show CDD. Desensitization of GluN1/2C and 
GluN1/2D receptors does not depend on [Ca2+]i. Points represent individual values, bars and error bars 
show mean ± SEM; 2-tailed Student t-test, **p < 0.01, ***p < 0.001,****p < 0.0001. Intracellular Ca2+-
buffering conditions for each internal solution used (i.e. [Ca2+]T and buffer) are given in Table 3, and [B]T for 
each buffer is given in Table 2. Memantine IC50 and ISS/IPeak numeric values for all subtypes are summarized 






Table 4. Memantine block and desensitization of GluN1/2 diheteromeric receptors in low 
and high [Ca2+]i. 
Values represent means ± sem (n).  
 Memantine IC50 (μM) ISS/IPeak 
NMDAR Subtype [Ca2+]i  <1 nM [Ca2+]i = 10 μM [Ca2+]i  <1 nM [Ca2+]i = 10 μM 
GluN1/2A 2.76 ± 0.27 (9) 0.69 ± 0.05 (5) 0.77 ± 0.02 (12) 0.53 ± 0.05 (5) 
GluN1/2B 0.90 ± 0.06 (9) 0.83 ± 0.03 (7) 0.79 ± 0.01 (14) 0.72 ± 0.02 (6) 
GluN1/2C 0.73 ± 0.03 (5) 0.76 ± 0.04 (3) 0.95 ± 0.01 (8) 0.94 ± 0.03 (3) 








2.4.4 The relation between Ca2+-dependent channel block and Ca2+-dependent 
desensitization depends on NMDAR subtype 
Why do we observe a relation between CDD and memantine block of GluN1/2A receptors, 
but not GluN1/2B receptors, in our experiments? First, in conditions of low [Ca2+]i the GluN1/2A 
receptor channel may sample a conformation inaccessible to GluN1/2B receptors that exhibits 
weaker memantine affinity. Alternatively, GluN1/2B receptors could require greater buildup of 
Ca2+i and/or greater duration of exposure to high [Ca2+]i to reach full desensitization, limiting 
expression of [Ca2+]i-dependent memantine block. To test this second possibility, we increased 
[Ca2+]i to 50 μM and measured GluN1/2A and GluN1/2B receptor desensitization and memantine 
potency at intervals of 5, 10, and 15 min after whole-cell break-in. We found that although 50 μM 
Ca2+i did not elicit greater GluN1/2B desensitization than 10 μM Ca2+i at 5 min post break-in, both 
GluN1/2A (Figure 8A,B) and GluN1/2B (Figure 9A,B) desensitization greatly increased with 
duration of exposure to 50 μM Ca2+i. This increase in desensitization is similar to a previously 
described form of [Ca2+]i-and-time-dependent desensitization (Tong & Jahr, 1994; Krupp et al., 
2002).   
Despite the substantial increase in desensitization over time, memantine IC50 remained 
stable at all time points for both GluN1/2A (Figure 8C) and GluN1/2B receptors (Figure 9C). As in 
previous experiments, memantine IC50 was dependent on [Ca2+]i for GluN1/2A receptors (Figure 
8D) but not GluN1/2B receptors (Figure 9D). Together, these results confirm that memantine 
block of GluN1/2B receptors is unaffected by [Ca2+]i or desensitization. These results also confirm 
that the relation between CDD and memantine block of NMDARs is subtype-specific, and that 
Ca2+-dependent memantine block is unique to GluN1/2A receptors.  
To investigate the mechanism underlying this time-dependent form of CDD, we also 




activity with the SRC-family tyrosine kinase inhibitor dasatinib and the broad-spectrum kinase 
inhibitor staurosporine (500 nM each). Interestingly, although CDD was still observed (no kinase 
inhibition: ISS/IPeak = 0.79 ± 0.01 at [Ca2+]i < 1 nM 5-10 min post break-in (Figure 7N); with kinase 
inhibition: Iss/IPeak = 0.67 ± 0.01 at 50 μM [Ca2+]i 5 min post break-in (Figure 9F)), the degree of 
desensitization did not increase with duration of exposure to high [Ca2+]i (Figure 9E,F), suggesting 






Figure 8. Desensitization, but not memantine inhibition, of GluN1/2A receptors depends on 
duration of exposure to high [Ca2+]i. 
A, Overlay of GluN1/2A receptor responses in conditions of [Ca2+]i = 50 μM recorded at 5 (light red) and 15 
(red) min after break-in. Currents are normalized to IPeak. B, Progression of GluN1/2A receptor 
desensitization as a function of duration of exposure to [Ca2+]i = 50 μM. Desensitization greatly increases 
with duration of exposure to high [Ca2+]i (5 min: Iss/IPeak = 0.60 ± 0.04; 10 min: Iss/IPeak= 0.48 ± 0.06; 15 min: 
Iss/IPeak = 0.29 ± 0.04). Repeated measures one-way ANOVA with test for linear trend (***p < 0.001). C, 
Memantine IC50 plotted as a function of duration of exposure to [Ca2+]i = 50 μM. Memantine potency is not 
related to duration of exposure to high [Ca2+]i (5 min: IC50 = 0.73 ± 0.02 μM; 10 min: IC50 = 0.74 ± 0.07 μM; 
15 min: IC50 = 0.70 ± 0.06 μM). Repeated measures one-way ANOVA with test for linear trend (p = 0.29). 
D, Summary and comparison of memantine IC50 values in conditions of [Ca2+]i < 1 nM (IC50 = 2.76 ± 0.27), 
[Ca2+]i = 10 μM (IC50 = 0.69 ± 0.05 μM), and [Ca2+]i = 50 μM (red; IC50 = 0.70 ± 0.06 μM). Data replotted 




the [Ca2+]i < 1 nM and [Ca2+]i = 10 μM groups, and at 15 min post break-in for [Ca2+]i = 50 μM.  Memantine 
potency in [Ca2+]i = 50 μM is stronger than in [Ca2+]i < 1 nM (p*** < 0.001) but does not differ from potency 
in [Ca2+]i = 10 μM; analysis same as reported in Figure 4C (one-way ANOVA with Tukey post hoc test). 
Points represent individual values, bars and error bars depict mean ± SEM. Intracellular Ca2+-buffering 
conditions for each internal solution used (i.e. [Ca2+]T and buffer) are given in Table 3, and [B]T for each 







Figure 9. Desensitization, but not memantine inhibition, of GluN1/2B receptors depends on 
duration of exposure to high [Ca2+]i 
A, Overlay of GluN1/2B receptor responses in conditions of [Ca2+]i = 50 μM recorded at 5 (light red) and 15 
(red) min after break-in. Currents are normalized to IPeak. B, Progression of GluN1/2B receptor 
desensitization as a function of duration of exposure to [Ca2+]i = 50 μM. Desensitization greatly increases 
with duration of exposure to high [Ca2+]i (5 min: Iss/IPeak = 0.73 ± 0.04; 10 min: Iss/IPeak= 0.60 ± 0.07; 15 min: 
Iss/IPeak = 0.41 ± 0.04). Repeated measures one-way ANOVA with test for linear trend (****p < 0.0001). C, 
Memantine IC50 plotted as a function of duration of exposure to [Ca2+]i = 50 μM. Memantine potency is not 
related to duration of exposure to high [Ca2+]i (5 min: IC50 = 0.78 ± 0.07 μM; 10 min: IC50 = 0.76 ± 0.06 μM; 




D, Summary of memantine IC50 values in conditions of [Ca2+]i < 1 nM (IC50 = 0.90 ± 0.06), [Ca2+]i = 10 μM 
(IC50 = 0.85 ± 0.05 μM), and [Ca2+]i = 50 μM (IC50 = 0.79 ± 0.05 μM). Data were recorded at 5 – 10 min post 
break-in for measurement of IC50 values plotted for the [Ca2+]i < 1 nM and [Ca2+]i = 10 μM groups, and at 
15 min post break-in for [Ca2+]i = 50 μM. Memantine inhibition of GluN1/2B receptors does not depend on 
[Ca2+]i. One-way ANOVA with Tukey post hoc test. Points represent individual values, bars and error bars 
depict mean ± SEM. E, Overlay of GluN1/2B receptor responses recorded at 5 (light red) and 15 (red) min 
after break-in with [Ca2+]i = 50 μM and kinase activity inhibited. Currents are normalized to IPeak. F, 
Progression of GluN1/2B receptor desensitization as a function of duration of exposure to [Ca2+]i = 50 μM 
with kinase activity inhibited. Kinase inhibition removed the dependence of desensitization on duration of 
exposure to high [Ca2+]i (5 min: Iss/IPeak = 0.67 ± 0.01; 10 min: Iss/IPeak= 0.67 ± 0.03; 15 min: Iss/IPeak = 0.63 ± 
0.04). Repeated measures one-way ANOVA with test for linear trend (p = 0.07). Intracellular Ca2+-buffering 
conditions for each internal solution used (i.e. [Ca2+]T and buffer) are given in Table 3, and [B]T for each 







2.4.5 Ca2+-dependent block of native NMDARs by memantine 
We next examined whether memantine inhibition of native NMDARs is [Ca2+]i-dependent. 
Transfected cell lines offer the advantage of studying isolated NMDAR subtypes. However, 
properties of native NMDARs can differ from recombinant receptors due to differences in 
posttranslational modifications and interactions with distinct proteins or lipids (Chazot et al., 1995; 
Kornau et al., 1995; Standley & Baudry, 2000; Kloda et al., 2007; Sornarajah et al., 2008). Many, 
if not all, neurons also co-express multiple different GluN2 subunits, which can coassemble to 
form triheteromeric receptors (Stroebel et al., 2018). To examine the effect of [Ca2+]i on 
memantine block of native NMDARs, we performed IC50 measurements in cultured primary 
cortical neurons while clamping [Ca2+]i at <1 nM or [Ca2+]i = 50 μM using the same internal 
solutions as experiments with tsA201 cells. Our cortical neuronal cultures almost exclusively 
express GluN1, GluN2A, and GluN2B subunits (Qian et al., 2005), with GluN2A subunit 
expression beginning at ~14 days in vitro (Zhong et al., 1994; Li et al., 1998; Sinor et al., 2000). 
Therefore, all IC50 measurements in cultured neurons were performed after DIV 14. Since the 
GluN2B subunit is highly expressed in cortical neurons, and often co-assembles with GluN1 and 
GluN2A subunits to form GluN1/2A/2B triheteromers (Sheng et al., 1994; Luo et al., 1997; Gray 
et al., 2011; Rauner & Köhr, 2011; Tovar et al., 2013), we performed IC50 measurements in both 
the absence and presence of the highly selective GluN1/2B receptor antagonist CP101,606. At 1 
μM, CP101,606 inhibits ~90% of GluN1/2B receptor currents while only inhibiting GluN1/2A/2B 
receptor currents by ~25% (Hansen et al., 2014). Thus, experiments without CP101,606 allowed 
us to assess the effect of [Ca2+]i on memantine block of the entire population of NMDARs, and 
experiments with CP101,606 allowed us to assess the effect of [Ca2+]i on memantine block of 




Experiments without CP101,606 showed that memantine inhibition of native NMDARs 
strongly depends on [Ca2+]i, revealing a ~2-fold increase in memantine potency in conditions of 
[Ca2+]i = 50 μM relative to [Ca2+]i <1 nM (Figure 10A-C). Potency of ketamine was again found to 
be [Ca2+]i-independent (Figure 10D,E). Surprisingly, the memantine IC50 value in [Ca2+]i = 50 μM 
and both ketamine IC50 values were skewed upward in comparison to experiments in tsA201 cells 
(Figure 4C,H). This could potentially be due to weaker space clamp of the larger, heavily branched 
neurons in comparison to the much more electrotonically compact tsA201 cells. In contrast, the 
memantine IC50 values in conditions of [Ca2+]i < 1nM, were roughly equivalent across our neuronal 
and tsA201 cell recordings (Figure 4C), suggesting that GluN1/2B receptors were also 
contributing to our observed IC50 values. Indeed, inhibition of GluN1/2B receptors with CP101,606 
significantly increased the memantine IC50 measured in [Ca2+]i <1 nM conditions (Figure 10C) 
without affecting IC50 values measured in [Ca2+]i = 50 μM, augmenting the dependence of 
memantine potency on [Ca2+]i. These results provide firm evidence that memantine inhibition of 







Figure 10. Memantine inhibition of native NMDARs is [Ca2+]i-dependent. 
A, Overlay of current traces used to measure memantine concentration-inhibition curves from native 
NMDARs in cultured cortical neurons at [Ca2+]i < 1 nM (grey) and [Ca2+]i = 50 μM (red). Traces are 
normalized to steady-state current before application of memantine to facilitate comparison of inhibition 
between conditions. Black bar depicts Glu application; red bars depict memantine applications; blue bar 
depicts application of the selective GluN1/2B antagonist CP101,606 (1 μM). B, Memantine concentration-
inhibition curves measured in conditions of [Ca2+]i < 1 nM (gray) and [Ca2+]i = 50 μM (red) in DIV 15-22 
cultured cortical neurons. Curves and fractional current values measured in the absence of CP101,606 are 
depicted with dashed lines and open circles; curves and fractional current values measured in the presence 
of CP101,606 are depicted with solid lines and circles. C, Summary of memantine IC50 values measured at 
[Ca2+]i of < 1 nM and 50 μM in the presence and absence of CP101,606. Memantine potency was 
significantly lower at [Ca2+]i < 1 nM than [Ca2+]i = 50 μM in the absence (2.63 ± 0.12 μM vs 1.48 ± 0.12 μM) 
and presence (3.46 ± 0.34 μM vs 1.56 ± 0.0.08 μM) of CP101,606. CP101,606 weakened memantine 
potency in conditions of [Ca2+]i < 1 nM (3.46 ± 0.34 μM vs 2.63 ± 0.12 μM). One-way ANOVA with Tukey’s 
post hoc test; *p < 0.05, **p < 0.01, ****p < 0.0001. D, Ketamine concentration-inhibition curves for [Ca2+]i 
< 1 nM (grey) and [Ca2+]i = 50 μM (red) in the presence of CP101,606. E, Summary of ketamine IC50 values 




D, data are depicted as mean ± SEM and some error bars are smaller than symbols. For C and E, points 
represent individual values, bars and error bars depict mean ± SEM. Intracellular Ca2+-buffering conditions 
for each internal solution used (i.e. [Ca2+]T and buffer) are given in Table 3, and [B]T for each buffer is given 








Preferential targeting of specific receptor states could have broad implications for the 
pharmacological profile of memantine. The state-specific nature of memantine inhibition allows 
memantine activity to be regulated by both physiological context and NMDAR subtype, which 
likely contributes to memantine’s ability to inhibit select subpopulations of NMDARs. Here, we 
systematically investigated the relation between NMDAR desensitization and memantine 
inhibition. We uncovered a previously uncharacterized form of state-specific antagonism of 
NMDARs, [Ca2+]i-dependent channel block, that confers both context and subtype dependence 
to the action of memantine. We found that inhibition of GluN1/2A receptors by memantine is 
powerfully dependent on [Ca2+]i, with memantine potency increasing ~4-fold as [Ca2+]i was raised 
from < 1 nM to 5 μM. Experiments utilizing mutant receptors that do not exhibit CDD revealed that 
the [Ca2+]i-dependence of memantine inhibition is intrinsically intertwined with CDD. Together, 
these results strongly support the hypothesis that the [Ca2+]i dependence of memantine inhibition 
results from stabilization of a Ca2+-dependent desensitized NMDAR state. Our findings 
demonstrate a logical mechanism by which memantine can preferentially target specific NMDAR 
subpopulations and act as a neuroprotectant: preferential inhibition of receptor subpopulations 
subjected to intense stimulation and prolonged durations of high [Ca2+]i, i.e., NMDARs mediating 
excitotoxicity.   
Our findings mesh well with previous results detailing the effects of NMDAR activity level 
on memantine potency and the ability of memantine to enhance CDD (Glasgow et al., 2017). 
Memantine inhibits GluN1/2A receptor responses to long duration glutamate exposures more 
effectively than responses to brief, synaptic-like applications (Glasgow et al., 2017). This is 
consistent with our results, as long glutamate applications would allow for prolonged buildup of 




increased memantine potency. Glasgow et al., 2017 also reported that memantine slows 
GluN1/2A receptor RfD in a [Ca2+]e-dependent manner, suggesting that memantine stabilizes a 
Ca2+-dependent desensitized receptor state. We replicated these results and then expanded on 
the relation between CDD and the mechanism of action of memantine by directly testing whether 
receptor machinery required for CDD is also required for the effects of Ca2+ on memantine action. 
Truncation of the GluN1 CTD, a region required for CDD, ablates both the effect of memantine 
on RfD (Figure 5) and the effect of [Ca2+]i on memantine potency (Figure 6), confirming that 
memantine action powerfully depends on CDD of GluN1/2A receptors.  
Our findings also provide insight into mechanisms of NMDAR desensitization. NMDAR 
CDD is elicited by a complex series of molecular interactions involving calmodulin, α-actinin, and 
various kinases and phosphatases (Tong et al., 1995; Wyszynski et al., 1997; Zhang et al., 1998; 
Krupp et al., 1999; Rycroft & Gibb, 2002, 2004; Merrill et al., 2007). However, whether multiple 
forms of CDD exist is currently unknown. Our investigation of the relation between memantine 
potency and CDD revealed that desensitization of GluN1/2A and GluN1/2B receptors is increased 
both by increasing [Ca2+]i and by prolonging the duration of exposure of receptors to high [Ca2+]i. 
Our data showing that both GluN1/2A and GluN1/2B receptors exhibit CDD (Figure 7) is 
consistent with a recent study reporting that GluN1/2A and GluN1/2B receptors undergo CDD 
(Iacobucci & Popescu, 2020). Interestingly, although memantine potency for GluN1/2A receptors 
increased alongside increasing [Ca2+]i, memantine potency was unaffected by the progressive 
increase in desensitization elicited by prolonged exposure to [Ca2+]i (Figure 8). Memantine 
potency for GluN1/2B receptors was also unrelated to this progressive, time-dependent increase 
in desensitization (Figure 9). In addition, the time-dependent desensitization we observed in 
Figure 8 & 9 experiments appears remarkably similar to a previously reported form of glycine-
independent desensitization that depends on duration of exposure to [Ca2+]i (Lieberman & Mody, 




that the [Ca2+]i-dependent and the [Ca2+]i-and-time-dependent phenomena we observe may 
represent different, separable forms of CDD. This conclusion is bolstered by our experiments 
testing the role of kinase activity on GluN1/2B receptor CDD. Although we still observed CDD of 
GluN1/2B receptors with kinase inhibitors in the pipette, the progressive time-dependent increase 
in desensitization was completely ablated (Figure 9). These results provide strong evidence for 
the existence of two separable forms of CDD with different underlying mechanisms. 
Ketamine acts as a powerful negative control in our experiments. Unlike memantine, 
ketamine does not affect GluN1/2A desensitization (Glasgow et al., 2017) and its potency shows 
no dependence on [Ca2+]i in recombinant (Figure 4) or native NMDARs (Figure 10). This further 
supports our conclusion that the [Ca2+]i dependence of memantine potency is derived from 
stabilization of a specific receptor state by memantine, and that the relation between CDD and 
channel block is not due to general effects of [Ca2+]i on channel block. Differences between the 
effects of memantine and ketamine on NMDAR gating are particularly interesting. Memantine and 
ketamine, despite sharing overlapping binding sites in the NMDAR channel (Ferrer-Montiel et al., 
1998; Kashiwagi et al., 2002), exhibit strikingly divergent clinical profiles (Krystal et al., 1994; 
Parsons, Danysz, & Quack, 1999; Chen & Lipton, 2006; Johnson et al., 2015). The difference we 
observe between the effects of [Ca2+]i on memantine and ketamine potency could direct each 
drug to target distinct NMDAR subpopulations, a mechanism proposed to underpin some of the 
differences observed between the clinical profiles of memantine and ketamine (Gideons et al., 
2014; Johnson et al., 2015; Kavalali & Monteggia, 2015).  
NMDAR CDD and the effect of [Ca2+]i on memantine potency both depend on NMDAR 
subunit composition (Figure 7). However, perhaps surprisingly, the expression of CDD by an 
NMDAR subtype does not necessitate that memantine block of that subtype is [Ca2+]i-dependent. 
We report that while both GluN1/2A receptors and GluN1/2B receptors exhibit CDD, only 




for GluN1/2A receptors in cells with [Ca2+]i = 10 μM was nearly identical to the IC50 values 
measured in both low and high [Ca2+]i conditions for the other NMDAR subtypes. In contrast, 
memantine inhibition of GluN1/2A receptors in cells with [Ca2+]i < 1 nM was weaker than 
memantine inhibition of any other NMDAR subtype tested, regardless of condition. Therefore, our 
results suggest that GluN1/2A receptors, in conditions of low [Ca2+]i, exhibit a unique 
conformational state that (1) other subtypes are unable to access and (2) exhibits weaker affinity 
for memantine. The existence of a unique GluN1/2A receptor state with weaker affinity for 
memantine, and the ability of [Ca2+]i to reduce occupancy of this state and increase memantine 
potency, may allow memantine to act somewhat like a low-pass filter for GluN1/2A receptor 
activity. In conditions of weak NMDAR stimulation, memantine would permit relatively normal 
activity of GluN1/2A receptors while limiting activity of GluN1/2B, GluN1/2C, and GluN1/2D 
NMDARs. As stimulation increases, buildup of [Ca2+]i initiates CDD mechanisms that push 
GluN1/2A-containing receptor channels into a conformation that resembles the binding sites of 
other NMDAR subtypes, increasing memantine inhibition of GluN1/2A receptors. This filter-like 
action of memantine could contribute to its surprising combination of clinical efficacy and 
tolerability by permitting NMDAR activity in healthy neurons while limiting NMDAR activity in 
neurons subjected to pathological insults. Importantly, our experiments show that memantine 
inhibition of GluN1/2A receptors is dynamically regulated by fluctuations of [Ca2+]i across both 
physiological and pathological ranges, and that memantine inhibition of a mixed population of 
native NMDARs containing both GluN2A- and GluN2B-containing receptors is [Ca2+]i-dependent. 
Thus, the [Ca2+]i dependence of inhibition of NMDARs by memantine has the potential to 





3.0 STRUCTURAL BASIS OF CA2+-DEPENDENT CHANNEL BLOCK OF NMDA 
RECEPTORS BY MEMANTINE 
3.1 OVERVIEW 
N-methyl-D-aspartate receptors (NMDARs) are Ca2+-permeable ligand-gated ion 
channels expressed at nearly all excitatory vertebrate synapses. NMDAR-mediated Ca2+ influx is 
essential for many critical neuronal functions and NMDAR dysfunction is implicated in numerous 
nervous system pathologies. Thus, drugs targeting NMDARs are of great clinical interest. 
Memantine and ketamine are both clinically useful NMDAR open channel blockers with similar 
pharmacological properties but paradoxically different clinical profiles. Recent work from our lab 
has revealed key biophysical differences in how memantine and ketamine act on NMDARs. 
Inhibition of NMDARs by memantine, but not ketamine, is dynamically regulated by intracellular 
Ca2+ concentration ([Ca2+]i), a phenomenon resulting from the ability of memantine to stabilize a 
Ca2+-dependent desensitized NMDAR state. Here, we integrate molecular dynamics simulations 
with whole-cell recordings to identify differences in the memantine and ketamine binding sites and 
test the role of these differential interactions in the relation between channel blocker binding and 
NMDAR desensitization. We discovered that mutation of a single residue in the NMDAR pore 
alters memantine potency without affecting ketamine potency, greatly affects NMDAR 
desensitization, and influences the [Ca2+]i dependence of memantine potency. These experiments 
provide evidence supporting the hypothesis that the differential effects of memantine and 







NMDARs are ionotropic glutamate receptors involved in nearly every aspect of synaptic 
function including synaptogenesis, synaptic transmission, and synaptic plasticity. This ubiquitous 
involvement in synaptic function allows NMDARs to regulate neuronal function on a large scale 
by contributing to excitation/inhibition balance, neuronal oscillations, and dendritic integration. 
Unsurprisingly, aberrant NMDAR activity contributes to a wide breadth of neuronal dysfunctions 
that can drive nervous system disorders (Javitt, 2004; Zhou & Sheng, 2013). Modulating NMDAR 
activity with therapeutic drugs has proven to be excruciatingly complicated. The NMDAR open 
channel blockers memantine and ketamine provide two particularly interesting examples of the 
complex effects of NMDAR antagonism. Both memantine and ketamine show significant 
therapeutic utility, but despite sharing similar affinities, binding kinetics, and overlapping binding 
sites in the NMDAR transmembrane domain (TMD), possess wildly divergent clinical profiles 
(Ferrer-Montiel et al., 1998; Parsons, Danysz, & Quack, 1999; Kashiwagi et al., 2002; Chen & 
Lipton, 2006; Emnett et al., 2013; Johnson et al., 2015). Ketamine, but not memantine, shows 
great efficacy in the treatment of pain and major depressive disorder (Persson, 2013; Abdallah et 
al., 2015; Kavalali & Monteggia, 2015) but is a drug of abuse and produces/exacerbates 
symptoms of schizophrenia (Krystal et al., 2003; Bondi et al., 2012; Corazza et al., 2013). In 
contrast, Mem is well-tolerated, approved for treatment of Alzheimer’s disease, and shows 
promise in treatment of other disorders including, paradoxically, schizophrenia (Chen & Lipton, 
2006; Lipton, 2006; Parsons et al., 2007; Danysz & Parsons, 2012; Parsons & Raymond, 2014; 
Di Iorio et al., 2017). Our current understanding of the mechanisms of action of memantine and 
ketamine is unable to account for their divergent systemic effects. 
Some clinical differences between memantine and ketamine, such as the hypnotic effect 




However, there is substantial evidence that the effects of memantine and ketamine depend 
predominantly on inhibition of NMDARs ((Javitt, 2004; Wenk et al., 2006; Parsons et al., 2007; 
Bondi et al., 2012), but see (Zanos et al., 2016) for additional potential mechanisms of Ket in 
depression). Furthermore, differences between memantine and ketamine pharmacokinetics 
minimally contribute to the observed differences in their behavioral effects (Kotermanski et al., 
2013). Therefore, understanding the mechanisms underlying the differential effects of memantine 
and ketamine requires deeper insight into the biophysical action of each drug on NMDARs.  
To this end, an attractive target of study is our discovery that inhibition of NMDAR by 
memantine, but not ketamine, is dynamically regulated by intracellular Ca2+ concentration 
([Ca2+]i). In Chapter 2 we reported that increasing [Ca2+]i increases memantine potency, and that 
the [Ca2+]i dependence of memantine inhibition results from stabilization of a Ca2+-dependent 
desensitized NMDAR state. This state specificity allows memantine to both block current flow 
through open receptors and stabilize closed receptors to varying degrees based on [Ca2+]i. Ca2+ 
dynamics and handling vary heavily by subcellular region and neuronal subtype (Schwaller, 2010; 
Higley & Sabatini, 2012), and desensitization of NMDARs plays a key role in shaping postsynaptic 
responses and plasticity (Jones & Westbrook, 1996; Urakubo et al., 2008). Thus, the [Ca2+]i 
dependence of memantine inhibition could provide a mechanism through which memantine 
preferentially targets different subpopulations of NMDARs than ketamine, potentially 
underpinning many of the striking dissimilarities observed between the two drugs. Additionally, 
the [Ca2+]i dependence of memantine inhibition suggests an innovative, logical mechanism of 
neuroprotection: preferential inhibition of NMDARs that are exposed to large and prolonged 
increases of Ca2+i, i.e. receptors likely to mediate excitotoxic cell death (Zorumski & Olney, 1993; 
Rothman & Olney, 1995; Hasbani et al., 1998; Hardingham & Bading, 2010; Wroge et al., 2012; 




The mechanism by which memantine stabilizes closed channels is currently unknown. 
Given that memantine and ketamine show differential effects on GluN1/2A receptor 
desensitization, it is likely that the structural interactions between each drug and the GluN1/2A 
channel also differ. However, despite their clinical relevance, there have been no direct 
comparisons of the memantine and ketamine binding sites. Here, we utilize a powerful 
combination of molecular simulations with atomistic GluN1/2A TMD models and whole-cell 
electrophysiology in transfected cells to investigate the relation between channel blocker-
GluN1/2A channel interactions, desensitization, and the [Ca2+]i dependence of memantine 
inhibition. 
3.3 MATERIALS AND METHODS 
3.3.1 Molecular modeling  
All simulations were carried out using fully atomistic models of the GluN1/2A TMD. The 
GluN1/2A TMD model shown in Figure 11 (referred to as the 2017 model) and used for initial 
docking simulations for memantine and ketamine was developed in collaboration with the 
Kurnikova Lab of Carnegie Mellon University (Mesbahi-Vasey et al., 2017). The 2017 model was 
initially constructed by homology modeling based on NaK (PDB 2AHY; (Shi et al., 2006)) and 
AMPAR (PDB 3KG2; (Sobolevsky et al., 2009)) crystal structures and was refined with targeted 
MD simulations to incorporate data from an NMDAR crystal structure (PDB 3KG2; (Lee et al., 
2014)). I developed and optimized models of memantine and ketamine using the software 
Gaussian 09 (M.J. Frisch, 2009). All docking simulations were carried out using the software 




Kurnikova Lab.  For docking simulations, side chains of memantine and ketamine were allowed 
to rotate while protein side chains were held rigid. Memantine and ketamine were docked to 20 
different snapshots of the closed 2017 model. Each docking simulation produced 9 predicted 
docking poses for each drug. The most commonly predicted poses were then assessed for 
consistency with experimental predictions of channel blocker binding sites, i.e. whether the 
charged amine group of the blocker was in close proximity to the critical asparagine residues  
GluN1 N616 and GluN2A N614, which are heavily implicated in NMDAR channel block 
(Burnashev, Schoepfer, et al., 1992; Mori et al., 1992; Kuner & Schoepfer, 1996; Ferrer-Montiel 
et al., 1998; Kashiwagi et al., 2002; Chen & Lipton, 2005; Mesbahi-Vasey et al., 2017). 
The GluN1/2A TMD model shown in Figure 14 (referred to as the 2019 model) and used 
for molecular dynamics (MD) simulations was developed from a cryo-EM density structure 
template (PDB 6MM9; (Jalali-Yazdi et al., 2018)) by our collaborators Drs. Dhilon Patel and Maria 
Kurnikova of Carnegie Mellon University. After generation of the model, it was placed in an 
equilibrated 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) bilayer, solvated with 
water, Na+ and Cl- ions, and equilibrated. Initial docking of memantine to this model was also 
performed with Autodock Vina. MD simulations were carried out with the MD software package 
Amber18 using the pmemd.cuda program (Case et al., 2017). Pressure and temperature of the 
simulated system were maintained at 1 bar and 300 K, respectively. MD simulations of memantine 
binding to the NMDAR channel were carried out for WT as well as GluN1/2A(F641A) and 
GluN1/2A(F641W) receptors. Two 200 ns simulations were performed for each receptor-




3.3.2 Cell culture and transfection 
All experiments were performed in tsA201 cell cultures (European Collection of 
Authenticated Cell Cultures). tsA201 cells were maintained as previously described (Glasgow & 
Johnson, 2014) in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum and 1% GlutaMAX (Thermo Fisher Scientific). Cells were plated at a density of 105 
cells/dish in 35 mm petri dishes on 15 mm glass coverslips treated with poly D-lysine (0.1 mg/ml) 
and rat-tail collagen (0.1 mg/ml). 18-24 hours after plating, the cells were transfected using 
FuGENE 6 (Promega) with complementary DNA (cDNA) coding for enhanced green fluorescent 
protein (EGFP; Genbank ACS32473 in pCI-neo) to identify transfected cells, WT rat GluN1-1a 
(GluN1; GenBank U08261 in pCI-neo), and either WT GluN2A (GenBank M91561 in pcDNA1) or 
GluN2A mutated at residue 641. Mutations were made using the Stratagene QuikChange II XL 
sited directed mutagenesis kit. EGFP was expressed using a specialty plasmid, pCI-
neo:EGFP:GluN1-1a (a kind gift from Dr. Kasper Hansen), that allows for co-expression of 
independent EGFP and GluN1 subunit proteins. pCI-neo:EGFP:GluN1-1a was constructed by 
inserting cDNA encoding EGFP in pCI-neo under transcriptional control of the CMV promoter, 
between the CMV promoter and the GluN1 open reading frame (Yi et al., 2018).  Cells were 
transfected with cDNA ratios of 1 GluN1: 1 GluN2A. 200 μM of the competitive NMDAR antagonist 
dl-APV was added to medium at the time of transfection to prevent NMDAR-mediated cell death.  
3.3.3 Electrophysiology 
All patch-clamp electrophysiological experiments were performed in the whole-cell 
voltage-clamp configuration. Recordings from tsA201 cells were performed 18-30 hours after 




were amplified with Axopatch 1D, 200A, or 200B amplifiers and digitized using a Digidata 1440A 
digitizer (Molecular Devices). Current signals were low-pass filtered at 5 kHz and sampled at 20 
kHz using pCIamp10.7 (Molecular Devices). Series resistance was compensated between 85 – 
90% in all experiments. An empirically determined liquid junction potential of -6 mV between the 
internal and external solutions was corrected for in all experiments.  
Control bath solution (referred to as external solution) for tsA201 cell experiments 
contained (in mM): 140 NaCl, 2.8 KCl, 10 HEPES, 0.01 EDTA, 0.1 glycine, and either 0, 0.1 or 1 
CaCl2. Agonist (1 mM glutamate from 1 M stock) and antagonists (various memantine and 
ketamine concentrations from 10 mM stock in dH2O) were added to external solutions on day of 
experiments. For IC50 experiments, antagonist solutions were prepared via serial dilution. Control, 
agonist, and antagonist solutions were delivered to the patched cell via polyimide barrels using 
our in-house fabricated rapid-switching fast perfusion system (Glasgow & Johnson, 2014). 
Switches between solutions were performed by moving the barrel position relative to the patched 
cell with a voice-coil motor controlled by a custom program (Blanpied et al., 1997). Solution flow 
rate was maintained at 1 – 2 mL/min for all experiments.  
3.3.4 Intracellular solution preparation 
All intracellular solutions contained 125 – 130 mM CsCl, 10 mM HEPES, and 4 mM 
MgATP and were pH balanced to 7.2 ± 0.05 with CsOH. For experiments in Figures 12, 13, 15, 
and 16, intracellular solutions contained 10 mM BAPTA. For experiments comparing the effects 
of [Ca2+]i block and desensitization, we utilized the Ligand Optimization Method (LOM (McGuigan 
et al., 1991, 2006)) as described in Chapter 2.3.3 to help prepare an intracellular solution 




10 μM internal solution contained 10 mM HEDTA and 7.34 mM CaCl2;  the [Ca2+]i < 1 nM 
contained 10 mM BAPTA and no added CaCl2. 
3.3.5 Analysis 
All electrophysiologic data were analyzed with Clampfit 10.7 (Molecular Devices) and 
Prism 7-9 (Graphpad). Baseline current was subtracted from all current measurements. 
Concentration-inhibition relations for channel blockers were measured using the protocol shown 
in Figure 12A. Agonist was applied until current reached steady-state, then sequentially 
increasing concentrations of antagonist were applied the in the presence of constant [agonist]. 
Each [antagonist] was applied until a steady level of inhibition was reached (10 – 20 s). 
Antagonists were then removed and agonist alone was reapplied to allow recovery from channel 
block. Cells in which current did not recover to at least 85% of the steady-state current elicited by 
the initial agonist application were excluded from analysis. IC50 values were estimated as 
described in Chapter 2.3.4.  
For experiments investigating the effects of Ca2+ and the GluN2A mutations on 
desensitization, desensitization was quantified as a ratio of steady-state current (Iss) to peak 
current (Ipeak) Iss was measured as the mean current taken over the final 1 s of agonist application. 
Ipeak was measured as the mean current over a 30 ms window set 5 ms centered on the peak 
absolute current. To allow for comparison of effects of mutations on CDD, ISS/IPeak in 1 mM 





3.4.1 GluN2A residue 641 is predicted to interact with memantine, but not ketamine 
The differential effects of memantine and ketamine on the stability of closed GluN1/2A 
channels suggests that the two channel blockers may differentially interact with channel residues. 
To assess whether memantine and ketamine interact with distinct channel residues, we utilized 
computational simulations to model the memantine and ketamine binding sites in the NMDAR 
channel. Using our recently published atomistic model of the GluN1/2A TMD (Mesbahi-Vasey et 
al., 2017), we generated models of memantine and ketamine docked to a closed NMDAR channel 
using the software Autodock Vina (Trott & Olson, 2010). The most commonly predicted binding 
poses for memantine and ketamine placed them above the selectivity filter with their hydrophobic 
moieties nestled between the GluN1-GluN2A interface (Figure 11C,D). We then identified and 
compared residues within 3 Å of the predicted memantine and ketamine binding sites. Importantly, 
both memantine and ketamine were predicted to bind in close proximity to critical asparagine 
residues (GluN1 N616 and GluN2A N614; Figure 11E,F) that are key components of the NMDAR 
selectivity filter and heavily implicated in channel block (Burnashev, Schoepfer, et al., 1992; Mori 
et al., 1992; Kuner & Schoepfer, 1996; Ferrer-Montiel et al., 1998; Kashiwagi et al., 2002; Chen 
& Lipton, 2005; Mesbahi-Vasey et al., 2017).  
The predicted binding sites of memantine and ketamine heavily overlapped. Most residues 
within 3 Å of the docked blockers were identical. However, we identified a phenylalanine (F) 
residue in the M3 helix of the GluN2A subunit (F641) predicted to interact with memantine, but 
not ketamine (Figure 11E,F). To test the accuracy of this prediction, we experimentally 
investigated whether GluN2A 641 contributes to memantine or ketamine potency by making a 




memantine and ketamine IC50 (Figure 12A-F; Table 5). Interestingly, the GluN2A(F641L) mutation 
increased memantine potency relative to WT receptors (Figure 12G). The GluN2A(F641L) 
mutation had no effect on ketamine potency (Figure 12H).  These results support the idea that 





Figure 11. Docking of memantine and ketamine to 2017 GluN1/2A TMD model. 
A, B, Bond-line structures of memantine (A) and ketamine (B) shown with protonated amines, the 
predominant form of each blocker at neutral pH (memantine pKa = 10.3 (Freudenthaler et al., 1998); 
ketamine pKa = 7.5 (Budavari, 1989)). C, D, View of entire 2017 GluN1/2A TMD model (Mesbahi-Vasey et 
al., 2017) with memantine (C) and ketamine (D) docked within the channel. GluN1 is depicted as gray-blue 
ribbons; GluN2A is depicted as cyan ribbons. Blockers are depicted as space-filling structures. Box depicts 
regions blown up in E and F. E, F, Magnified view of docking sites for memantine (E) and ketamine (F). 
Both blockers share close proximity with key asparagine residues and generated similar docking scores 
(memantine = - 7.1 kcal/mol; ketamine = - 8.8 kcal/mol). Residue N2A(F641) is predicted to be within 3 Å 
of memantine, but not ketamine. All other residues within 3 Å are shared. Colors: C = pink (drug), green 





Figure 12. GluN2A F641 influences memantine potency but not ketamine potency. 
A, B, Representative current traces for experiments measuring memantine (A) and ketamine (B) IC50s for 
WT GluN1/2A receptors in [Ca2+]e = 1 mM. C, D, Representative current traces for experiments measuring 
memantine (C) and ketamine (D) IC50s for mutant GluN1/2A(F641L) receptors. Bars represent glutamate 




and ketamine (F) potency at WT GluN1/2A and mutant GluN1/2A(F641L) receptors. Green line and 
symbols represent values for WT receptors; blue line and symbols represent values for mutant receptors. 
Data are depicted as mean ± SEM; some error bars are smaller than symbols. Lines depict best fit of Hill 
equation (Equation 3) to data. G, H, Summary and comparison of IC50 values for memantine (G) and 
ketamine (H) at WT GluN1/2A and GluN1/2A(F641L) receptors. Memantine IC50 was significantly lower for 
GluN1/2A(F641L) receptors than WT receptors. Ketamine IC50 did not differ between groups. IC50 values 







3.4.2 Size of GluN2A residue 641 influences inhibition by memantine, but not ketamine 
Interestingly, the GluN2A(F641L) mutation reduced memantine IC50. This effect could be 
due to multiple factors, including direct steric effects of the GluN2A F641 side chain on memantine 
binding, changes in receptor dynamics that contribute to memantine binding, or alteration of CDD. 
To further assess the contribution of GluN2A F641 to memantine potency, we generated 
additional mutant receptors with either a small residue (alanine; A) or a large aromatic residue 
(tryptophan; W) at position GluN2A F641 and measured memantine IC50 (Figure 13; Table 5). We 
found that mutations to smaller residues (A or L) significantly increased memantine potency 
(Figure 13A,B,I,K). Mutation to the larger W residue decreased memantine potency in comparison 
to GluN1/2A(F641A), GluN1/2A(F641L), and WT receptors (Figure 13C,D,I,K). Thus, size of 
GluN2A residue 641 influences memantine potency.  
To ensure that the GluN1/2A(F641A) and GluN1/2A(F641W) mutations do not elicit 
changes in NMDAR dynamics that broadly affect channel block, we also measured and compared 
ketamine IC50s. Importantly, none of the GluN2A F641 mutations altered ketamine potency 
(Figure 13 E-H,J,L; Table 5). These results confirm that mutation of GluN2A F641 does not 
broadly affect channel block and support the model predictions that GluN2A F641 specifically 





Figure 13. Size of GluN2A residue 641 influences memantine, but not ketamine, potency. 
A-H, Representative GluN1/2A receptor currents used to measure memantine (A-D) and ketamine (E-H) 
concentration-inhibition relations in 1 mM Ca2+e. Traces are shown in order (Left → Right) of increasing 
residue size at position GluN2A 641. Peaks of Glu responses for GluN2A(F641A) and GluN2A(F641L) are 
truncated. I, J, Concentration-inhibition curves for memantine (I) and ketamine (J). Legend inset in I 
identifies amino acid residue at GluN2A position 641. Data expressed as mean ± SEM; error are bars 
smaller than symbols for WT, F641A, and F641W receptors. K, L, Summary of memantine IC50 values (K) 
and ketamine IC50 values (L). Memantine IC50 depends on residue size at GluN2A position 641, with IC50 
decreasing with residue size (K). Ketamine IC50 does not depend on residue size at GluN2A position 641 
(L). Points represent individual values, bar represents mean, and error bars depict SEM. **p < 0.01 , ***p 
< 0.001; ****p < 0.0001; one-way ANOVA with Tukey post hoc analysis. IC50 values are summarized in 




3.4.3 GluN2A residue 641 regulates memantine binding via inter-subunit interactions  
Multiple possible mechanisms could account for the effect of GluN2A residue 641 size on 
memantine IC50. Firstly, the large WT F and mutant W residues could form direct, energetically 
unfavorable interactions with memantine, limiting the stability of the TMD-memantine complex. 
Any steric hindrance generated by the larger residues would be removed by mutating GluN2A 
F641 to smaller residues (i.e., A or L), resulting in improved stability of memantine in the TMD. 
Another possibility is that GluN2A F641 may interact with other TMD residues that help form the 
memantine binding pocket, which could allow GluN2A F641 to indirectly affect memantine 
potency. However, our experimental data do not allow us to distinguish between direct and 
indirect contributions of GluN2A F641 to memantine binding. Therefore, we turned to molecular 
dynamics (MD) simulations to further investigate the role of GluN2A F641 in memantine binding.  
For MD simulations, we used an updated, more advanced NMDAR TMD model developed from 
a recent cryo-EM density structure of a GluN1/2A receptor (Jalali-Yazdi et al., 2018). The 2019 
model (Figure 14A,B) holds the advantage over the 2017 model (Figure 11; (Mesbahi-Vasey et 
al., 2017) of being constructed based on an GluN1/2A receptor template rather than NaK, 
AMPAR, and GluN1/2B receptor channel templates. In addition, the 2019 model includes the 
linker residues connecting the first and second transmembrane helices (M1 and M2) as well as 
the helical pre-M1 region.  
To investigate the role of GluN2A F641 on memantine binding, we docked memantine to 
the 2019 model using Autodock Vina (Trott & Olson, 2010) and used the docking positions as 
starting points for MD simulations. We then performed MD simulations with the memantine-TMD 
complex immersed in a POPC lipid bilayer (Figure 14A). Interestingly, we observed no direct 
interactions between GluN2A F641 and memantine in our simulations. Therefore, we performed 




GluN2A(F641W) mutants affect memantine binding. Simulations with GluN2A(F641A) and 
GluN2A(F641W) mutants again did not show direct interaction of memantine with GluN2A residue 
641. However, we instead observed that mutation of GluN2A F641 produced a pronounced 
change in an adjacent GluN1 residue, GluN1 M641.  
Our simulations revealed that GluN1 M641 adopts one of two possible conformations 
depending on the size of GluN2A 641. In GluN1/2A(F641A) receptors, the GluN1 M641 side chain 
adopts a conformation projecting into the channel cavity, where it forms an energetically favorable 
interaction with memantine (Figure 14C). In contrast, the F641 residue of the WT GluN2A subunit 
forms an energetically favorable interaction with GluN1 M641, encouraging the side chain of 
GluN1 M641 to adopt a conformation projecting away from the channel cavity into a position 
where it is unlikely to interact with memantine (Figure 14D). In GluN1/2A(F641W) receptors, the 
interaction between GluN1 M641 and the large GluN2A W641 residue is strengthened, further 
restricting the movement of the GluN1 M641 side chain to this “outward” conformation and thus 
limiting its ability to interact with memantine (Figure 14E). In simpler terms, the large GluN2A 
F641 and mutant GluN2A W641 side chains can effectively compete with memantine for 
interaction with GluN1 M641. In contrast, the mutant GluN2A(F641A) residue is too small to 
strongly interact with GluN1 M641, allowing GluN1 M641 to preferentially adopt the “inward” 
conformation in which it favorably interacts with memantine. The results of our simulations mesh 
well with our experimental data showing that memantine potency depends on the size of GluN2A 
641 (Figure 13). Thus, our modeling results suggest that GluN2A residue 641 indirectly regulates 








Figure 14. Mutation of GluN2A residue 641 affects dynamics of GluN1 M641.  
A, Top-down view of 2019 GluN1/2A TMD model showing symmetry and central channel. For all panels, 
protein is depicted using a ribbon diagram; GluN1 subunits are blue and orange, GluN2A subunits are red 
and green. Memantine is shown as a stick model in the center of the channel. B, Snapshot of 2019 
GluN1/2A TMD-memantine complex inserted into POPC bilayer. POPC head groups are shown as yellow 
sticks, with phosphates as purple spheres and fatty acid chains as pink spheres. C, Zoomed in top-down 
snapshot of memantine bound in GluN1/2A(F641A) receptor channel. Red arrows show large distance 
between GluN1 M641 and GluN2A A641. Due to lack of interaction with GluN2A(F641A), GluN1 M641 
projects toward the center of the channel and engages in memantine binding. D, Zoomed in top-down 
snapshot of memantine binding site in WT GluN1/2A receptor channel. Black arrows show distance 
between GluN1 M641 and GluN2A F641. Due to interaction with GluN2A F641, GluN1 M641 adopts a 
conformation away from the center of the channel cavity, limiting favorable interactions with memantine. E, 




arrows show short distance between GluN1 M641 and GluN2A(F641W). Due to strong interaction with 
GluN2A(F641W), GluN1 M641 adopts a conformation away from the center of the channel cavity, 
preventing its favorable interaction with memantine.  





3.4.4 GluN2A residue 641 plays a key role in both Ca2+-independent and Ca2+-dependent 
desensitization of NMDARs 
In addition to affecting memantine potency, mutation of GluN2A F641 has obvious effects 
on NMDAR desensitization (Figure 12C,D; Figure 13A,B,E,F). Given the link between memantine 
potency and CDD (Chapter 2), we next sought to investigate the role of GluN2A F641 in NMDAR 
desensitization.  We measured desensitization of WT and mutant receptors in conditions of 0.1 
and 1 mM Ca2+e to determine the effects of GluN1/2A F641 mutations on both Ca2+-independent 
and Ca2+-dependent desensitization. Experiments in 0.1 mM Ca2+e allowed us to assess effects 
of mutations specifically on Ca2+-independent desensitization, while experiments in 1 mM Ca2+e 
allowed us to assess effects of mutants on total desensitization due to both Ca2+-dependent and 
Ca2+-independent mechanisms. GluN1/2A(F641A) and GluN1/2A(F641L) receptors exhibited 
robust desensitization in both 0.1 mM and 1 mM Ca2+e (Figure 15A,B). Interestingly, 
GluN1/2A(F641L) receptors exhibited stronger desensitization (i.e., smaller Iss/IPeak) than 
GluN1/2A(F641A) receptors in 0.1 mM Ca2+e (Figure 15C), despite showing similar Iss/IPeak in 1 
mM Ca2+e (Figure 15D). This suggests that GluN1/2A(F641L) receptors undergo greater Ca2+-
independent desensitization than GluN1/2A(F641A) receptors. As expected, WT receptors 
displayed moderate desensitization in 1 mM Ca2+e and weak desensitization in 0.1 mM Ca2+e. 
GluN1/2A(F641W) mutants displayed weak desensitization in both conditions, and significantly 
weaker desensitization than WT receptors in 1 mM Ca2+e (Figure 15D). These results, similarly to 
our IC50 experiments, revealed a clear role of GluN2A residue 641 in desensitization, with 
desensitization in both 0.1 and 1 mM Ca2+ generally decreasing as residue size at position 
GluN2A 641 increases (Figure 15C,D).  
We then assessed the effect of GluN2A 641 mutations on CDD by comparing ISS/IPeak 




size and CDD (Figure 16).  GluN1/2A(F641A) (Figure 16A,E), GluN1/2A(F641L) (Figure 16B,F), 
and WT (Figure 16C,G) receptors displayed clear CDD, with GluN1/2A(F641A) receptors 
exhibiting robust CDD. In contrast, desensitization of GluN1/2A(F641W) receptors showed no 
dependence on [Ca2+]e (Figure 16D,H). Interestingly, despite strongly affecting Ca2+-independent 
desensitization (Figure 15C), the GluN1/2A(F641L) mutation had no effect on CDD in comparison 
to WT (Figure 16I). This surprising result may suggest that the structure of Ca2+-dependent 
desensitized states may differ from Ca2+-independent desensitized states. Overall, these 
experiments suggest that CDD, like memantine IC50 and nonspecific NMDAR desensitization, 
depends on the size of GluN2A residue 641, with CDD generally decreasing as residue size 
increases (Figure 16I). These results are consistent with our previous data supporting the idea 






Figure 15. Mutation of GluN2A(F641) alters NMDAR desensitization. 
A, B, Representative GluN1/2A receptor currents used to measure ISS/IPeak for WT receptors and indicated 
GluN2A F641 mutants in 0.1 mM Ca2+e (A) and 1 mM Ca2+e (B). Traces are normalized to IPeak for 
visualization of differences in desensitization. C, D, Summary of values for WT receptors and GluN2A(F641) 
mutants in 0.1 mM Ca2+e (C) and 1 mM Ca2+e (D). Mutation of GluN1/2A(F641) significantly altered 
desensitization in both 0.1 mM Ca2+e and 1 mM Ca2+e. Points represent individual values, bar represents 
mean, and error bars depict SEM; *p < 0.05, ****p < 0.0001; one-way ANOVA with Tukey post hoc analysis. 






Figure 16. Size of GluN2A residue 641 plays a key role in [Ca2+]i-dependent desensitization. 
A – D, Representative current traces from WT and mutant GluN1/2A(F641X) receptors used to measure 
ISS/IPeak in 0.1 (grey) and 1 mM Ca2+e (N2A(F641A), red; N2A(F641L), blue; WT, green; N2A(F641W), 
purple). Traces are shown in order (Left → Right) of increasing residue size at position GluN2A 641. Traces 
are normalized to IPeak for visualization of differences in desensitization. E – H, Comparison of ISS/IPeak values 
measured in 0.1 and 1 mM Ca2+e for WT and mutant GluN1/2A(F641X) receptors. GluN1/2A(F641A) (E), 
GluN1/2A(F641L) (F), and WT (G) receptors all display significant CDD. GluN1/2A(F641W) receptors do 




paired t-test. I, Summary of normalized ISS/IPeak values (1 mM Ca2+e ISS/IPeak normalized to 0.1 mM Ca2+e 
ISS/Ipeak) for WT receptors and GluN2A(F641) mutants. CDD depends on residue size at GluN2A position 
641, with the amount of CDD increasing as residue size decreases. Points represent individual values, bar 
represents mean, and error bars depict SEM; one-way ANOVA with Tukey post hoc analysis. For E – I, *, 
p < 0.05; **, p < 0.01;  ***, p < 0.001; ****, p < 0.0001. ISS/IPeak and normalized ISS/IPeak values summarized 





Table 5. Memantine block and desensitization of WT and GluN1/2A(F641) mutant receptors. 
Values represent means ± sem (n).  
 
 
IC50 (μM) ISS/IPeak 
Normalized 
ISS/IPeak 
Receptor Memantine Ketamine [Ca2+]e =  0.1 mM [Ca2+]e =  1 mM 
1/0.1 mM 
[Ca2+]e 
GluN1/2A(F641A) 1.07 ± 0.05 (6) 0.94 ± 0.07 (3) 0.36 ± 0.02 (4) 0.27 ± 0.03 (4) 0.73 ± 0.02 (4) 
GluN1/2A(F641L) 1.11 ± 0.12 (11) 0.99 ± 0.27 (4) 0.23 ± 0.02 (6) 0.19 ± 0.02 (6) 0.83 ± 0.02 (6) 
WT  1.83 ± 0.05 (5) 0.89 ± 0.08 (7) 0.78 ± 0.01 (7) 0.65 ± 0.01 (9) 0.85 ± 0.01 (7) 





3.4.5 GluN2A residue 641 contributes to the effects of [Ca2+]i on desensitization and 
memantine inhibition of NMDARs 
Given the role of GluN2A F641 in memantine potency and desensitization, we next 
assessed whether mutation of GluN2A F641 affects the [Ca2+]i dependence of memantine 
inhibition. We measured desensitization and memantine IC50 for GluN2A(F641A), WT, and 
GluN2A(F641W) receptors while using specially prepared, Ca2+-buffering pipette solutions to 
maintain [Ca2+]i at either < 1 nM or 10 μM. We did not include GluN2A(F641L) receptors in these 
experiments, as the L mutation showed no effect on CDD (Figure 16I). Inhibition of 
GluN2A(F641A) and WT receptors by memantine was powerfully dependent on [Ca2+]i (Figure 
17A,B,E). Despite showing enhanced CDD in comparison to WT receptors, memantine inhibition 
of GluN2A(F641A) receptors did not exhibit greater dependence on [Ca2+]i, perhaps suggesting 
that the [Ca2+]i dependence of memantine inhibition reaches a floor at IC50 ≈ 0.7 μM (Figure 17E). 
Surprisingly, memantine inhibition of GluN1/2A(F641W) mutants also displayed some degree of 
[Ca2+]i dependence. However, the effect of [Ca2+]i on memantine block of GluN1/2A(F641W) 
mutants was much weaker than the effects observed in WT or GluN1/2A(F641A) receptors 
(Figure 17E), which is consistent with our previous data showing that the GluN2A(F641W) 
mutation weakens CDD (Figure 16D,H,I). 
As expected, desensitization of both GluN1/2A(F641A) and WT receptors was augmented 
by high [Ca2+]i (Figure 17F). However, in surprising contrast to experiments manipulating [Ca2+]e, 
desensitization of GluN2A(F641W) receptors was also dependent on [Ca2+]i. Furthermore, the 
magnitude of [Ca2+]i-dependent desensitization of GluN2A(F641W) receptors was similar to that 
exhibited by WT receptors (Figure 17F). This result seems inconsistent with the idea that the 
effects of the GluN2A(F641W) mutation on memantine potency are related to its effects on 




manipulating [Ca2+]i may result from a different mechanism than our previous experiments 
manipulating [Ca2+]e (Figure 16). Regardless of mechanism, it is clear that mutation of GluN2A 







Figure 17. GluN2A residue 641 influences [Ca2+]i-dependent desensitization and the [Ca2+]i 
dependence of memantine inhibition. 
A, B, Concentration-inhibition curves for memantine inhibition of (A) GluN1/2A(F641A) and (B)  
GluN1/2A(F641W) receptors in conditions of [Ca2+]i < 1 nM  and [Ca2+]i = 10 μM. Line depicts best fit of 
data to the Hill equation (Equation 3). Points and error bars show mean ± SEM. Some error bars are 
smaller than points. C, Summary of the [Ca2+]i dependence of memantine IC50 for WT receptors and 
GluN2A(F641) mutant receptors. IC50 values are compared between conditions of [Ca2+]i < 1 nM  and [Ca2+]i 
= 10 μM (black significance symbols and brackets) and across identity of GluN2A residue 641 (gray 
significance symbols and brackets). D, Summary of the [Ca2+]i dependence of desensitization of WT 
receptors and GluN2A(F641) mutant receptors. ISS/IPeak values are compared between conditions of [Ca2+]i 
< 1 nM  and [Ca2+]i = 10 μM and across identity of GluN2A residue 641. Points represent individual values, 
bar represents mean, and error bars depict SEM. Data for E – F analyzed by way of two-way ANOVA with 





Inhibition of NMDARs by memantine, but not ketamine, is dynamically regulated by 
intracellular Ca2+ concentration ([Ca2+]i), a phenomenon resulting from the ability of memantine to 
stabilize a Ca2+-dependent desensitized NMDAR state. In this chapter, we integrated 
computational simulations of NMDAR structure with electrophysiological experiments to 
investigate the role that differential blocker-NMDAR TMD interactions may play in the relation 
between NMDAR channel block and desensitization. We provide multiple lines of evidence in 
support of the hypothesis that the differential effects of memantine and ketamine on NMDAR 
desensitization result from their differential interactions with residues in the NMDAR channel, but 
significant caveats must be considered when interpreting modeling results and data from mutant 
receptors. 
Our docking simulations identified a TMD residue, GluN2A F641, that was predicted to 
interact with memantine but not ketamine. Electrophysiological experiments supported this 
prediction, as mutation of GluN2A F641 altered memantine potency without affecting ketamine 
potency. However, docking simulations have significant limitations, such as use of rigid protein 
and ligand structure, and our electrophysiological data only test for functional effects of the 
mutations on memantine potency, not structural interactions. Indeed, our more sophisticated MD 
simulations suggested that GluN2A F641 does not form direct interactions with memantine. Our 
MD simulations instead describe a mechanism by which GluN2A F641 can indirectly influence 
memantine potency – by influencing the structure of the memantine binding site (Figure 14). 
Indirect effects of other residues on blocker potency have been previously reported (Siegler 
Retchless et al., 2012), supporting the plausibility of this result. Interestingly, GluN1 M641, a 
residue predicted to be (1) involved in memantine binding and (2) influenced by GluN2A F641, 




binding sites (Figure 11). However, GluN2A F641 does not contribute to ketamine potency 
(Figures 12 and 13), suggesting that memantine and ketamine may differentially interact with 
residues shared by their overlapping binding sites. A clear next step for the comparative analysis 
of the memantine and ketamine binding sites is experimentally testing the contribution of GluN1 
M641 to memantine and ketamine potency. 
An attractive interpretation of our data is that size of GluN2A residue 641 regulates 
desensitization, which in turn regulates memantine potency. Indeed, we found that mutation of 
GluN2A F641 to a smaller A residue enhances CDD and memantine potency, while mutation of 
GluN2A F641 to a larger W residue weakens desensitization and memantine potency (Figures 
13, 15, and 16). Although the idea that GluN2A 641 residue size regulates memantine inhibition 
and NMDAR desensitization via a common mechanism is enticing, the effects of Ca2+ on 
memantine inhibition and desensitization of GluN2A(F641L) and GluN2A(F641W) mutants are 
complex.  
GluN1/2A(F641L) mutant receptors display increased memantine potency (Figure 13) and 
Ca2+-independent desensitization in comparison to WT receptors (Figure 15), but similar 
magnitudes of CDD (Figure 16). This finding argues against the idea that the effects of GluN2A 
F641 mutation on CDD underlies their differences in memantine potency. Interestingly, the data 
for GluN1/2A(F641L) mutants also shows far greater variability than data for other receptors 
tested, in nearly all experiments. It is possible that the relatively high flexibility of L contributes to 
the variability we see in its data as well as its differences from the other receptors. In contrast to 
WT and the other mutant GluN2A 641 residues, which are either large and rigid (W and F) or 
small with no meaningful rotatable bonds (A), L can sample a broad range of conformations. 
Therefore, the GluN1/2A(F641L) mutant may form unexpected contacts that stabilize or 
destabilize multiple states that we cannot easily resolve with electrophysiological experiments. 




GluN1/2A(F641L) receptors would allow for further comparison with WT and the other mutant 
receptors, and in silico mutagenesis MD simulations may provide further insight into the role of 
residue flexibility on the electrophysiological characteristics of GluN1/2A(F641L) receptors. 
The effects of Ca2+ on memantine inhibition and desensitization of GluN1/2A(F641W) 
mutant receptors are also intriguing. GluN2A(F641W) receptors did not exhibit CDD in 
experiments manipulating [Ca2+]e (Figure 16), but both desensitization and memantine inhibition 
of GluN2A(F641W) receptors were dependent on [Ca2+]i (Figure 17). This could be interpreted as 
evidence for the existence of multiple mechanisms of CDD, similar to our interpretation of Chapter 
2 data (2.4.4) regarding the time dependence of [Ca2+]i-dependent desensitization. However the 
[Ca2+]i-and-time-dependent form of CDD, which is likely to be the form displayed by 
GluN1/2A(F641W) receptors due to the similarity in conditions for experiments in Figures 8 and 
17 (high [Ca2+]i internal solutions, 5-10 min wait time post-break in), showed no relation to the 
[Ca2+]i dependence of memantine potency of WT receptors (Figure 8). Furthermore, 
desensitization of GluN2A(F641W) receptors in conditions of high [Ca2+]i is comparable to that 
exhibited by WT receptors, but memantine inhibition of GluN2A(F641W) receptors was shown to 
be less dependent on [Ca2+]i than inhibition of WT receptors (Figure 17). This reduction in 
sensitivity to [Ca2+]i is consistent with the reduced CDD exhibited by GluN1/2A(F641W) receptors 
in experiments manipulating [Ca2+]e (Figure 16), but inconsistent with results from experiments 
manipulating [Ca2+]i (Figure 17). Therefore, although it is clear that GluN2A(F641W) receptors 
undergo some form of CDD, the relation between CDD and the [Ca2+]i dependence of memantine 
inhibition of GluN1/2A(F641W) mutants remains unclear. 
Interpretation of GluN2A(F641A) receptor data was far more straightforward, but not 
without some surprises. Despite exhibiting a lower memantine IC50 than WT receptors in 
conditions of 1 mM [Ca2+]e with a 10 mM BAPTA internal solution (Figure 13) and displaying 




GluN2A(F641A) receptors did not differ from WT receptors in either [Ca2+]i condition (Figure 17). 
This suggests that memantine inhibition of GluN2A(F641A) receptors and WT receptors is 
similarly sensitive to [Ca2+]i. However, it is equally possible that the IC50 values generated by our 
experiments, which utilized extremely low (< 1 nM) and high (10 μM) [Ca2+]i conditions, may only 
represent the maximal and minimal memantine IC50 values for GluN2A(F641A) receptors, i.e. the 
floor and ceiling levels of the effect of [Ca2+]i on memantine IC50. Generation of a [Ca2+]i-
memantine IC50 curve (as shown in Figure 4 for WT receptors) would allow for a more direct 
assessment of differences in the effect of [Ca2+]i on memantine inhibition of GluN1/2A(F641A) 





4.0 ELECTROPHYSIOLOGICAL CHARACTERIZATION OF NOVEL NMDA RECEPTOR 
CHANNEL BLOCKING COMPOUNDS  
Chapter 4 is adapted from Appendix B (Leiva et al., 2018). Minor revisions were made to 
language and structure to facilitate integration of additional data. 
4.1 OVERVIEW 
NMDAR activity is critical for many types of synaptic plasticity and is a key player in 
memory formation and learning. Conversely, aberrant NMDAR activation is implicated in a variety 
of nervous system disorders. Excessive NMDAR activity can lead to build up of pathological levels 
of intracellular calcium and lead to cell death, a process known as excitotoxicity. Pharmacological 
targeting of NMDARs with channel blockers has shown therapeutic promise for protection from 
excitotoxicity as well as treatment of Alzheimer’s disease. Despite sharing similarities in binding 
site and mechanism of inhibition, the clinical utility of NMDAR channel blockers with differing 
structure can vary dramatically. Further investigation into how channel blockers differentially affect 
receptor function may provide insight into their varying clinical efficacy and aid in future drug 
design. Here we characterize and compare the Alzheimer’s disease drug memantine with four 
novel channel blockers. We find that subtle variation in channel blocker structure alters blocker 
characteristics. Excitingly, we show that potency of the novel channel blocker RL-208 depends 
on [Ca2+]i. The experiments and data detailed in this chapter lay the groundwork for future studies 
that will determine the structural determinants of [Ca2+]i-dependent channel block, potentially 





NMDARs are expressed at nearly all vertebrate synapses and play key roles in neuronal 
development, plasticity, and survival. Ca2+ influx through NMDARs is a signal of paramount 
importance for synaptic plasticity, including long-term potentiation and long-term depression, 
physiological processes that are the cellular basis of many forms of learning and memory (Morris, 
2013). However, NMDAR overstimulation triggers excessive Ca2+ influx and leads to 
excitotoxicity, which is the primary mediator of neuronal death following stroke and is believed to 
play a key role in the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease 
(AD) and Parkinson’s disease (PD) (Zorumski & Olney, 1993; Lipton, 1999, 2004; Hynd et al., 
2004; Koutsilieri & Riederer, 2007; Dong et al., 2009; Olivares et al., 2012; Mota et al., 2014; 
Gardoni & Di Luca, 2015; Wang & Reddy, 2017). Hence, NMDAR antagonists able to prevent 
overactivation of NMDARs are of interest as neuroprotective drugs. 
Multiple types of NMDAR antagonists have been tested in clinical trials. Several 
competitive NMDAR antagonists failed trials for neurodegenerative disorders and related 
conditions, likely due to nonspecific NMDAR inhibition, i.e., the blocking of both physiological and 
pathological NMDAR activity, which leads to unacceptable side effects (Ikonomidou & Turski, 
2002; Lipton, 2004; Muir, 2006). NMDAR open channel blocking antagonists have also been 
tested as therapeutic agents. In contrast to competitive antagonists, NMDAR channel blockers 
bind at sites that overlap with the Mg2+ binding site and can only bind and unbind when the channel 
is open (Blanpied et al., 2005; Johnson & Kotermanski, 2006; Johnson et al., 2015). Most NMDAR 
channel blockers also failed clinical trials, and several were found to be neurotoxic when 
administered at high doses to control animals (Olney et al., 1989), including dizocilpine (MK-801), 
phencyclidine, and ketamine. Nevertheless, two adamantane derivatives, amantadine and 




NMDAR channel blockers, have been found to be moderately effective for treatment of PD and 
AD (Danysz et al., 1997; Lipton, 2006; Danysz & Parsons, 2012; Hubsher et al., 2012; Alam et 
al., 2017). 
Several hypotheses have been proposed to explain the divergent clinical effects of 
NMDAR channel blockers. The kinetics of recovery from inhibition, which are much faster for 
memantine than dizocilpine, have been proposed to be a major determinant of clinical tolerability 
(Chen & Lipton, 2006; Lipton, 2006, 2007). Another hypothesis is that the utility of memantine 
may derive from an ability to preferentially inhibit extrasynaptic NMDARs, activation of which has 
been proposed to be especially neurotoxic (Hardingham & Bading, 2010; Gladding & Raymond, 
2011; Parsons & Raymond, 2014). However, it is clear that overactivation of synaptic NMDARs 
also can be neurotoxic (Wroge et al., 2012; Zhou et al., 2013), so it unlikely that preferential 
inhibition of extrasynaptic NMDARs fully explains memantine’s high tolerability. Another recent 
proposal is that clinical safety may be associated with preferential inhibition of NMDARs that 
undergo Ca2+-dependent desensitization following exposure to high intracellular Ca2+, a property 
exhibited by memantine but not ketamine (Glasgow et al., 2017). The work presented in Chapter 
2 of this dissertation further supports this idea, revealing that memantine inhibition depends on 
intracellular Ca2+ concentration ([Ca2+]i). The [Ca2+]i dependence of memantine inhibition could 
provide a mechanism through which memantine preferentially targets different subpopulations of 
NMDARs than ketamine. It also suggests a logical mechanism of neuroprotection: preferential 
inhibition of NMDARs that are exposed to large and prolonged increases of Ca2+i, i.e. receptors 
likely to mediate excitotoxic cell death (Zorumski & Olney, 1993; Rothman & Olney, 1995; Hasbani 
et al., 1998; Hardingham & Bading, 2010; Wroge et al., 2012; Zhou et al., 2013). Thus, many 
features of NMDAR channel blockers could potentially contribute to their clinical effects. 
Unfortunately, although memantine is well-tolerated by patients, it possesses limited 




antagonists with similar but distinct pharmacological properties are of interest (Chen & Lipton, 
2006; Lipton, 2006, 2007). Thus, we began a project to design, synthesize, and characterize novel 
NMDAR channel blocking compounds to help us better understand mechanisms of channel block, 
with the end goal of developing new NMDAR-targeting neurotherapeutics with improved 
pharmacological profiles. In this chapter, I provide electrophysiological characterization of four 
novel channel blockers (Figure 18): the benzo-derivative EV-19 and the polycyclic amine 






Figure 18. Structure of memantine and novel channel blockers. 
Structures of organic channel blockers characterized in Chapter 4. All blockers are displayed in charged 
form and shown in bond-line format. EV-19, RL-202, RL-208, and MFV-4 were all designed and synthesized 







4.3 MATERIALS AND METHODS 
4.3.1 Cell culture and transfection 
All electrophysiological experiments were performed at room temperature using the 
tsA201 cell line (European Collection of Authenticated Cell Cultures). Cells were maintained as 
previously described (Glasgow & Johnson, 2014) in DMEM supplemented with 10% fetal bovine 
serum, 1% GlutaMAX (Thermo Fisher Scientific), and for some experiments 1% 
penicillin/streptomycin (Sigma). Cells were plated at 1 x 105 cells/dish in 35 mm petri dishes with 
three 15 mm glass coverslips treated with poly D-lysine (0.1 mg/ml) and rat-tail collagen (0.1 
mg/ml, BD Biosciences). 
12-24 hours after plating, tsA201 cells were transiently cotransfected (FuGENE 6 
Transfection Reagent) with mammalian expression plasmids containing complementary DNA 
(cDNA) coding for enhanced green fluorescent protein (EGFP GenBank ACS32473 in pIRES) to 
identify transfected cells, WT rat GluN1-1a (GluN1; GenBank X63255 in pcDNA3.1), and GluN2A 
(D13211 in pIRES). EGFP was expressed using a specialty plasmid, EGFP:pIRES:GluN2A, gifted 
by Dr. Kasper Hansen. EGFP:pIRES:GluN2A was constructed by inserting cDNA encoding EGFP 
in pIRES between the CMV promoter and the GluN2A open reading frame, and allows for co-
expression of independent EGFP and NMDAR subunit proteins. Cells were transfected with cDNA 
ratios of 1 GluN1: 1 GluN2A. Culture medium was supplemented with 200 μM dl-APV at the time 




4.3.2 Solution preparation 
For experiments in Figures 19 - 23, intracellular pipette solution contained (in mM): 130 
CsCl, 10 HEPES, 10 BAPTA, and 4 MgATP with pH balanced to 7.2 ± 0.05 with CsOH and an 
osmolality of 280 ± 10 mOsm. To allow for study of the effects of constant [Ca2+]i on channel block 
by RL-208 (Figure 26), a high free Ca2+ (Ca2+F) internal solution containing 130 CsCl, 10 HEPES, 
10 HEDTA, 6.2 CaCl2, and 4 MgATP (pH balanced to 7.2 ± 0.05 with CsOH; osmolality = 280 ± 
10 mOsm) was prepared using predictions from the program MAXCHELATOR (Bers et al., 2010). 
The original intention was to [Ca2+]F = 10 μM solution using MAXCHELATOR estimates, but 
MAXCHELATOR does not account for buffer purity or background solution composition and uses 
non-standardized buffer Kd values (McGuigan et al., 2016; Tran et al., 2018). Therefore, I 
empirically measured [Ca2+]F using the Ligand Optimization Method (LOM; as described in 
Chapter 2.3.3) to gather an accurate estimate of [Ca2+]F in this solution. We found that the HEDTA 
Kd value utilized by MAXCHELATOR is substantially higher than measurements made by the 
LOM for our solutions (MAXCHELATOR Kd = 7.2 μM; LOM Kd = 2.24 μM). This inaccuracy 
resulted in preparation of a solution with substantially lower [Ca2+]F than predicted 
(MAXCHELATOR predicted [Ca2+]F = 10 μM; LOM measured [Ca2+]F = 4.89 μM). Therefore, 
[Ca2+]F ≈ 5 μM for the high [Ca2+]i internal solution used for experiments in Figure 26. 
Extracellular recording solution contained (in mM) 140 NaCl, 2.8 KCl, 1 CaCl2 (or 0.1 for 
experiments in Figure 26), 10 HEPES, 0.01 EDTA, and 0.1 glycine, and was balanced to pH 7.2 
± 0.05 with NaOH and to osmolality 290 ± 10 mOsm with sucrose. Channel blockers were diluted 
from concentrated stock solutions (memantine stock = 10 mM in dH20; MgCl2 stock = 1 M in dH2O; 
EV-19 stock = 10 mM in 140 mM NaCl and 2% DMSO; RL-202, RL-208, and MFV-4 stocks = 40 





Whole-cell voltage-clamp recordings were performed 18 – 30 hours after transfection. 
Pipettes were pulled from borosilicate capillary tubing (OD = 1.5 mm, ID = 0.86 mm) using a 
Flaming Brown P-97 electrode puller (Sutter Instruments) and subsequently fire-polished to a 
resistance of 2.5 – 4.5 MΩ using an in-house fabricated microforge. Whole-cell currents were 
recorded using either an Axopatch 1D or Axopatch 200A patch-clamp amplifier (Molecular 
Devices). The current signal was low-pass filtered at 5 kHz and sampled at 20 kHz in pCIamp 10 
(Molecular Devices). Series resistance was compensated 80-90% in all experiments. A -6 mV 
liquid junction potential between the intracellular pipette solution and extracellular solution was 
corrected in all experiments. Glutamate and drug solutions were delivered to the cell via an in-
house fabricated ten-barreled gravity-fed fast perfusion system (Glasgow & Johnson, 2014). 
4.3.4 Analysis 
Concentration-inhibition relations for EV-19 and Mg2+ were measured using the protocol 
shown in Figure 19A. Glutamate was applied until current reached steady state, then sequentially 
increasing concentrations of antagonist (channel blocker) were applied in the presence of 
constant [glutamate] until a steady level of inhibition was reached (10 – 20 s). Antagonists were 
then removed and agonist alone was reapplied to allow recovery from channel block. 
Concentration-inhibition relations for memantine, RL-202, RL-208, and MFV-4 were measured 
using the protocol shown in Figures 20 – 23, A and B. Glutamate was applied until current reached 
steady-state (20 s), then channel blocker at the plotted concentration was applied in the presence 
of constant [agonist] until a new steady-state current level was reached (30 s). Glutamate in the 




Cells in which recovery from inhibition did not reach 90% of steady-state current during initial 
glutamate application were excluded from analysis. IC50 and nH (Hill coefficient) were estimated 
by fitting Equation 3 to concentration-inhibition data as described in Chapter 2.3.4. 
Voltage dependence of channel block by each blocker was measured using the protocol 
shown in Figures 19 – 23, C and D. Cells were subjected to voltage jumps from -65 mV to nine 
voltages ranging from -105 to +55 mV. The protocol at each voltage consisted of: a 4-s wait in 
extracellular solution following the voltage step; application of 1 mM glutamate for 10 s; application 
of drug with 1 mM glutamate for 15 s; application of 1 mM glutamate for 15 s to allow drug 
unbinding; application of extracellular solution for 2 s. Voltage was then returned to -65 mV for 4 
s before the next voltage jump was made. ~2 times the IC50 of each drug was used in voltage 
dependence experiments. Voltage dependence of block was calculated using the Woodhull 
equation, Equation 6: 
where IC50(–65 mV) is the IC50 at –65 mV calculated in concentration-inhibition experiments, and 
V0 represents the change in voltage (in mV) that results in an e-fold change in the IC50 of the drug. 
IDrug/IGlu was calculated as described for concentration-inhibition data. V0 was the only free 
parameter during fitting. An estimate of the fraction of the total membrane voltage field felt by the 
blocker at its binding site (δ;(Woodhull, 1973)) was calculated using Equation 7: 
where R, T, z and F have their usual meanings. Note that, although δ is useful for comparing 


















permeant ions (Antonov et al., 1998). Therefore, δ should be used only as a rough estimate of 
binding site location in the voltage field. 
4.3.5 Molecular modeling  
The closed GluN1/2A TMD model used for docking simulations for memantine, RL-202, 
and RL-208 was developed in collaboration with the Kurnikova Lab of Carnegie Mellon University 
(Mesbahi-Vasey et al., 2017) as described in Chapter 3.3.1. I developed and optimized models 
of memantine, RL-202, and RL-208 using the software Gaussian 09 (M.J. Frisch, 2009), and 
performed docking simulations using the software Autodock Vina (Trott & Olson, 2010) with the 
assistance of Dr. Chamali Narangoda as described in Chapter 3.3.1.  
4.4 RESULTS 
4.4.1 Characteristics of NMDAR inhibition by EV-19  
We characterized NMDAR inhibition by EV-19 using whole-cell patch-clamp recordings 
from tsA201 cells expressing GluN1/2A receptors. Inhibition by EV-19 was measured as a 
function of drug concentration (Figure 19A) and used to calculate the EV-19 IC50 in cells held at -
65 mV. The IC50 of EV-19 was found to be 4.40 ± 0.15 μM. (Figure 19B, C), well within the range 
of therapeutically beneficial NMDAR antagonists (e.g. ketamine IC50 ~ 1 μM; memantine IC50 ~ 1 
– 2 μM; amantadine IC50 ~ 40 – 75 μM (Bresink et al., 1996; Parsons et al., 1996, 2007; Blanpied 
et al., 1997, 2005; Parsons & Gilling, 2007; Kotermanski & Johnson, 2009; Otton et al., 2011; 




NMDAR channel blockers share overlapping binding sites in the NMDAR channel 
(Burnashev, Schoepfer, et al., 1992; Mori et al., 1992; Kashiwagi et al., 2002; Chen & Lipton, 
2005). Thus, many organic NMDAR channel blockers (e.g. amantadine, memantine, and 
ketamine) show competitive binding with the endogenous blocker Mg2+ (MacDonald et al., 1991; 
Kotermanski & Johnson, 2009; Otton et al., 2011; Nikolaev et al., 2012; Glasgow et al., 2018). To 
ascertain whether EV-19 inhibits NMDARs via channel block, we tested the effect of extracellular 
Mg2+ on EV-19 potency. As predicted, the inclusion of 0.2 mM Mg2+ in the recording solution led 
to a substantial rightward shift in the EV-19 IC50 curve and a significant increase in EV-19 IC50 
(IC50 = 4.40 ± 0.15 μM in 0 Mg 2+ vs 21.41 ± 0.56 μM in 0.2 mM Mg2+; p < 0.0001, two-sample 
Student t-test, n = 10 and 6, respectively; Figure 19B, C). This roughly 5-fold decrease in EV-19 
potency suggests a competitive interaction between Mg2+ and EV-19 in the NMDAR channel. 
We next determined the voltage dependence of inhibition by 10 μM (~2-fold IC50 at -65 
mV) EV-19. As predicted of a positively charged channel blocker, inhibition by EV-19 was 
markedly weaker at depolarized potentials (Figure 19D-F). Equation 6 and Equation 7 were 
used to quantify V0, the change in voltage (in mV) that results in an e-fold change in the IC50 of a 
drug, and δ, an estimate of the fraction of the total transmembrane voltage field felt by the blocker 
at its binding site (Woodhull, 1973). Inhibition of GluN1/2A receptors by EV-19 is strongly voltage-
dependent, as reflected by the drug’s small V0 (25.43 ± 0.54 mV) and large δ (1.01 ± 0.02). The 
EV-19 V0 and δ values are similar to previously reported values for monovalent organic channel 
blockers (e.g. V0 ~ 26 – 30 mV, δ ~ 0.8 – 1.0 for memantine, ketamine, and recently synthesized 
polycyclic amines (Blanpied et al., 1997; Parsons, Danysz, & Quack, 1999; Gilling et al., 2009; 
Otton et al., 2011; Leiva et al., 2018)). The profound dependence of EV-19 inhibition on [Mg2+] 
and on membrane potential strongly supports the conclusion that EV-19 inhibits NMDARs by 





Figure 19. Characteristics of GluN1/2A receptor channel block by EV-19.  
A, Representative current trace from one cell depicting inhibition of GluN1/2A receptors by EV-19 at -65 
mV. Current evoked by application of 1 mM glutamate (Glu; black bars) was reduced as [EV-19] (red bars) 
increased. B, Concentration-inhibition relation for EV-19 in 0 Mg2+ (black line, filled symbols) and in 0.2 mM 
Mg2+ (purple line, open symbols). Symbols represent means, error bar are smaller than symbols. Lines 
show best fits of Equation 3 to data. C, Comparison of IC50 values in 0 and 0.2 mM Mg2+.  0.2 mM Mg2+ 
greatly reduces EV-19 potency (IC50 = 4.40 ± 0.15 μM in 0 Mg 2+ vs 21.41 ± 0.56 μM in 0.2 mM Mg2+; n = 
10 and 6, respectively; p < 0.0001, two-sample Student t-test, n = 10 and 6, respectively). Data shown as 
individual values, line and error bars depict mean ± SEM. D, Representative current traces from one cell 
depicting the voltage dependence of inhibition by 10 μM EV-19. For clarity, traces from only five of the 
tested membrane potentials are displayed. E, Current-voltage relation for GluN1/2A receptors in 1 mM Glu 




to current at 55 mV (I55 mV) for each cell. Symbols represent means, error bars represent SEM; some error 
bars are smaller than symbols. F, Mean current-voltage relation data replotted as fractional current in the 
presence of 10 μM EV-19. Solid line shows best fit of Equation 6 to estimate V0 (25.43 ± 0.54 mV; n = 7). 
V0 was subsequently used to calculate δ (1.01 ± 0.02; n = 7) with Equation 7. Error bars in F are smaller 
than symbols. Colors of symbols in E and F correspond to colors of example traces in D; black symbols 






4.4.2 Concentration and voltage dependence of NMDAR inhibition by memantine 
analogues  
Whole-cell patch-clamp recordings from tsA201 cells expressing GluN1/2A receptors 
were used to assess the pharmacological properties of three promising memantine analogues, 
primary amines RL-202 and RL-208 and guanidine MFV-4. Experiments measuring the IC50 and 
voltage-dependence of block by compound memantine were performed for comparison. In cells 
held at -65 mV, inhibition by each drug was measured at increasing drug concentrations (Figures 
20 - 23, A) and used to calculate the IC50 and Hill coefficient (nH, which reflects the steepness of 
the concentration-inhibition curve; Equation 3). The IC50 value and Hill coefficient measured for 
memantine (Figure 20B) are similar to previously-reported values measured under similar 
conditions (Gilling et al., 2007, 2009; Glasgow et al., 2017). RL-202, RL-208 and MFV-4 were 
found to have moderate IC50 values (Figures 21 – 23, B). The IC50s of RL-208 (1.01 ± 0.13 μM) 
and MFV-4 (0.48 ± 0.09 μM) were significantly lower than the IC50s of memantine (1.84 ± 0.39 
μM) or RL-202 (2.78 ± 0.25 μM), and the IC50 of memantine was significantly lower than the IC50 
of RL-202 (Figure 24A). There were no significant differences between the nH of the drugs, i.e., 
1.07 ± 0.27, 0.98 ± 0.08, 1.01 ± 0.11, and 1.00 ± 0.03 for memantine, RL-202, RL-208 and MFV-
4, respectively.  
To measure voltage dependence of inhibition by memantine, RL-202, RL-208 and MFV-
4, inhibition elicited by roughly twice the IC50 of each drug was measured at 9 different voltages 
(examples from 5 voltages are shown in Figures 20 - 23, C). The inhibition produced by the drugs 
decreased as voltage was depolarized (Figures 20 - 23, C and D), as expected of positively 
charged channel blockers. Fitting of Equation 6 to current-voltage data was used to quantify V0, 
the change in voltage (in mV) that results in an e-fold change in the IC50 of a drug. Equation 7 




by the blocker at its binding site. The value of δ is calculated from the value of V0; strong voltage 
dependence is reflected by a large δ and a small V0. All compounds displayed strongly voltage-
dependent block, i.e., for memantine, V0 = 28.0 ± 2.2 mV and δ = 0.91 ± 0.08; for RL-202, V0 = 
26.5 ± 1.8 mV and δ = 0.99 ± 0.05; for RL-208, V0 = 29.9 ± 1.9 mV and δ = 0.87 ± 0.05; for MFV-
4, V0 = 33.6 ± 1.5 mV and δ = 0.76 ± 0.03 (Figures 20 – 23, D). The voltage dependence of 






Figure 20. Concentration and voltage dependence of NMDAR inhibition by memantine.  
A, Representative current traces from one cell depicting effect of memantine on GluN1/2A receptor 
currents. Application of 1 mM Glu (black bars) elicited an inward current that was antagonized by application 
of memantine (red bars). B, Concentration-inhibition relation for memantine. Line shows best fit of Equation 
3 (IC50 = 1.84 ± 0.39 μM, nH = 1.07 ± 0.27; n=5). C, Representative voltage (Vm; top) and current (bottom) 
traces depicting effect of membrane potential upon inhibition by 3 μM memantine. Traces from 5 of the 9 
membrane potentials tested are displayed for clarity. D, Current-voltage relation of inhibition by memantine. 
Line shows best fit of Equation 6 (V0 = 28.0 ± 2.2; n=5).  Points in B and D represent mean fractional 
currents measured at each concentration (B) or voltage (D); error bars represent SEM and are sometimes 
smaller than symbols. Comparison of the concentration and voltage dependence of NMDAR inhibition by 
memantine, RL-202, RL-208 and MFV-4 is shown in Figure 24. Summary of IC50, V0, and δ values are given 





Figure 21. Concentration and voltage dependence of NMDAR inhibition by RL-202.  
A, B, Same as Figure 20A, B, except concentration-inhibition measurements made using RL-202. Line in 
B shows best fit of Equation 3 (IC50 = 2.78 ± 0.25 μM, nH = 0.98 ± 0.08; n=7). C, D, Same as Figure 20C, 
D, except measurements of voltage-dependence made using 5 μM RL-202. Line in D shows best fit of 
Equation 6 (V0 = 26.5 ± 1.8; n=7). Comparison of the concentration and voltage dependence of NMDAR 
inhibition by memantine, RL-202, L-208 and MFV-4 is shown in Figure 24. Summary of IC50, V0, and δ 





Figure 22. Concentration and voltage dependence of NMDAR inhibition by RL-208.  
A, B, Same as Figure 20A, B, except concentration-inhibition measurements made using RL-208. Line in 
B shows best fit of Equation 3 (IC50 = 1.01 ± 0.13 μM, nH = 1.01 ± 0.11; n=7). C, D, Same as Figure 20C, 
D, except measurements of voltage-dependence made using 2 μM RL-208. Line in D shows best fit of 
Equation 6 (V0 = 29.9 ± 1.9; n=8). Comparison of the concentration and voltage dependence of NMDAR 
inhibition by memantine, RL-202, RL-208 and MFV-4 is shown in Figure 24. Summary of IC50, V0, and δ 





Figure 23. Concentration and voltage dependence of NMDAR inhibition by MFV-4.  
A, B, Same as Figure 20A, B, except concentration-inhibition measurements made using MFV-4. Line in B 
shows best fit of Equation 3 (IC50 = 0.48 ± 0.09 μM, nH = 1.00 ± 0.03; n=4). C, D, Same as Figure 20C, D, 
except measurements of voltage-dependence made using 1 μM MFV-4. Line in D shows best fit of 
Equation 6 (V0 = 33.6 ± 1.5; n=4). Comparison of the concentration and voltage dependence of NMDAR 
inhibition by memantine, RL-202, RL-208 and MFV-4 is shown in Figure 24. Summary of IC50, V0, and δ 





Figure 24. Comparison of NMDAR channel blocker properties.  
A, Comparison of blocker IC50 values measured at -65 mV. B, Comparison of voltage dependence of 
inhibition by the blockers. All comparisons made by one-way ANOVA with Tukey post hoc analysis; *p<0.01, 





Table 6. IC50 and voltage dependence of inhibition for memantine and novel channel 
blockers. 
Values represent means ± sem (n).  
Channel blocker IC50 (μM) V0 (mV) δ 
Memantine 1.84 ± 0.39 (5) 28.0 ± 2.2 (5) 0.91 ± 0.08 (5) 
EV-19 4.40 ± 0.15 (10) 25.43 ± 0.54 (7) 1.01 ± 0.02 (7) 
RL-202 2.78 ± 0.25 (7) 26.5 ± 1.8 (8) 0.99 ± 0.05 (8) 
RL-208 1.01 ± 0.13 (8) 29.9 ± 1.9 (8) 0.87 ± 0.05 (8) 





4.4.3 Docking predicts overlapping binding sites for RL compounds and memantine 
To provide insight into the binding sites of the novel polycyclic amines, we performed and 
compared docking simulations of memantine, RL-202, and RL-208. Docking simulations of 
memantine predicted a binding pose in the channel between the GluN1 and GluN2A subunits 
(Figure 25A,D) and in close proximity to GluN1 residue M641 and critical asparagine residues 
(GluN1 N616 and GluN2A N614) that are key components of the NMDAR selectivity filter and 
heavily implicated in channel block ((Burnashev, Schoepfer, et al., 1992; Mori et al., 1992; Kuner 
& Schoepfer, 1996; Ferrer-Montiel et al., 1998; Kashiwagi et al., 2002; Mesbahi-Vasey et al., 
2017); Figure 25G). This predicted memantine binding pose is identical to previous docking 
simulations (shown in Figure 11), highlighting the consistency of Autodock Vina simulations. RL-
202 and RL-208 were also predicted to bind in the channel above the selectivity filter, between 
the GluN1 and GluN2A subunits (Figure 25B,C,E,F). Nearly all residues predicted to be in close 
proximity with the RL compounds were shared with memantine (Figure 15G,H,I). The “R-group” 
containing the primary amine of RL-208 is predicted to project slightly farther out into the channel 
than the R-groups of memantine and RL-202, potentially allowing it to interact with an additional 
critical asparagine (GluN1 614; Figure 25I), and memantine is predicted to interact with additional 
hydrophobic residues GluN2A F641 and GluN1 A627. The similarities between the predicted 
binding sites is consistent with our data showing the general similarities between the 







Figure 25. Predicted binding sites of memantine, RL-202, and RL-208. 
A – C, Top-down view of memantine (A), RL-202 (B), and RL-208 (C) docked to the GluN1/2A channel. D 
– F, Full scale view of memantine (D), RL-202 (E), and RL-208 (F) docked within the GluN1/2A receptor 
channel model (Mesbahi-Vasey et al., 2017). GluN1 is depicted as gray-blue ribbons; GluN2A is depicted 
as cyan ribbons. Blockers are depicted as space-filling structures. Boxes in (D) – (F) depicts regions blown 
up in (G) – (I). G – I, Magnified view of docking sites for memantine (G), RL-202 (H), and RL-208 (I). 
Residues are shown as stick models. All three blockers are predicted to bind in close proximity with key 
asparagine residues. Memantine, but not the RL compounds, is predicted to bind in close proximity to 
residues GluN1 A627, GluN2A F641 (labeled in G), and GluN2A V612. RL-208 is predicted to interact with 
GluN1 N614 of both GluN1 subunits. All other residues within 3 Å are shared. Drug C = pink (drug) or green 




4.4.4 [Ca2+]i dependence of inhibition by RL-208 
Given the similarities between both the electrophysiological characteristics and the 
predicted binding sites of memantine and the RL compounds, we next tested whether inhibition 
of GluN1/2A receptors by RL-208 depended on [Ca2+]i. We measured the RL-208 IC50 in 
conditions of low (< 1 nM) and high (5 μM) [Ca2+]i and found that inhibition of RL-208 was heavily 
dependent on [Ca2+]i. RL-208 potency was roughly 3-fold higher in conditions of [Ca2+]i = 5 μM 
than conditions of [Ca2+]i < 1 nM (Figure 26). The degree of [Ca2+]i-dependence of RL-208 potency 










Figure 26. Inhibition by RL-208 depends on [Ca2+]i. 
A, Concentration-inhibition curve for RL-208 at [Ca2+]i <1 nM and [Ca2+]i =  5 μM, measured using recordings 
from recombinant GluN1/2A receptors. Points represent mean; error bars smaller than points. B, Summary 
of RL-208 IC50 values for GluN1/2A receptors in conditions of [Ca2+]i = <1 and 5 μM. RL-208 potency 
depends on [Ca2+]i ([Ca2+]i < 1 nM: 2.34 ± 0.14 μM; [Ca2+]i = 5 μM: 0.88 ± 0.06 μM). Unpaired Student’s t-





NMDAR channel blockers are clinically useful therapeutic drugs, but their clinical profiles 
can be surprisingly diverse and difficult to predict. Amongst channel blockers, memantine is 
particularly interesting due to its combination of clinically efficacy and high tolerability (Parsons, 
Danysz, & Quack, 1999; Lipton, 2004; Parsons & Gilling, 2007; Parsons et al., 2007; Johnson et 
al., 2015). Here we characterize and compare with memantine four novel NMDAR antagonists, 
the benzo-derivative EV-19 and the novel memantine analogues RL-202, RL-208, and MFV-4. All 
drugs tested displayed IC50s well within the 0.5 – 75 μM range of therapeutically beneficial 
NMDAR antagonists (Bresink et al., 1996; Parsons et al., 1996, 2007; Blanpied et al., 1997, 2005; 
Parsons & Gilling, 2007; Kotermanski & Johnson, 2009; Otton et al., 2011; Leiva et al., 2018). 
Multiple lines of evidence support the conclusion that EV-19, RL-202, RL-208, and MFV-4 all act 
as channel blockers. EV-19 potency is greatly reduced in the presence of the prototypical NMDAR 
channel blocker Mg2+ (Figure 19), suggesting competition for binding. Docking simulations predict 
that RL-202 and RL-208 share nearly identical binding sites to memantine (Figure 25), which is 
known to bind in the NMDAR channel. Finally, inhibition by all four drugs is voltage-dependent 
(Figures 19, 21-24), which is a hallmark of positively charged channel blockers.  
Interestingly, subtle differences between the memantine analogues had substantial 
influence on their potency. RL-202, despite having the most similar structure to memantine out of 
the novel compounds tested, was found to have a 1.5-fold higher IC50 than memantine. Even 
more impressively, RL-208 was found to have a > 2.5-fold lower IC50 than RL-202, despite 
differing by only a single CH2. MFV-4, which possesses multiple additional carbons and nitrogens 
in comparison to memantine and the RL compounds, was the most potent blocker tested. It is 
possible that guanidine group of MFV-4 allows for easier coordination by the critical asparagine 




hydrophobic residues surrounding the pore, resulting in increased potency. Sophisticated MD 
simulations would provide crucial insight into the mechanism of interaction between each novel 
compound and the GluN1/2A TMD, giving us a strong starting point for experiments that further 
probe the effect of blocker structure on potency.  
Unlike potency, structure had little influence over the voltage dependence of inhibition by 
each blocker. Even the benzodiazepine derivative EV-19, despite its slightly higher IC50 and vastly 
different structure, exhibited comparable V0 and δ values to memantine and the memantine 
analogs (will tabulate values). MFV-4 was the only blocker to show a significant difference in 
voltage dependence, displaying slightly weaker voltage dependence than memantine and RL-
202. This could be related to the ability of MFV-4’s guanidine R-group to easily delocalize its 
positive charge due to resonance, in contrast to the other blockers which possess primary amine 
R-groups. Although the mechanisms underlying the pharmacological differences between 
memantine, its analogs, and EV-19 are still unclear, our data provides strong evidence that even 
small differences in NMDAR channel blocker structure can greatly influence potency. 
 It is important to note that we observed differences between EV-19 IC50s measured using 
intracellular Ca2+ measurements from cerebellar granule neurons (1.93 ± 0.21 μM, personal 
communication with Santi Vazquez of University of Barcelona) and patch-clamp recordings from 
tsA201 cells expressing GluN1/2A receptors (Figure 19). We also observed a similar trend In 
previous comparisons of NMDAR channel blocker IC50s across these two experimental 
preparations, with intracellular Ca2+ measurements from cerebellar granule neurons again 
generating lower IC50 values for memantine, the RL compounds, and MFV-4 than whole-cell 
recordings (Leiva et al., 2018). This discrepancy may result from inherent differences between 
the recording techniques and/or from expression of GluN2 subunits other than GluN2A by 




across NMDAR subtype and in cultured neurons will help us further understand the subtle 
differences between these compounds. 
Excitingly, our data shows that inhibition of GluN1/2A receptors by RL-208 depends on 
[Ca2+]i. RL-208 is the first channel blocker other than memantine to display [Ca2+]i-dependent 
channel block. This is perhaps unsurprising, given the similarities in the predicted memantine and 
RL-208 binding sites. The [Ca2+]i dependence of RL-208 potency suggests that RL-208 also 
stabilizes a Ca2+-dependent desensitized receptor state, and may preferentially target receptors 
exposed to high [Ca2+]i for prolonged durations. A clear next step is to test whether RL-202 
potency is also [Ca2+]i-dependent. An ideal neuroprotective drug would show weak interaction 
with receptors unaffected by pathological insults while strongly inhibiting receptors involved in 
neurotoxicity. Thus, the weaker potency of RL-202 could make it a strong candidate for a 
neuroprotectant if its potency shows strong [Ca2+]i dependence. Furthermore, investigation of the 
[Ca2+]i dependence of EV-19, RL-202, MFV-4 potency would lay the groundwork for future studies 
that determine the structural determinants [Ca2+]i-dependent channel block. Understanding the 
structural bases of the mechanisms of action of channel blockers will improve our understanding 
of how channel blockers affect NMDAR gating and may help guide the development of more 





5.0 GENERAL DISCUSSION 
The work presented in this dissertation focuses on the interplay between the effects of 
intracellular Ca2+ (Ca2+i) on NMDAR channel block and desensitization. Through investigation of 
the relation between NMDAR desensitization and channel block, we discovered that potency of 
the clinically efficacious channel blocker memantine was powerfully dependent on [Ca2+]i. In 
contrast, potency of neither the endogenous channel blocker Mg2+ nor another clinically useful 
channel blocker, ketamine, was found to be [Ca2+]i-dependent. Utilizing this discrepancy, we then 
further probed the mechanism underlying the relation between memantine block and NMDAR 
desensitization by comparing the memantine and ketamine binding sites. We identified a residue 
in the GluN2A transmembrane domain (TMD) that strongly contributes to NMDAR desensitization 
and memantine potency, providing insight into how memantine may interact with the NMDAR 
channel. Finally, we characterized novel NMDAR channel blockers to help us better understand 
how blocker structure contributes to the pharmacological characteristics of channel block. 
Excitingly, we discovered that potency of a memantine derivative was also dependent on [Ca2+]i, 
providing optimism for the directed design of future NMDAR channel blockers with improved 
therapeutic benefits. This chapter discusses the implications of our findings on our understanding 
of NMDAR desensitization, the relation between channel block and NMDAR gating, and the utility 






5.1 MULTIPLE MECHANISMS OF, AND NAMES FOR, CA2+-DEPENDENT 
DESENSITIZATION 
Despite a wealth of research, the mechanisms underlying CDD have been the subject of 
much debate. The confusion surrounding CDD mechanisms is due, in part, to the lack of 
consistent definitions and terminology used to refer to CDD processes that are potentially driven 
by distinct mechanisms. The data presented in this dissertation, particularly from experiments 
addressing the relation between desensitization and NMDAR block by memantine, provide new 
evidence that helps delineate different CDD mechanisms. 
There are likely, at minimum, two separable forms of CDD: a fast mechanism that occurs 
over the course of 0.01 – 5 s, and a slow mechanism that takes minutes to develop. A rapid 
reduction in NMDAR activity caused by NMDAR-mediated Ca2+ influx was first reported by Mayer 
and Westbrook in 1985 and was referred to as desensitization (Mayer & Westbrook, 1985). Eight 
years later, the Westbrook lab revisited the effect of intracellular Ca2+ on rapid NMDAR 
desensitization and termed it Ca2+-dependent inactivation (CDI) to “avoid confusion with other 
forms of NMDA receptor desensitization” (Legendre et al., 1993). Other studies reported slower 
forms of NMDAR desensitization, referred to as glycine-insensitive desensitization or “Ca2+-
dependent activation of NMDAR desensitization”, that were regulated by Ca2+ and related to the 
duration of elevated [Ca2+]i (Sather et al., 1992; Lieberman & Mody, 1994; Tong & Jahr, 1994; 
Tong et al., 1995). Despite being observed under different experimental conditions (i.e. outside-
out patches vs whole cell recordings, long recordings vs short recordings, etc.), these 
desensitization processes were eventually absorbed by the monolithic term CDI (Iacobucci & 
Popescu, 2017, 2020). 
Many interactions between NMDARs and downstream signaling molecules, 




been implicated in processes referred to as CDI (Ehlers et al., 1996; Wyszynski et al., 1997; 
Zhang et al., 1998; Krupp et al., 1999; Rycroft & Gibb, 2002; Iacobucci & Popescu, 2017). The 
most complete hypothesis for a CDI mechanism posits that buildup of [Ca2+]i leads to activation 
of CaM, which displaces α-actinin from its binding site on the GluN1 CTD, releasing the channel 
from the actin cytoskeleton (Zhang et al., 1998; Krupp et al., 1999). The displacement of α-actinin 
by CaM could even lead to desensitization by itself, since the α-actinin-GluN1 interaction is 
thought to stabilize an open NMDAR state (Wyszynski et al., 1997; Krupp et al., 1999). Some 
evidence suggests that direct binding of Ca2+ by α-actinin can drive the dissociation of α-actinin 
from GluN1 without the need for CaM (Krupp et al., 1999), but it is well-accepted that direct 
interaction of CaM with the GluN1 CTD is the primary driver of CDI (Ehlers et al., 1996; Zhang et 
al., 1998; Rycroft & Gibb, 2002, 2004; Iacobucci & Popescu, 2017). Thus, CDI is most accurately 
defined as a fast CDD process that depends on the direct binding of CaM to the GluN1 CTD. 
Our understanding of the slower form of CDD is far less advanced. Slow CDD, originally 
referred to as a glycine-independent desensitization mechanism, can be broadly defined as a 
progressive increase in desensitization following whole-cell break-in or outside-out patch 
formation (Sather et al., 1992; Lieberman & Mody, 1994; Tong & Jahr, 1994; Villarroel et al., 
1998). Glycine-independent desensitization, or at least a form of it, was shown to depend on Ca2+ 
by experiments that prevented rises of [Ca2+]i either through chelation of Ca2+ by high intracellular 
[BAPTA] or through manipulation of NMDAR-mediated Ca2+ influx (Lieberman & Mody, 1994; 
Tong & Jahr, 1994; Medina et al., 1995; Krupp et al., 2002). There are clear kinetic differences 
between this Ca2+-dependent, glycine-independent desensitization process and the CaM-binding-
dependent CDI. CDI occurs over the course of milliseconds (Legendre et al., 1993; Ehlers et al., 
1996; Zhang et al., 1998; Krupp et al., 1999). In contrast, this Ca2+-dependent, glycine-
independent desensitization develops over the course of minutes (Lieberman & Mody, 1994; Tong 




scale, the slower form of CDD has also been referred to as CDI (Iacobucci & Popescu, 2017, 
2020).  
The molecular mechanisms underlying slow CDD are unclear. The most heavily implicated 
driver of slow CDD is calcineurin, a Ca2+-CaM-activated serine/threonine protein phosphatase. 
Calcineurin has been reported to regulate NMDAR desensitization in response to prolonged 
elevations of [Ca2+]i or transient synaptic Ca2+ influx (Lieberman & Mody, 1994; Tong & Jahr, 
1994; Tong et al., 1995; Krupp et al., 2002; Rycroft & Gibb, 2004). Inhibition of calcineurin has 
been reported to ablate the time-dependent, Ca2+ dependent increase in desensitization following 
whole-cell break-in or outside-out patch formation (Lieberman & Mody, 1994; Tong & Jahr, 1994; 
Krupp et al., 2002). Krupp et al. 2002 further narrowed down the mechanism of slow CDD by 
showing that (1) dephosphorylation of multiple sites on the GluN2A CTD by calcineurin is 
necessary for slow CDD and (2) that truncation of the GluN1 CTD had no effect on slow CDD, 
fully distinguishing slow CDD from CDI. However, a recent study (Iacobucci & Popescu, 2017) 
reported that calcineurin inhibition had no effect on desensitization elicited by prolonged exposure 
to [Ca2+]i (high [Ca2+]F in pipette, 15 min post-break-in). To further complicate matters, Iacobucci 
& Popescu 2017 (who refer to this Ca2+-dependent, progressive increase in desensitization as 
CDI) also reported that truncation of the GluN1 CTD ablated the sensitivity of all forms of NMDAR 
desensitization to [Ca2+]i. These inconsistencies make it difficult to definitively state that the slow 
and fast CDD processes are mediated by distinct mechanisms. 
Through investigating the mechanisms underlying the [Ca2+]i dependence of memantine 
potency, we uncovered evidence supporting the existence of distinct Ca2+-dependent 
desensitized states. Our data support the hypothesis that the [Ca2+]i dependence of memantine 
potency arises from the ability of memantine to stabilize a Ca2+-dependent desensitized GluN1/2A 
receptor state. Stabilization of a receptor state by memantine necessitates an energetically 




memantine for that state. Both memantine potency and NMDAR desensitization increase with 
increasing [Ca2+]i, and ablating CDD also ablates the effect of [Ca2+]i. This suggests that 
memantine has a higher affinity for this Ca2+-dependent desensitized state. We also found that 
desensitization of GluN1/2A receptors is further increased by prolonging the duration that 
receptors are subjected to high [Ca2+]i. However, memantine inhibition of GluN1/2A receptors 
does not progressively increase alongside this progressive [Ca2+]i-and-time-dependent increase 
in desensitization. Therefore, our data suggest there are at least two distinct Ca2+-dependent 
desensitized conformational states: one conformation with a higher affinity for memantine, and 
one conformation with unchanged affinity for memantine. 
 Our data makes a strong case for the existence of two distinct desensitized 
conformational states, both dependent on [Ca2+]i, with different interactions with memantine. 
However, it is difficult to conclude definitively which mechanisms underlie which desensitization 
process. It is almost certain that the desensitization process that produces the state stabilized by 
memantine is relatively fast. This conclusion is supported by our data showing that the [Ca2+]i 
dependence of memantine potency does not depend on duration of exposure to [Ca2+]i, as well 
as by previous data from our lab showing that memantine potency increases in conditions that 
allow for increased buildup of [Ca2+]i via NMDAR-mediated influx over short timescales (Glasgow 
et al., 2017). Notably, in our experiments, both the [Ca2+]i dependence of memantine potency and 
a form of CDD are reliant on the presence of the GluN1 CTD. This suggests that the mechanism 
of CDD related to memantine potency is likely similar to the “canonical” CDI mechanism, which 
requires interactions between CaM, α-actinin, and the GluN1 CTD (Zhang et al., 1998; Krupp et 
al., 1999). The slower [Ca2+]i-and-time-dependent desensitization in our experiments is similar to 
the slow form of CDD previously reported by the Jahr and Westbrook labs (Tong & Jahr, 1994; 
Krupp et al., 2002). This conclusion, however, is complicated by conflicting data from the 




mechanism of CDD (Krupp et al., 2002; Iacobucci & Popescu, 2017). Future experiments 
assessing the role of calcineurin in the [Ca2+]i dependence of memantine potency and the role of 
the GluN1 CTD in [Ca2+]i-and-time-dependent desensitization will help clarify the mechanism 
underlying the slow form of CDD observed in our experiments. 
5.2 STRUCTURAL UNDERPINNINGS OF [CA2+]I-DEPENDENT CHANNEL BLOCK 
Our results support the idea that the [Ca2+]i dependence of memantine potency arises from 
the ability of memantine to stabilize a Ca2+-dependent desensitized GluN1/2A receptor state, 
which suggests that memantine has a higher affinity for receptors in this state. This finding has 
the potential to deepen our understanding of the structural features underlying the conformational 
changes that occur during NMDAR state transitions. Understanding the structural features that 
govern the relation between memantine potency and CDD may also aid in the design of future 
channel blockers that more selectively target specific receptors states. Our experiments have 
identified several key structural features that contribute to both the [Ca2+]i dependence of 
memantine potency and CDD. 
The most obvious structural feature of the NMDAR that contributes to both the [Ca2+]i 
dependence of memantine potency and CDD is the GluN1 CTD. Both the [Ca2+]i dependence of 
memantine potency and CDD require the GluN1 CTD. However, the GluN1 CTD is relatively 
distant from regions making up the NMDAR pore. Therefore, in order to reach the conformation 
stabilized by memantine, the channel must receive some long-distance allosteric signal from the 
GluN1 CTD. NMDARs are particularly notorious for long-distance allosteric transduction between 
receptor domains (Paoletti et al., 1997, 2000; Zheng et al., 1998, 2001; Rachline et al., 2005; 




Jalali-Yazdi et al., 2018; Esmenjaud et al., 2019; Vyklicky et al., 2021). Unfortunately, how 
conformational changes in the GluN1 CTD contribute to channel gating is unknown, and there are 
currently no NMDAR crystal or cryo-EM structures that include the GluN1 CTD (or any other 
NMDAR subunit CTD). Improved structural models may provide further insight into the role of 
TMD-CTD coupling in CDD and the [Ca2+]i dependence of memantine potency. 
Our investigation into the role of the GluN2 subunit in the effects of [Ca2+]i on memantine 
potency also provided insights into the structural underpinnings of the relation between 
memantine potency and CDD. The identity of the GluN2 subunit determines the effects of [Ca2+]i 
on desensitization and memantine potency. [Ca2+]i dependence of memantine inhibition is a 
GluN2A subunit-specific phenomenon;  block of GluN1/2B, GluN1/2C, and GluN1/2D receptors 
by memantine is [Ca2+]i-independent. Memantine inhibition of GluN1/2A receptors in cells with 
[Ca2+]i < 1 nM was significantly weaker than memantine inhibition of any other NMDAR subtype 
tested, regardless of condition. This suggests that GluN1/2A receptors can sample a unique 
channel conformation, inaccessible to other subtypes, with weak memantine affinity. In contrast, 
the memantine IC50 measured for GluN1/2A receptors with [Ca2+]i = 10 μM was nearly identical to 
the IC50 values measured for all other NMDAR subtypes, regardless of condition. This finding 
suggests that Ca2+i drives the GluN1/2A channel, and its memantine binding site, into a 
conformation that is similar to the other receptor subtypes. The high degree of sequence 
homology in the pore-lining regions of the GluN2 subunits (Traynelis et al., 2010; Siegler 
Retchless et al., 2012) suggests that that variations in channel conformations between the 
subtypes result from differences in regions outside the channel. Furthermore, given that the 
GluN1 CTD is an essential determinant of CDD and the Ca2+ dependence of memantine potency, 
it is highly likely that differences in inter-subunit interactions govern the subtype-dependent 
differences in the effects of [Ca2+]i on desensitization and memantine potency. Indeed, Vissel et 




interaction with residues 834 – 843 of the GluN1 CTD C0 region (Vissel et al., 2002).  Investigation 
of the role of the GluN2A M2-M3 loop in memantine potency may provide further insight into the 
structural interactions governing the [Ca2+]i dependence of GluN1/2A receptor inhibition by 
memantine. 
Little is known about conformational changes or residue-residue interactions at the level 
of the TMD during NMDAR desensitization. Our simulations and experiments in Chapter 3 
identified residues in the NMDAR TMD, GluN1 M641 and GluN2A F641, that may play key roles 
in NMDAR desensitization and the [Ca2+]i dependence of memantine potency. We found that both 
desensitization and memantine inhibition of GluN1/2A receptors is influenced by a residue in the 
GluN2A M3 helix, GluN2A F641. Mutation of GluN2A F641 had powerful effects on NMDAR 
desensitization, with mutation of the WT F residue to smaller residues (A or L) in comparison to 
the larger WT F residue greatly increasing desensitization. Interestingly, though both mutations 
enhanced desensitization, the GluN2A(F641A) and GluN2A(F641L) mutations displayed key 
differences in which type of desensitization they enhanced. GluN1/2A(F641L) receptors only 
enhanced Ca2+-independent desensitization, while GluN1/2A(F641A) receptors enhanced both 
Ca2+-independent desensitization and CDD in comparison to WT receptors. These finding 
suggests intriguing possibilities for the role of GluN2A F641 in desensitization. Firstly, our data 
suggests that GluN2A F641 is likely involved in interactions that affect the relative stability of open 
and closed states of the NMDAR channel. Secondly, the differential ability of the GluN2A(F641A) 
and GluN2A(F641L) mutations to stabilize different desensitized states suggests that different 
desensitized states have different conformations at the level of the TMD. This idea is further 
supported by our finding that memantine stabilizes a specific Ca2+-dependent desensitized 
receptor state rather than broadly stabilizing all closed states. Using MD simulations to identify 
channel residues that differentially interact with GluN2A(F641A) and GluN2A(F641L), and then 




determining structural differences between Ca2+-independent and Ca2+-dependent desensitized 
states. 
Interestingly, our results do not suggest that mutation of GluN2A F641 influences 
memantine inhibition simply by affecting NMDAR desensitization. Although our MD simulations 
did not suggest a direct interaction between GluN2A F641 and memantine, the simulations 
suggested that GluN2A F641 instead regulated memantine potency through interaction with 
GluN1 M641. GluN1 M641 was predicted to form energetically favorable interactions with both 
memantine and GluN2A F641. Simulations suggested that the size of GluN2A residue 641 
contributes to its strength of interaction with GluN1 M641, with larger residues forming stronger 
interactions. Stronger interaction of GluN1 M641 with GluN2A F641 reduces interaction of GluN1 
M641 with memantine, increasing memantine IC50 in comparison to the IC50 for GluN1/2A(F641A) 
receptors. This modeling prediction is supported by our experimental data, which show that size 
of the residue at GluN2A 641 is correlated with memantine IC50. Thus, our simulations suggest 
that memantine and GluN2A F641 compete for interaction with GluN1 M641. It is important to 
note, however, that neither our simulations nor our experiments rule out the possibility that 
interaction of GluN2A F641 with GluN1 M641 could regulate desensitization. Larger GluN2A 641 
residues and stronger interaction with GluN1 M641 may aid in stabilizing a receptor open state, 
reducing desensitization, while mutation of GluN2A 641 to smaller residues may remove this 
interaction with GluN1 M641, allowing for stronger interaction of GluN1 M641 with memantine 
and stabilization of a receptor closed/desensitized state. This prediction could be tested by 
experimentally investigating the effects of GluN1 M641 mutations on desensitization, memantine 
potency, and the Ca2+ dependence of memantine potency. 
Excitingly, we found that memantine is not the only channel blocker that displays [Ca2+]i-
dependent potency. Inhibition of GluN1/2A receptors by the novel memantine analog RL-208 




RL-208 also stabilizes a Ca2+-dependent desensitized receptor state. There are clear structural 
similarities between memantine and RL-208. Both memantine and RL-208 (see Figure 18) are 
essentially polycyclic carbon balls with multiple methyl groups and a primary amine. It is likely that 
these general structural features govern the ability of memantine and RL-208 to stabilize a Ca2+-
dependent desensitized receptor state. Further structural comparison of memantine and RL-208 
with ketamine (see Figure 11 for structure), which does not display [Ca2+]i-dependent potency, 
reveals several notable differences that may contribute to the differential interactions these drugs 
have with desensitized states.  
Both memantine and RL-208 (Figure 18) are primary amines, while ketamine (Figure 11) 
is a secondary amine. It is possible that the additional methyl group attached to the ketamine 
nitrogen forms interactions with residues near the critical Asn residues that are unable to be 
reached by memantine and RL-208. Ketamine is much “flatter” and more flexible than memantine 
and RL-208. Ketamine consists of two 6-carbon rings - a phenyl chloride and a cyclohexanone - 
adjoined by a single C-C bond. In comparison to the polycyclic carbon balls that make up the bulk 
of memantine and RL-208, the flatter rings of ketamine can more easily form energetically 
favorable interactions with hydrophilic or aromatic residues in the channel pore (Dougherty, 2007). 
Additionally, the single C-C bond that connect the ketamine rings is rotatable, allowing ketamine 
to adopt a greater number of conformations than memantine and RL-208. In contrast, the rigid, 
bulky, and relatively symmetric memantine and RL-208 molecules have a greater potential to 
favorably coordinate with hydrophobic residues. Indeed, simulations and structural modeling 
performed by Song et al. 2018 suggested that memantine may stabilize a closed channel state 
by coordinating with hydrophobic residues near the bundle crossing (Song et al., 2018), a TMD 
region critically involved in iGluR gating (Chang & Kuo, 2008; Sobolevsky et al., 2009; Twomey 
& Sobolevsky, 2018).  A clear next step is to investigate the dependence of RL-202, MFV-4, and 




whether a channel blocker can stabilize a Ca2+-dependent desensitized receptor state. In addition, 
by expanding our structural comparison of the binding sites beyond the conservative range used 
for Chapter 3 experiments, we can identify additional TMD residues that differentially contribute 
to the binding of the memantine analogs and ketamine. This may lead us toward identification of 
additional residues involved in CDD. Thus, although the structural underpinnings of [Ca2+]i-
dependent channel block are still unresolved, memantine, ketamine, and the novel channel 
blockers should serve as effective experimental probes for interrogating the structure of a Ca2+-
dependent desensitized state and, subsequently, the mechanisms underlying [Ca2+]i-dependent 
channel block.  
5.3 LIMITATIONS OF MOLECULAR MODELING 
Molecular modeling can aid in the interpretation of complicated electrophysiological data 
and facilitate the development of novel hypotheses. However, results of simulations are easy to 
overinterpret and both our docking and MD simulations are subject to notable limitations. Docking 
simulations, when used alone, have many weaknesses. The predominant limitation of docking 
simulations is the use of rigid protein structures. We utilized a stochastic conformational search 
method in which rotatable bonds in the ligand (i.e., the channel blocker) can be rotated by the 
program to give the most favorable conformations, as determined by a predefined scoring 
function, for docking to specific regions of the protein (Trott & Olson, 2010). Though this allowed 
us to partially account for the conformational dynamics of the blockers, the protein was held static 
during docking. Therefore, our docking simulations were limited to static snapshots of the 
GluN1/2A TMD taken from an MD simulation. In addition, scoring functions used to determine 




complex (Sousa et al., 2006; Gaillard, 2018). Therefore, Autodock Vina simulations alone are 
unable to distinguish between resides that directly contribute to the binding of a ligand and 
residues that are merely in close proximity to a ligand’s predicted binding site. Autodock Vina also 
does not account for solvent molecules, which can play key roles in NMDAR channel block 
(Mesbahi-Vasey et al., 2017). Thus, Autodock simulations are best used as a preliminary tool to 
predict the general site of ligand-protein interactions before experimental validation. 
To overcome some of the limitations of docking simulations, we utilized atomistic MD 
simulations to further model interactions of memantine with the GluN1/2A TMD. Our MD 
simulations highlighted a weakness of Autodock Vina simulations, suggesting that a residue 
predicted to contribute to the memantine binding site by Autodock Vina (GluN2A F641) did not 
directly interact with memantine. In addition, these simulations provided a logical explanation for 
the effect of GluN1/2A F641 mutations on memantine IC50 that was consistent with our 
electrophysiological data. However, our MD simulations are limited in scope. We are currently 
limited to only modeling TMD dynamics. NMDAR desensitization is heavily modulated by regions 
distal to the TMD, primarily the NTD and the CTD (Ehlers et al., 1996; Krupp et al., 1996, 1998, 
2002; Villarroel et al., 1998; Vissel et al., 2002; Thomas et al., 2006). However, the impact of 
these distal regions on the structural dynamics of the TMD is not incorporated into our current 
model. This limitation is predominantly due to the lack of knowledge concerning how long-range 
conformational signaling affects TMD structure, as well as the computational burden associated 
with atomistic simulation of large-scale conformational changes.  
It is also important to note that we are simulating the binding of memantine to a closed 
channel state of unknown identity. Since there are no crystal or cryoEM structures of NMDARs in 
confirmed desensitized states, little is known about the conformational differences between 
different closed states. However, the ability of memantine to stabilize only a specific desensitized 




Furthermore, as noted previously, our models do not contain the GluN1 CTD, a structural 
component necessary for CDD and [Ca2+]i-dependent memantine block. Therefore, it is possible 
that our MD simulations do not capture interactions between memantine and the TMD that are 
relevant to CDD. Despite these limitations, our simulations provided interesting insights into the 
structure of the memantine binding site, demonstrating the power of integrating theoretical and 
experimental approaches. 
5.4 THERAPEUTIC RELEVANCE OF STATE-SPECIFIC NMDAR INHIBITION 
Indiscriminate inhibition of NMDARs can generate deleterious side effects in patients, 
including sedation, psychosis, and even neurotoxicity (Olney et al., 1989; Zorumski & Olney, 
1993; Krystal et al., 1994, 2003; Chen & Lipton, 2006). Therefore, for an NMDAR antagonist to 
be clinically acceptable, it must somehow inhibit NMDARs involved in pathological processes 
while leaving NMDAR activity involved in normal physiology relatively intact. State-specific 
inhibition, the targeting of specific receptor states, could allow for preferential inhibition of select 
populations of NMDARs and thus limit off-target and negative side effects. In this dissertation, we 
present multiple lines of evidence that memantine acts not only by blocking ion flux through 
NMDARs, but also by stabilizing a desensitized state of the NMDAR channel. Thus, our results 
strongly support the idea that memantine is a state-specific inhibitor of GluN1/2A receptors. 
The ability to stabilize a Ca2+dependent desensitized receptor state enables memantine 
to differentially target NMDARs based on a combination of physiological context (i.e. activity level) 
and subunit composition. Indeed, our experiments revealed that memantine inhibition of 
GluN1/2A receptors is dynamically regulated by fluctuations of [Ca2+]i in both physiological and 




have clear implications for neuroprotection. The [Ca2+]i dependence of memantine potency should 
allow memantine to inhibit NMDARs in cellular populations subjected to pathological levels of 
Ca2+ influx, i.e., NMDARs likely to mediate excitotoxic cell death (Zorumski & Olney, 1993; 
Rothman & Olney, 1995; Okamoto et al., 2009; Hardingham & Bading, 2010), more readily than 
NMDARs involved in normal physiological signaling. Thus, our results provide a logical 
explanation for how memantine may preferentially target subpopulations of NMDARs involved in 
disease, which has long been a leading hypothesis regarding the unique clinical safety of 
memantine (Zhao et al., 2006; Léveillé et al., 2008; Okamoto et al., 2009; Xia et al., 2010).  
In addition to clear implications for neuroprotection, the subtype- and context-specificity of 
memantine action may allow memantine to preferentially target specific subpopulations of 
neurons. GluN2A-containing receptors are likely the most prevalent NMDARs expressed by 
neurons in the adult hippocampus and cortex (Rauner & Köhr, 2011; Tovar et al., 2013; Stroebel 
et al., 2018). However, while mature excitatory pyramidal cells almost exclusively express GluN2A 
and GluN2B subunits, inhibitory interneurons strongly express GluN2A as well as GluN2C and 
GluN2D subunits (Monyer et al., 1994; Kinney et al., 2006). The differential subunit expression 
pattern observed between excitatory neurons and inhibitory neurons has major implications for 
channel block. GluN1/2A and GluN1/2B receptors, and GluN1/2A/2B triheteromeric receptors, 
are much more sensitive to Mg2+ block than GluN1/2C and GluN1/2D receptors (Monyer et al., 
1994; Kuner & Schoepfer, 1996; Hansen et al., 2014). The subtype-dependence of Mg2+ block 
has a profound effect on the subtype selectivity of memantine. Given that memantine and Mg2+ 
compete for binding in the NMDAR channel, memantine inhibits GluN1/2C and GluN1/2D 
receptors more effectively than GluN1/2A and GluN1/2B receptors in physiological [Mg2+] 
(Kotermanski & Johnson, 2009). Therefore, the high expression level of GluN2C and GluN2D by 
inhibitory in comparison to excitatory neurons should direct memantine to preferentially inhibit 




slices have reported that memantine inhibits spiking activity of inhibitory interneurons more 
effectively than excitatory neurons (Povysheva & Johnson, 2016). 
The GluN2A specificity of the [Ca2+]i dependence of memantine inhibition likely 
compounds with the effect of Mg2+ competition on subtype selectivity of memantine. Data 
presented in Chapter 2 suggest that GluN1/2A receptors, in conditions of low [Ca2+]i, sample a 
unique conformational state that exhibits weaker affinity for memantine and cannot be accessed 
by GluN1/2B, GluN1/2C, or GluN1/2D receptors. Therefore, in the absence of strong excitation, 
memantine potency for GluN1/2A receptors is greatly reduced by both Mg2+ competition and the 
[Ca2+]i dependence of memantine potency. Furthermore, endogenous Ca2+-buffering capacity and 
dynamics can vary greatly between neuronal class due to differential expression of Ca2+-buffering 
proteins. In particular, parvalbumin interneurons exhibit fast spiking activity and unique Ca2+ 
dynamics that allow for prolonged elevations of Ca2+i (Schwaller, 2010). Thus, the GluN2 
expression pattern, high-frequency activity, and slow, large Ca2+ transients displayed by many 
inhibitory interneurons make them prime targets for preferential inhibition by memantine.  
The ability of memantine to preferentially target inhibitory neurons could contribute to its 
neurotherapeutic benefits, particularly for Alzheimer’s disease. Alzheimer’s patients have been 
reported to have decreased cortical activity, reduced metabolism in the prefrontal cortex, and 
strong degeneration of excitatory neurons in comparison to inhibitory neurons (Hof et al., 1991; 
Rombouts et al., 2000; Hof & Morrison, 2004; Schroeter et al., 2012). Therefore, evidence 
suggests that the excitation/inhibition (E/I) balance of cortical activity is altered by the progression 
of Alzheimer’s disease, with a shift toward inhibition. By preferentially inhibiting inhibitory neurons, 
memantine would allow for increased excitatory neuron activity and lead to a shift of the E/I 
balance back toward physiological levels.  
Many NMDAR channel blockers are thought to preferentially target inhibitory interneurons 




Homayoun & Moghaddam, 2007; Widman & McMahon, 2018). However, excessive inhibition of 
inhibitory neurons and subsequent runaway excitation has been proposed to be the mechanism 
by which poorly tolerated NMDAR channel blockers such as ketamine, MK-801, and 
phencyclidine produce psychotomimetic effects and kill neurons (Sharp et al., 2001; Homayoun 
& Moghaddam, 2007). Why, then, does memantine not produce these unacceptable side effects? 
It is possible that the [Ca2+]i dependence of memantine inhibition of GluN1/2A receptors acts as 
a fail-safe preventing runaway excitation. Under normal conditions, memantine may preferentially 
target GluN1/2C and GluN1/2D receptors on inhibitory neurons over GluN1/2A and GluN1/2B 
receptors on excitatory neurons due to differences in Mg2+ block. Then, as excitatory neuron 
activity increases due to disinhibition, Mg2+ block of GluN1/2A receptors is relieved and [Ca2+]i 
increases in excitatory neurons. As [Ca2+]i increases, memantine inhibition of GluN1/2A receptors 
in excitatory neurons increases to levels similar to that of GluN1/2B, GluN1/2C, and GluN1/2D 
receptors. This increase in memantine potency at GluN1/2A receptors, when coupled with Mg2+ 
unblock, could weaken the preference of memantine for inhibitory interneurons. Thus, the [Ca2+]i 
dependence of memantine inhibition of GluN1/2A receptors could allow memantine to subtly 
increase cortical excitability while preventing runaway excitation. Though this hypothesis is likely 
oversimplified, it highlights that subtle mechanistic differences in pharmacodynamics may have 
substantial impact on the clinical profiles of channel blockers. 
5.5 FUTURE DIRECTIONS 
In this dissertation, we present the first characterization of a novel form of state-specific 
NMDAR antagonism, [Ca2+]i-dependent channel block of GluN1/2A receptors by memantine. 




into NMDAR desensitization and the structure of the memantine binding site. Lastly, we 
characterized the electrophysiological properties of newly synthesized NMDAR channel blockers, 
and discovered that potency of a memantine analog is also dependent on [Ca2+]i. This section will 
highlight additional questions generated by our data that have not yet been addressed.  
The experiments presented in Chapter 2 only scratch the surface of the effects of [Ca2+]i 
on desensitization and memantine inhibition of triheteromeric NMDARs and native NMDAR 
populations. GluN1/2A/2B receptors are likely to be the most prevalent form of NMDAR expressed 
in the adult neocortex and hippocampus (Sheng et al., 1994; Luo et al., 1997; Gray et al., 2011; 
Rauner & Köhr, 2011; Paoletti et al., 2013; Tovar et al., 2013; Stroebel et al., 2018). Although we 
showed that memantine inhibition of a mixed population of native NMDARs containing both 
GluN2A- and GluN2B-containing receptor is [Ca2+]i-dependent, we have not directly tested 
whether memantine inhibition of triheteromeric NMDARs is [Ca2+]i-dependent. As mentioned 
previously, isolation of triheteromeric receptors is difficult. Current methods that allow for 
investigation of triheteromeric NMDARs in transfected cells rely on modifications to receptor 
regions involved in either Mg2+ (Hatton & Paoletti, 2005) block or desensitization (Hansen et al., 
2014; Stroebel et al., 2014), and thus are unsuitable for our purposes. Development of new 
methods for isolation of triheteromeric NMDARs will be critical for evaluating the relation between 
desensitization and channel block of GluN1/2A/2B receptors.  
The [Ca2+]i dependence of memantine potency may contribute to the preferential targeting 
of inhibitory interneurons. Previous work from our lab has shown that memantine inhibition of 
synaptic NMDAR responses in excitatory neurons is enhanced in conditions allowing for buildup 
of Ca2+i (Glasgow et al., 2017). However, the effect of [Ca2+]i on memantine inhibition of inhibitory 
neurons has not been directly tested, nor compared with the effect of [Ca2+]i on memantine 
inhibition of excitatory neurons. Furthermore, different types of inhibitory neurons express distinct 




future experiments comparing the effects of [Ca2+]i on desensitization and memantine inhibition 
of different types of inhibitory neurons may provide insight into the effects of endogenous Ca2+ 
buffers on CDD and memantine inhibition.  
Our simulations and experiments in Chapter 3 provided insight into the structure of the 
memantine binding site. However, interpretations of our simulation results are limited due to our 
lack of knowledge about structures of NMDAR desensitized states and our inability to model long-
distance domain-domain interactions. Future studies could ameliorate some of these issues 
through utilization of elastic network models (ENMs). Elastic network models treat the protein 
backbone as harmonic springs between Cα atoms, greatly reducing the computational 
requirements for simulations (Atilgan et al., 2001; Bahar et al., 2010). Due to this reduction in 
computational cost, ENMs are particularly useful for modeling long-range conformational changes 
that are typically beyond the scope of atomistic MD simulations. Although ENMs are coarse-
grained models that lack the resolution of atomistic MD simulations, simulations with ENMs have 
been successfully integrated with atomistic MD simulations to provide interesting insights into the 
conformational dynamics of iGluRs (Dutta et al., 2015; Krieger et al., 2015, 2019; Lee et al., 2019). 
Therefore, integration of our MD simulations with ENM simulations may be a useful strategy for 
investigating the role of non-TMD regions in CDD and memantine binding.  
We have so far only identified two blockers, memantine and RL-208, that show [Ca2+]i-
dependent potency. However, we have only examined the effects of [Ca2+]i on potencies of four 
channel blockers in total: memantine, RL-208, ketamine, and Mg2+. Characterization of the effects 
of [Ca2+]i on the potencies of EV-19, RL-202, and MFV-4 will provide further insight into the 
structural properties that determine whether a blocker stabilizes a Ca2+-dependent desensitized 
GluN1/2A receptor state. Atomistic simulations of blocker binding will also provide further insight 
into the structural mechanisms governing GluN1/2A receptor CDD and channel block. Overall, 




powerful combination of experimental and computational/theoretical approaches to ultimately aid 
in the future design of more clinically efficacious NMDAR-targeting neurotherapeutics and deepen 
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Abstract: Drugs that inhibit ion channel function by binding in the channel and preventing current flow, 
known as channel blockers, can be used as powerful tools for analysis of channel properties. Channel 
blockers are used to probe both the sophisticated structure and basic biophysical properties of ion 
channels. Gating, the mechanism that controls the opening and closing of ion channels, can be profoundly 
influenced by channel blocking drugs. Channel block and gating are reciprocally connected; gating 
controls access of channel blockers to their binding sites, and channel-blocking drugs can have profound 
and diverse effects on the rates of gating transitions and on the stability of channel open and closed states. 
This review synthesizes knowledge of the inherent intertwining of block and gating of excitatory ligand-
gated ion channels, with a focus on the utility of channel blockers as analytic probes of ionotropic 
glutamate receptor channel function. 
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1. Introduction 
Neuronal information processing depends on the distribution and properties of the ion channels 
found in neuronal membranes. Channel gating, perhaps the most basic characteristic of ion channels, refers 
to the ability of ion channels to either open and allow transmembrane ion flux or to close and prevent ion 
flux. The gating mechanisms employed by ligand-gated ion channels are divided into three general 
categories, namely, activation, deactivation, and desensitization. Activation refers to the transition of ion 
channels from closed to open states following application of agonist. Deactivation refers to the transition 
of channels from open to closed states following removal of agonist. Desensitization is canonically defined 
as a decrease in the fraction of channels that are in the open state (termed open probability, or Popen) in the 
maintained presence of agonist [1]. Desensitization is typically a direct consequence of agonist binding. A 
fourth gating mechanism that resembles desensitization but is not driven by agonist binding was referred 
to both as desensitization and inactivation [2–4], although inactivation is a term typically used to describe 
a different mechanism employed by voltage-gated channels [5]. Although driven by different underlying 
mechanisms, both desensitization and inactivation ultimately describe nonconducting channel states that 
do not respond to typical activating stimuli [1,5]. Gating mechanisms of ion channels are finely tuned and 
are essential to normal nervous system function, with even minor aberrations of channel gating often 
resulting in disease. While most known channelopathies involve dysfunction of voltage-gated channels, 
naturally occurring genetic variants that alter the gating of ligand-gated ion channels are increasingly 
associated with neurological disorders, including epilepsy, intellectual disability, and autism [6]. 
Studies of drugs that inhibit channel function provide valuable insight into ion channel gating 
mechanisms. Channel blockers, antagonists that bind in and prevent ion flux through ion channels, have 
been successfully used to probe both the structure of ion channel pores and the kinetics of channel gating. 




conduction pathway), and channel blockers are known to interact differentially with channels in open, 
closed, inactivated, and desensitized states [3,7–10]. Thus, channel blockers are exceptionally well-
positioned, both figuratively and literally, for use as analytic probes in studies of channel gating. Here, we 
discuss the interaction between channel block and channel gating of excitatory ligand-gated ion channels, 
with a focus on ionotropic glutamate receptors. 
 
Reciprocal Interactions between Channel Block and Channel Gating  
Channel gating can profoundly influence channel block, and channel block can profoundly influence 
channel gating. The initial binding of channel blockers often depends on gating state. Most blockers of 
ligand-gated ion channels can only enter and bind to the channel while agonist is bound and the channel 
is in the open state (Figure 1A). Such blockers are descriptively named open channel blockers and are the 
focus of this review. In some cases, open channel blockers are also termed “use-dependent” [11]. A blocker 
is termed use-dependent if inhibition by the blocker (1) requires activation of the channel, and (2) increases 
with duration of channel activation until an equilibrium between blocker binding and unbinding is reached 
(Figure 1A). The actions of almost all known ligand-gated ion channel blockers have been found to be at 
least partially dependent on channel opening, binding either exclusively or with much faster kinetics when 
the channel is open.  
Channel blocker unbinding also depends on gating transitions. If closure of the channel gate and 
agonist unbinding can occur while the blocker is bound, the blocker may become “trapped” in the channel 
(Figure 1C,D), unable to unbind until agonist is reapplied. Interestingly, some trapping blockers display 
the ability to escape from a fraction of blocked channels even after removal of agonist, a phenomenon 
termed “partial trapping” that is not fully understood [12–16]. On the other hand, sequential or “foot-in-
door” channel blockers physically occlude closure of the channel gate (Figure 1E). The depth of the blocking 
site, size of the channel blocker, location of the channel gate, and gating-associated conformational changes 
all contribute to whether channels can close while the blocker is bound. These features dictate the structural 
interactions between channel blockers and the receptor’s gating machinery, which in turn determine the 
influence that the channel blocker can reciprocally exert on gating transitions.  
Bound channel blockers can affect gating transitions in three general ways. Blockers can:  
4. Alter agonist binding and/or unbinding kinetics; 
5. Stabilize channel open states; 
6. Stabilize channel closed states. 
For example, the binding of large sequential blockers to open channels prevents both transition of 
channels into closed states (Figure 1E) and agonist unbinding [7,17–20]. In contrast, smaller trapping 
blockers can interact with either open or closed channel states and can therefore have many possible effects 
on channel gating (Figure 1D). For example, trapping blockers can stabilize open or closed channels and/or 
facilitate entry into or recovery from desensitized states [3,8,21]. The inherent intertwining of channel 
gating and block allows channel blockers to be leveraged as powerful tools for the study of ion channel 





Figure 1. Interplay between channel gating and open channel block. (A) Schematic depicting inhibition of 
current (black line) by a prototypical open channel blocker. Three agonist applications (green bars) are 
shown. The first agonist application in the absence of blocker shows the control response. The second agonist 
application, which follows the application and removal of a blocker (red bar), shows that the blocker cannot 
access its binding site when the channel is closed. The third agonist application, which is made in the 
presence of a blocker, shows that the blocker can access its binding site and inhibit agonist-activated current 
when the channel is in the open state. Entry of a blocker into open channels accelerates the apparent decay 
of the response and decreases the steady state response. Because the blocker cannot bind until the channel 
opens, peak current in response to the first agonist application in the presence of the blocker may be 
unaffected, as shown here. However, if blocker binding is fast relative to current activation kinetics, the peak 
response may be reduced. (B) Ion channels can transition between open, ion permeable states and closed, 




size of channel blocking compounds (red) and depth of the blocking site affects blocker interactions with 
the channel gate. (C) Small channel blockers, such as inorganic cations, can block open channels without 
preventing channel closure or affecting gating transitions. kon is blocker binding rate and koff is blocker 
unbinding rate. When the channel is blocked by a blocker that does not interact with the gate, channel closing 
rate is k’c and channel opening rate is k’o. (D) Small-to-intermediate-sized organic channel blockers can block 
open channels without preventing channel closure, but nevertheless can interact with the channel gate, 
either accelerating or decelerating gating transitions. When the channel is blocked by a blocker that interacts 
with the gate, channel closing rate is k’’c and channel opening rate is k’’o. (E) Large, organic, sequential/foot-
in-door blockers can block open channels and prevent channel closure. k’’’c is channel closing rate when the 
channel is blocked by a sequential/foot-in-the-door blocker.  
Nicotinic Acetylcholine Receptors  
Since the turn of the 20th century, the study of nicotinic acetylcholine receptors (nAChRs) has played 
a critical role in our understanding of ionotropic receptor biophysics and pharmacology. The very concept 
of transmitter receptors arose from the observation that application of nicotine to denervated striated 
muscle elicited muscle contraction, resulting in John Newport Langley’s inference of the presence of a 
“receptive substance” on muscle fibers [22]. The nAChR has served as the prototypical ion channel since 
its discovery, being the first ion channel to be isolated, characterized, structurally imaged, and cloned [23–
31]. nAChRs additionally served as the subject for the first kinetic models of ion channel function [1,32] 
and for the development of patch-clamp electrophysiology [33,34]. Consistent with their vast historical 
importance, nAChRs mediate neuromuscular transmission and play key roles in nervous system function. 
Cholinergic signaling through nAChRs heavily modulates excitatory and inhibitory transmission in 
hippocampal and mesolimbic circuits, and thus is vital in shaping synaptic plasticity and learning [35–40]. 
Unsurprisingly, aberrant expression or activation of nAChRs is heavily implicated in many neurological 
and neuromuscular disorders, including addiction, schizophrenia, epilepsy, Alzheimer’s disease, 
myasthenia gravis, and Lambert–Eaton myasthenic syndrome, making nAChRs a major neurotherapeutic 
target [41–49].  
nAChRs are excitatory, cation-selective members of the Cys-loop receptor superfamily, a major class 
of ligand-gated ion channels named for a conserved loop of 13 amino acid residues formed by disulfide-
bonded cysteine residues in their extracellular domain. Other members of the Cys-loop family include the 
cation-selective serotonin (5-HT3) and zinc-activated (ZAC) receptors, as well as the anion-selective γ-
aminobutyric acid (GABAA) and glycine (Gly) receptors [50]. Like all Cys-loop receptors, nAChRs are 
pentameric protein complexes with broad subunit diversity. nAChRs are assembled from a large catalog 
of subunits consisting of 10 α subunits (α1–10; although α8 is only expressed in avian species), four β 
subunits (β1–4), and the singular γ, δ, and ε subunits. This high subunit diversity is augmented further by 
the “sidedness” of each subunit, which allows the specific order in which subunits assemble to affect the 
receptor’s biophysical properties, resulting in more than 1000 possible nAChR subtypes [38]. All 
neuromuscular junction (NMJ) nAChRs are heteropentameric, composed of α1, β1, γ, and either δ or ε 
subunits at a respective ratio of 2:1:1:1. Neuronal nAChRs, on the other hand, assemble either as α-
homomers or as heteromers composed of α(2–10) subunits complexed with β(2–4) subunits. Homomeric 
α7 and heteromeric α4β2 (2 α4, 3 β2) are the most commonly expressed nAChR subtypes in the brain [51–
53].  
All nAChR subunits possess a modular structure composed of a large extracellular N-terminal domain 
(NTD; the location of the Cys-loop), three-membrane spanning regions (M1-M3), a variable intracellular 
loop, another transmembrane region (M4), and a short extracellular C-terminal domain. Although most 
nAChR subtypes possess two acetylcholine (ACh) binding sites formed within the NTD at the interface 




sites differs broadly depending on subunit composition. For NMJ nAChRs, binding sites form at the α–γ 
or α–ε and at the α–δ subunit interfaces. Neuronal nAChRs again show greater diversity, with heteromeric 
receptors typically possessing two ACh binding sites located at α–β interfaces and homomeric receptors 
possessing five potential ACh binding sites [54–56]. The transmembrane regions (M1-M4) form a central, 
water-filled pore lined by the M2 transmembrane region that serves as a conduction pathway for the 
permeable cations Na+, K+, and Ca2+ [57,58]. Gating of nAChRs is initiated by binding of agonist in the 
extracellular domain, which begins a series of conformational changes that propagate to the 
transmembrane region and induce opening of the channel gate. Gating transitions of nAChRs are also 
heavily dependent on receptor subtype, but cycle through three basic states, namely, a resting closed state, 
an open state, and a desensitized state. nAChRs pass through multiple additional states after agonist 
binding prior to channel opening [59] and display many desensitized states. In fact, desensitization was 
first defined by Katz and Thesleff through the study of NMJ nAChR currents [1].  
 
Channel Block of nAChRs  
As with nearly every aspect of ion channel research, nAChRs were also the first ion channels to be 
investigated using antagonists. Experiments utilizing the arrow poison curare and the snake venom α-
bungarotoxin produced thorough descriptions of competitive antagonism and served as the starting point 
for the isolation of nAChRs and characterization of their function [29,60,61]. Early studies using channel 
blockers to investigate gating of ligand-gated ion channels also largely focused on nAChRs. Local 
anesthetics and barbiturates act as nonselective nAChR blockers (but also target voltage-gated Na+ channels 
[5] and GABAA receptors [62], respectively) and were among the first drugs used to probe ligand-gated ion 
channel block. Treatment of muscle fibers with local anesthetics (most notably, the lidocaine derivatives 
QX-222 and QX-314) converted the normally single exponential decay of motor endplate currents into a 
double exponential decay [63,64], an effect also observed with the barbiturates thiopentone, 
amylobarbitone, and methohexitone [65,66]. These observations served as the basis of a slew of studies that 
characterized the basic features of ion channel block. Adams provided the first extensive characterization 
of use-dependent ligand-gated ion channel block, providing (1) compelling evidence that nAChR channel 
blockade was strongly voltage-dependent, suggesting that the blocker binding site was within the 
membrane electric field, and (2) the first model of sequential channel block of a ligand-gated ion channel 
(Figure 1E; [65–67]). Around the same time, Ruff proposed a similar conceptual model for sequential 
channel block of nAChRs [19]. This model was soon validated by Neher and Steinback, who used single-
channel recordings to show that binding of QX-222 blocked current flow and that open, blocked channels 
could not close (Figure 1E; [20]). These pioneering studies laid the groundwork for the use of channel 
blockers as experimental probes for the study of ion channel gating and function.  
More recent studies of nAChR-channel blocker interactions provided further insight into nAChR 
gating mechanisms. Block of nAChRs by choline and millimolar concentrations of ACh prolong channel 
open times without affecting desensitization [10,68,69]. These findings led to the development of the “dual-
gate” hypothesis of nAChR gating, which posits that nAChR activation and desensitization are mediated 
by distinct gates. Photolabeling experiments utilizing chlorpromazine further supported this dual-gate 
model, showing that (1) chlorpromazine has multiple binding sites in the nAChR channel and (2) the state 
of the receptor (i.e., desensitized, activated, or non-activated) directs the binding of chlorpromazine to 
specific sites in the channel [9,70–72]. Structural and functional evidence supporting the dual-gate model 
of activation and desensitization have been further found for an array of other pentameric ion channels 
[73], providing yet another example of the power of channel blockers as analytic tools. 
 




Ionotropic glutamate receptors (iGluRs) are members of the pore loop superfamily of ion channels, 
integral membrane proteins that mediate the majority of ion flux across neuronal membranes [5]. Fast 
excitatory synaptic transmission in the central nervous system is primarily mediated by iGluRs, and proper 
functioning of iGluRs is vital to synaptogenesis, synaptic plasticity, signal integration, and information 
transfer [74,75]. Due to the integral roles iGluRs play in neuronal function and their ubiquitous expression, 
aberrant iGluR activity contributes to a wide variety of neuronal dysfunctions that can drive nervous 
system disorders [6,76–82]. 
iGluRs are divided into three main classes by structure: α-amino-3-hydroxyl-5-methyl-4-isoxazole-
propionate receptors (AMPARs), kainate receptors (KARs), and N-methyl-D-aspartate receptors 
(NMDARs). A fourth division of the iGluR family, δ receptors, shares substantial sequence homology with 
other iGluR subtypes. Surprisingly, despite forming functional ion channels [83–85], δ receptors show no 
ligand-gated ion channel function [86–89] and are therefore not discussed in this review. All iGluRs 
assemble as complexes of four membrane-spanning subunits that form a central pore. Each iGluR subunit 
contributes exclusively to one subtype of iGluR: GluA1–4 form AMPARs, GluN1, GluN2A-D, and 
GluN3A-B form NMDARs, and GluK1–5 form KARs. Despite this wide diversity, all iGluR subunits 
possess a similar general structure (shown in Figure 2A using an NMDAR as an example) consisting of 
four discrete, semiautonomous domains, namely, an extracellular amino-terminal domain (ATD), an 
extracellular ligand-binding domain (LBD), a transmembrane domain (TMD), and an intracellular carboxy-
terminal domain (CTD, which was deleted from the structure shown in Figure 2). Unlike nAChRs, each 
iGluR subunit possesses an agonist-binding site located within the LBD. The four TMDs of iGluRs form the 
pore, and thus the site of channel blocker binding (Figure 2B). Within the TMD lies the glutamine (Q) – 
arginine (R) – asparagine (N) (QRN) site, a site found at the tip of the re-entrant loop (M2 loop) in the iGluR 
pore (Figure 2C) that helps form the selectivity filter and plays a crucial role in the differential cation 
selectivity and channel block of the three iGluR classes [90–93]. Recent mid- and high-resolution structures 






Figure 2. General N-methyl-D-aspartate (NMDA) receptor structure and putative blocking site. (A) Recently 
published structure of N-methyl-D-aspartate receptor (NMDAR) in an “active” state showing domain 
topology shared by all iGluR subtypes (ATD, amino-terminal domain; LBD, ligand-binding domain; TMD, 
transmembrane domain; Protein Data Bank (PDB) code 6WHT; [98]). GluN1 subunit is depicted in dark blue 
and GluN2B in cyan. Horizontal lines show the approximate locations of the outer and inner surfaces of the 
membrane. (B) Blow-up of NMDAR TMD (boxes in A) with docked channel blocker memantine (space-
filled; carbons are red, nitrogen is orange) displaying typical site of channel block. Most channel blocking 
compounds show intimate interaction with the external tip of the iGluR selectivity filter formed by the re-
entrant M2 loops of each subunit (opaque; M1, M3, and M4 transmembrane helices are transparent for 
visualization of blocking site). (C) Magnified view of memantine coordination by the QRN site asparagine 




[99–103]. Autodock Vina was used for molecular docking of memantine to PDB 6WHT, and structural 
images were prepared using the program Visual Molecular Dynamics (VMD) [98,104,105]. 
Characteristics of AMPA and Kainate Receptor Block  
AMPARs and KARs display a number of common characteristics not shared with NMDARs. AMPARs 
and KARs can form both homomers and heteromers that possess four glutamate binding sites. Gating of 
AMPARs and KARs does not require all four subunits to be bound to an agonist, allowing single-channel 
currents to show multiple conductance levels depending on LBD occupancy [106–108]. Gating transitions 
of AMPARs and KARs are also very fast compared to NMDARs. Channel deactivation occurs within 5–10 
ms of agonist removal and desensitization generates a >90% decrease in current within 20 ms of channel 
opening in the continued presence of an agonist [75]. These rapid gating transitions allow AMPARs and 
KARs to mediate the time course of the fast component of synaptic transmission [109]. 
 
Channel Block of AMPAR and KAR is Regulated by Channel Gating  
Channel block of AMPARs and KARs is remarkably similar and is primarily governed by RNA editing 
at the QRN site in the channel pore. While the exons for all AMPAR and KAR subunits code for an 
uncharged glutamine (Q) at this site, RNA for the GluA2, GluK1, and GluK2 subunits can be edited, 
resulting in a change from the conserved glutamine to a positively charged arginine (R; [110–112]). GluA2-
lacking AMPARs and GluK1/2-lacking KARs, which contain the unedited Q at the QRN site, are permeable 
to calcium (Ca2+) and are readily blocked by endogenous intracellular polyamines such as spermine 
[91,92,111,113–116]. However, incorporation of a single edited GluA2, GluK1, or GluK2 subunit into an 
AMPAR or KAR, i.e., a subunit with a positively charged R at the QRN site, abolishes Ca2+ permeability as 
well as polyamine block [113–115]. Interestingly, editing at the QRN site also controls inhibition of KARs 
by fatty acids, with only fully edited KARs displaying sensitivity to fatty acid inhibition [117]. Although 
fatty acid inhibition is only weakly voltage-dependent and may involve interactions with residues outside 
the pore [118], the involvement of the QRN site suggests a possible interaction within the pore. For the 
remainder of this section, we focus on AMPARs and KARs with Q at the QRN site of each subunit. 
Polyamine block of iGluRs is strongly voltage-dependent and at least partially use-dependent 
[115,119,120]. Both AMPARs and KARs show birectifying responses in the presence of cytoplasmic 
polyamines [115], suggesting a common block mechanism. Recent cryo-electron microscopy (cryo-EM) 
structures of unedited GluA2(Q) receptors revealed the location and structure of the polyamine binding 
site in the pore [95,96]. Just below the QRN site lies a strongly electronegative portion of the channel, which 
likely contributes to both the cation selectivity of AMPARs [96] and the local membrane electric field 
[119,121,122]. Relief of polyamine block of AMPARs and KARs occurs via two separate mechanisms, i.e., 
permeation through the channel, which occurs at high positive voltages, and unblock to the cytoplasm, 
which occurs at negative voltages [115,123]. Polyamines are also trapping channel blockers and thus can 
only readily unbind when the channel is open [96,119]. Although trapping of polyamines seems 
counterintuitive, since they can unbind to either the intracellular or extracellular space, recent cryo-EM 
experiments provided compelling structural evidence of polyamine trapping. AMPAR structures 
produced by Twomey et al. suggested that closure of a gate near the extracellular entrance to the channel 
prevents polyamine permeation, while constriction of the selectivity filter prevents unbinding to the 
intracellular space by “pinching” the tail of the bound polyamine [96]. Thus, the gating state of AMPARs 
and KARs governs channel block by endogenous polyamines. 
 
Effects of Auxiliary Proteins on Gating of AMPARs and KARs Modulates Block by Endogenous Polyamines  
The interplay between gating and block of AMPARs and KARs is further regulated by the interaction 




receptor regulatory protein (TARP) stargazin [124], a wealth of studies identifying and characterizing 
additional auxiliary proteins have greatly increased our understanding of AMPAR and KAR regulation. 
Auxiliary proteins play an integral role in the trafficking, synaptic targeting, and gating of non-NMDAR 
iGluRs [121,122,125–131], and several in-depth reviews have been written concerning their function [131–
138].  
Through their regulation of channel gating, auxiliary proteins necessarily regulate channel block of 
AMPARs and KARs. Many auxiliary proteins, including stargazin, cornichon-3, and members of the 
CKAMP/Shisa family, substantially augment AMPAR currents by slowing desensitization and increasing 
mean channel conductance [122,139–146]. Similarly, the KAR auxiliary proteins Neto1 and Neto2 increase 
KAR currents by decreasing desensitization and increasing peak Popen ([121,129–131], but see [128]). 
Interaction with auxiliary proteins that increase channel conductance and/or Popen greatly attenuates 
polyamine block of AMPARs and KARs. Increasing Popen reduces the time that the channel spends in closed 
states, which in turn reduces polyamine trapping and facilitates permeation. Indeed, association of 
AMPARs with stargazin or cornichon-3 and KARs with Neto1/2 greatly increases polyamine permeation 
[121,122]. Although increasing Popen would also be expected to allow polyamines to more readily access 
their binding sites, AMPAR-auxiliary protein interactions were surprisingly found to slow the onset of 
polyamine block at negative voltages [147]. The enhancement of blocker permeation at positive voltages 
and reduction onset of block at negative voltages combine to profoundly weaken polyamine block. 
Association of AMPARs with stargazin or cornichon-3 attenuates polyamine block by 3–15-fold 
[122,140,146,147], and KAR association with Neto1/2 reduces block by 8- to 20-fold [121,148]. In contrast, 
the AMPAR auxiliary protein GSG1L reduces channel conductance while increasing polyamine-dependent 
rectification [125]. The structural underpinnings of this intrinsic relation between polyamine block and the 
regulation of AMPAR and KAR gating by auxiliary proteins are yet to be elucidated. Possible explanations 
include auxiliary protein-induced stabilization of receptor open states [146,149], alteration of pore structure 
due to interactions of auxiliary subunits with the AMPAR/KAR TMD [96,138,144], or interactions between 
auxiliary protein C-terminal domains and AMPAR/KAR intracellular domains [140,148]. 
 
Effects of Polyamine Block on Gating Transitions of AMPARs and KARs  
Although much is known about how channel gating regulates AMPAR and KAR blockade by 
polyamines, there is a dearth of knowledge about how polyamine occupancy of the channel affects AMPAR 
or KAR gating. To our knowledge, there are no reports of modulation of KAR gating by polyamine block. 
Polyamine block of AMPARs is known to contribute to frequency-dependent synaptic facilitation, but this 
effect appears unrelated to polyamine effects on gating. Instead, at negative potentials, repetitive 
stimulation of AMPARs can cause an increase in the rate of polyamine unblock without a concomitant 
increase in the rate of block [119,120,150]. However, there is some evidence that polyamine binding may 
stabilize or accelerate entry into AMPAR closed states [119]. The presence of trapped spermine in the 
channel of unedited GluA2(Q) receptors causes a delay in channel activation upon presentation of agonist, 
suggesting that spermine stabilizes a closed receptor state. Furthermore, kinetic models suggest that the 
observed acceleration of channel deactivation in the presence of spermine could be explained by a doubling 
of the rate of channel closure [119]. Acceleration of channel closure could potentially result from 
polyamines emptying and excluding other permeant ions from the pore, an effect observed in studies of 
voltage-gated potassium channel block [151]. Stabilization of a channel closed state by polyamines could 
also be due to allosteric modulation, a mechanism suggested for certain blockers of Cys-loop receptors [73]. 
Given the roles Ca2+-permeable, non-NMDAR iGluRs play in both normal physiological and disease states 
[138,152–155], it is important to further our understanding of AMPAR and KAR block not only to better 





Characteristics of NMDAR Channel Block  
NMDARs display myriad biophysical properties unique amongst the iGluR family, including high 
Ca2+ permeability, slow gating kinetics, dependence on co-agonism for gating, and voltage-dependent block 
by magnesium (Mg2+) ions [75,156–161]. These characteristics allow NMDARs to control the magnitude and 
timing of Ca2+ influx during synaptic activity and therefore play a pivotal role in synaptic development and 
plasticity [162–164]. NMDARs are obligate heterotetramers, typically composed of two GluN1 subunits 
(eight splice variants), which bind glycine or d-serine, and two GluN2 subunits (GluN2A–GluN2D), which 
bind glutamate. A third group of subunits, GluN3A/B, also bind glycine/d-serine (although d-serine acts 
only as a partial agonist [165]) and can assemble with GluN1 and GluN2 subunits to form NMDARs 
activated by glutamate and glycine/d-serine. Interestingly, GluN3 subunits can also assemble just with 
GluN1 subunits to form unconventional NMDARs activated solely by glycine/d-serine. However, these 
GluN1/3 receptors only pass weak currents in physiological conditions, so their role in neuronal function 
is largely unknown [165]. Conventional NMDARs consisting of two GluN1 subunits and two GluN2 
subunits rely on the binding of both glutamate and glycine/d-serine for activation [156,166] and, unlike 
AMPARs and KARs, require all four agonist binding domains to be occupied for the channel to transition 
to the open state [167–169]. Additionally, conventional NMDARs possess a conserved asparagine at the 
QRN site (Figure 2C) that confers high Ca2+ permeability even relative to Ca2+-permeable AMPAR and 
KARs, as well as sensitivity to block by Mg2+ [90,101,123].  
Channel block of NMDARs has been extensively studied. Known, well-characterized NMDAR 
channel blockers with slow kinetics displayed some degree of use dependence. Another highly conserved 
key feature of NMDAR channel blockers is voltage dependence. Most NMDAR channel blockers are 
monovalent or divalent cations and display far greater inhibition at negative than at positive membrane 
potentials [12,13,15,17,170–173]. Due to their many roles in normal and pathological brain function, 
NMDARs are attractive targets for development of neurotherapeutics. NMDAR channel blockers are 
currently the most clinically useful NMDAR-targeting drugs and show great promise in the treatment of 
multiple nervous system disorders, including neurodegenerative diseases, major depressive disorder, and 
neuron death following ischemia [174–182].  
NMDAR channel blockers display a strikingly diverse array of clinical effects, despite sharing 
overlapping binding sites and a similar general mechanism of inhibition ([99,183]; the putative blocking 
site for memantine is shown in Figure 2B,C). For example, the clinically relevant blockers memantine and 
ketamine share similar chemical properties (Table 1) and binding kinetics but possess vastly different 
effects on brain function. Ketamine is a drug of abuse and poorly tolerated, but possesses impressive 
efficacy in treating neuropathic pain and major depressive disorder [176,180,184,185]. On the other hand, 
memantine possesses weaker efficacy in treatment of neuropathic pain and little to no effect on major 
depressive disorder, but is well-tolerated with few side effects and shows efficacy in the treatment of 
neurodegenerative disorders such as Alzheimer’s disease [177,179,186–190]. The striking diversity in the 
clinical effects of NMDAR channel blockers may in part arises from their diverse effects on channel gating. 
Nearly all known NMDAR channel blockers show some effect on channel gating [191] and channel blockers 
are found to modulate nearly every aspect of gating [3,7,8,12,13,17,173,192–200].  
 
Sequential Blockers of NMDARs Prevent Channel Closure and Agonist Dissociation  
The sequential/foot-in-door blockers 9-aminoacridine (Table 1), tetrapentylammonium, and the 
amantadine derivative IEM-1857 (synthesized at the Institute of Experimental Medicine (IEM), St. 
Petersburg, Russia) are thought to force NMDARs to remain in open states by sterically prohibiting gate 




tetrapentylammonium, or 9-aminoacridine also prevents agonist dissociation and channel desensitization 
[7,17,173], suggesting that blocker unbinding and subsequent channel closure are required for agonist 
dissociation. This finding is consistent with models of sequential channel block of nAChRs proposed by 
[19,20,66,67]. An experimental procedure used to test whether a channel blocker prevents channel closure 
and agonist dissociation is to determine if the blocker induces “tail currents”. A tail current is a transient 
increase in receptor-mediated current observed upon rapid and simultaneous removal of blocker and 
agonist from the extracellular solution. If a blocker prevents channel closure, channels pass through the 
open, unblocked state following blocker unbinding, resulting in a tail current. However, any antagonist 
that unbinds more quickly than agonists can induce tail currents; thus, observation of tail currents does not 
provide unambiguous evidence that a blocker acts via a sequential mechanism. More powerful evidence 
that a blocker prevents channel closure can be provided by (a) observation that a blocker chops single-
channel currents into “bursts” of brief openings, and that the total channel open time during bursts is 
independent of blocker concentration [20], and (b) observation that the blocker concentration that inhibits 
responses by 50% (the IC50)  is inversely proportional to the receptor’s Popen, a prediction that can be tested, 
e.g., by recording the IC50 of a blocker over a range of agonist concentrations [191]. The finding that channel 
occupation by sequential blockers prevents agonist unbinding as well as channel closing provided 





Table 1. NMDAR channel blockers and their effects on gating. 
Compound Structure Type of Blocker Effects on Gating 
Magnesium 
 
Unclear—due to fast 
unblocking kinetics, trapping of 





Sequential [7,201].  








Strongly negative potentials: 
trapping [173]. 
Depolarized potentials: 
Stabilizes open state [173]. 
Amantadine 
 
Partial trapping [12,13]. 
Accelerates channel 
closure of native 














receptor recovery from 
desensitization [3]. 
Magnesium is depicted coordinating six water molecules, and all organic blockers are depicted in bond-line 
format. Blockers structures are scaled to depict approximate relative sizes. 
Organic channel blocking compounds were remarkably useful in determining the location of the 
channel gate itself. The size of a blocking molecule is a key determinant of whether the blocker prevents 
channel closure or is trapped in the channel upon gate closure. Experiments comparing block by IEM-1857 
and the similar but smaller blocker IEM-1754 (Table 1) found that while binding of IEM-1857 prevented 
channel closure independent of voltage, IEM-1754 only prevented channel closure at relatively depolarized 
membrane potentials. At more hyperpolarized potentials, IEM-1754 is “pulled” by the membrane electric 
field deeper into the channel where it no longer prevents channel closure, instead acting as a trapping 
channel blocker [173]. The voltage dependence of IEM-1754 block, as well as its interactions with permeant 
ions, demonstrated that IEM-1754 has two blocking modes, one that associates with a shallower site and 
places the bulk of the molecule in the way of the gate, and a second that associates with a deeper site and 
permits closure of the gate [173,205,206]. This finding strongly supported the idea that the NMDAR channel 
gate lies at the extracellular entrance to the channel, an idea that was recently validated by crystal and cryo-
EM structures of ligand-bound NMDARs [98,207]. 
 




Trapping channel blockers display more subtle effects on gating than sequential blockers. Early 
studies using a combination of patch-clamp electrophysiology and kinetic modeling concluded that the 
amino-adamantane derivatives memantine and amantadine and the phencyclidine derivative NEFA have 
clear effects on channel gating [12,192,193,197]. Initial proposals for the effects of amino-adamantane 
derivatives on NMDAR gating were wide-ranging, including models that suggested memantine and 
amantadine could stabilize open receptor states, as well as models that suggested memantine may stabilize 
closed receptor states [12,192,197]. It is possible that these discrepancies arose from the abilities of amino-
adamantane derivatives to escape from some blocked channels after agonist removal (partial trapping) and 
to inhibit NMDARs via association with a site accessible in the absence of agonist [12,16,192,197,208,209].  
Thorough evidence that amino-adamantane derivatives affect closed-state transitions came through 
investigation of the discrepancy between the equilibrium dissociation constant (Kd) and potency 
(represented by IC50) of amantadine. The relation between Kd and IC50 depends directly on how a channel 
blocker affects channel transitions after binding. Kd < IC50 implies that a blocker stabilizes channel open 
states. This is the case for sequential blockers, which inhibit less effectively as Popen decreases (IC50 = Kd/Popen, 
see Section 6.1; [5,191]). In contrast, Kd > IC50 implies that a blocker’s mechanism of inhibition likely involves 
stabilization of channel closed states, either through decreasing the rate of channel opening, increasing the 
rate of channel closure, or both. Such blockers therefore have two inhibitory actions: (1) blocking current 
flow through open channels and (2) stabilization of closed channels. Amantadine is an example of such a 
dual-mechanism channel inhibitor. Amantadine’s Kd (110 μM) is considerably greater than its IC50 (~35 μM; 
[8,15,192,210]). Investigation of amantadine block of single-channel and whole-cell NMDAR current 
revealed that binding of amantadine not only accelerates channel closure, but that this acceleration of 
channel closure is actually the predominant mechanism of inhibition by amantadine at concentrations 
lower than 100 μM [8]. 
Recent studies reported additional drug-specific and NMDAR subtype-specific effects of channel 
blockers on gating transitions. Investigation of mechanisms by which memantine and ketamine 
preferentially target distinct populations of NMDARs led to the discovery that memantine and ketamine 
have differential, subtype-specific effects on NMDAR desensitization [3]. While ketamine accelerated 
recovery from desensitization of GluN1/2B receptors, memantine binding profoundly slowed recovery 
from desensitization of GluN1/2A receptors. The effect of memantine on GluN1/2A receptor 
desensitization was not observed in low-Ca2+ conditions, suggesting that memantine stabilizes a Ca2+-
dependent desensitized state of GluN1/2A receptors. A comparison of IC50 values measured in low and 
high Ca2+ conditions with Kd values predicted by a kinetic model found that in high Ca2+, Kd > IC50, whereas 
in low Ca2+, Kd ≈ IC50, suggesting that memantine only alters GluN1/2A gating when Ca2+-dependent 
desensitization can occur [3].  
Visualization of NMDARs bound to trapping channel blockers was provided by recent structural 
studies. Song et al. crystalized the closed GluN1/2B channel in complex with the high affinity blocker MK-
801 and utilized long-timescale molecular dynamics to investigate the mechanism of block by MK-801 and 
memantine [21]. Both blockers were found to bind within the central cavity of the ion channel and promote 
closure of the channel gate [21], perhaps via a mechanism similar to amantadine [8]. Although this result 
may seem to contrast with the previous finding that memantine did not affect GluN1/2B receptor 
desensitization [3], it is important to note that (1) memantine could affect GluN1/2B channel closure 
without affecting desensitization, and (2) the crystalized MK-801-NMDAR construct lacked both the ATD 
and CTD, which play key roles in gating and desensitization [98,211–215]. Stabilization of closed channels 
by NMDAR channel blockers could have profound physiological implications by effectively increasing the 
potency of blockers under certain conditions. For example, the ability of memantine to stabilize a Ca2+-




NMDARs in cellular populations subjected to pathological levels of Ca2+ influx, i.e., NMDARs likely to 
mediate excitotoxic cell death [79,216–218].  
 
Channel Block by Mg2+ Does Not Appear to Affect NMDAR State Transitions 
The majority of NMDAR channel blockers affect gating, but at least one blocker exists as an exception 
to this rule: Mg2+ (Table 1). Binding of Mg2+ to the NMDAR channel does not prevent gate closure, agonist 
dissociation, or desensitization [7,13,157,219]. Mg2+ boasts nearly equivalent Kd and IC50 values [202], 
further suggesting that Mg2+ occupancy of the channel has no effect on state transitions. The unusual ability 
of Mg2+ to block without altering gating could be due to its small size. A large conformational change in the 
extracellular region of the NMDAR channel is associated with gating, a conclusion supported by structural 
studies [98] and the observation that large organic blockers prevent channel closure. Although smaller 
organic blockers generally permit channel closure, stabilizing or destabilizing interactions with channel 
residues may alter channel gating. It is possible that the small size of Mg2+ (which is likely to be mostly 
dehydrated when blocking the channel [103]), coupled with its limited interactions with channel residues 
outside of the ion selectivity filter [103], allows binding in the NMDAR channel without affecting gating 
machinery. Also, in contrast to most organic blockers, Mg2+ has not been directly shown to act as a use-
dependent open channel blocker or as a trapping blocker. Mg2+ displays extremely rapid binding and 
unbinding kinetics [157,219], preventing accurate determination in whole-cell recordings of the rapid 
component of block or unblock, measurements required for demonstration of use dependence and 
trapping. Kinetic modeling studies, however, suggested that Mg2+ does indeed act as an open channel 
blocker [13].  
Despite the lack of effects of Mg2+ block on NMDAR gating, depolarization-induced Mg2+ unblock 
clearly depends on gating. Mg2+ unblock from GluN1/2A and GluN2B receptors displays a slow component 
as well as an extremely rapid component [220–225]. Although kinetic models in which Mg2+ block affects 
gating transitions and/or agonist binding rates reproduced slow Mg2+ unblock [222,224], substantial 
experimental evidence demonstrated that Mg2+ does not affect NMDAR state transitions [7,13,157,219]. This 
disagreement was reconciled by the discovery of the inherent (i.e., Mg2+-independent) voltage-sensitivity 
of NMDAR gating, which underlies the slow component of Mg2+ unblock [221,225]. Thus, the interplay 
between Mg2+ block and NMDAR gating is unidirectional, whereby Mg2+ block depends on NMDAR 
gating, but NMDAR gating is unaffected by Mg2+ block.  
 
Conclusions  
Channel blockers are invaluable tools for the study of channel gating. The diverse array of effects that 
blockers exert on gating have facilitated numerous seminal discoveries into both the structure and the 
function of receptor channel gating machinery. The abilities to alter the rate of gating transitions and 
stabilize/destabilize channel states enable blockers to act as dual-mechanism drugs, both inhibiting current 
flow and modulating receptor function. The stabilization of specific receptor states also may contribute to 
the surprising diversity in the clinical effects of channel blockers. Future research determining the 
structural mechanisms by which channel blockers influence gating may aid in the directed design of more 
clinically efficacious neurotherapeutics. 
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featuring polycyclic scaffolds. Changes in the chemical structure modulate the potency and voltage 
dependence of inhibition. Two of the new antagonists display properties comparable to those of 
memantine, a clinically approved NMDAR antagonist. 
INTRODUCTION  
The amino acid L-glutamate1-2 is the main excitatory neurotransmitter in the central nervous 
system and activates a wide diversity of receptors comprising ionotropic (iGluRs) as well as 
metabotropic glutamate receptors. iGluRs, ligand-gated ion channels composed of four subunits, 
can be subdivided into three classes based on their subunit composition and their selective 
activation by the agonists (S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid 
(AMPA), kainate and N-methyl-D-aspartic acid (NMDA).3-5 Among iGluRs, the NMDA receptor 
(NMDAR) possesses unique properties including co-agonism, a high permeability for Ca2+ ions, 
and voltage-dependent channel blockade by Mg2+, which has to be relieved to allow ion flow 
through the channel.6-8 
NMDARs are heterotetrameric complexes derived from three main types of subunits, namely 
GluN1, GluN2 and GluN3, of which GluN1 is obligatory.9-14 Usually a single NMDAR is 
composed of two glycine-binding GluN1 subunits plus two glutamate-binding GluN2 subunits. 
There are eight known splice variants of the GluN1 subunit, four GluN2 subunit subtypes (A-D), 
and two GluN3 subunit subtypes (A,B).8,15-17 
NMDARs are expressed at nearly all vertebrate synapses and play key roles in neuronal 
development, plasticity, and survival. Ca2+ influx through NMDARs is a signal of paramount 
importance for synaptic plasticity, including long-term potentiation and long-term depression, 
physiological processes that are the cellular basis of many forms of learning and memory.18 




which is the primary mediator of neuronal death following stroke and is believed to play a key role 
in the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease (AD) and 
Parkinson’s disease (PD).9-20 Hence, NMDAR antagonists able to prevent overactivation of 
NMDARs are of interest as neuroprotective drugs. 
Multiple types of NMDAR antagonists have been tested in clinical trials. Several competitive 
NMDAR antagonists failed trials for neurodegenerative disorders and related conditions, possibly 
because they blocked the physiological as well as the pathological effects of NMDARs, leading to 
severe adverse effects.21-23 NMDAR open channel blocking antagonists have also been tested as 
therapeutic agents. In contrast to competitive antagonists, NMDAR channel blockers bind at sites 
that overlap with the Mg2+ site and can only bind and unbind when the channel is open.24-26  Most 
NMDAR channel blockers also failed clinical trials, and several were found to be neurotoxic when 
administered at high doses to control animals,27 including dizocilpine (MK-801), phencyclidine, 
and ketamine (compounds 1, 2, and 3, respectively, in Figure 1). Nevertheless, two adamantane 
derivatives, amantadine and memantine (compounds 4 and 5, respectively, in Figure 1), which are 
low- (amantadine) and moderate- (memantine) affinity voltage-dependent NMDAR channel 





Figure 1. Structures of NMDAR channel blocking antagonists 1-6. 
Several hypotheses have been proposed to explain the divergent clinical effects of NMDAR 
channel blockers. The kinetics of recovery from inhibition, which are much faster for memantine 
than dizocilpine, have been proposed to be a major determinant of clinical tolerability.29,33-34 An 
alternative hypothesis is that the utility of memantine may derive from an ability to preferentially 
inhibit extrasynaptic NMDARs, activation of which has been proposed to be especially 
neurotoxic.35-37 It is clear, however, that overactivation of synaptic NMDARs also can be 
neurotoxic.38,39 Another recent proposal is that clinical safety may be associated with preferential 
inhibition of NMDARs that undergo Ca2+-dependent desensitization following exposure to high 
intracellular Ca2+, a property exhibited by 5 but not 3.40 
Although memantine is well-tolerated by AD patients, it possesses limited clinical efficacy.41 
For this reason, new moderate-affinity NMDAR antagonists with similar but distinct 
pharmacological properties are of interest.29,33-34 Thus, we recently started a project aimed to 
design, synthesize, and characterize new polycyclic amines as analogues of 5 with improved 
pharmacological profiles. 
Taking into account that carbocyclic amines other than 4 and 5 display similar affinity to 
NMDARs (e.g, neramexane, 6 in Figure 1),42-45 and that the methyl groups of memantine are 
critical for optimal potency at NMDARs (memantine is roughly fifty-fold more potent than 
amantadine),46-47 we envisaged the synthesis of polycyclic amine 7 (Figure 2) and a few selected 
analogues. These new analogues included amines 8, for considering the impact of the distance 
between the polcyclic cage and the amino group; 9 and 10, for assessing the effect of 






Figure 2. Chemical structures of new putative NMDAR antagonists 7-11.  
 
RESULTS AND DISCUSSION  
Chemical synthesis. Compounds 9, 10 and 11 were prepared using procedures previously reported 
by our group.48-49 Primary amines 7 and 8 were synthesized following the sequence shown in 
Scheme 1, starting from known anhydride 12.50 Briefly, treatment of anhydride 12 with an excess 
of methanol at reflux furnished hemiester 13 in quantitative yield. Barton’s decarboxylation 
procedure led to ester 14, which upon hydrolysis yielded carboxylic acid 15. From this key 
intermediate, Curtius rearrangement led to primary amine 7. Finally, amine 8 was obtained by 
reduction of amide 16, in turn obtained from 15. Both target amines 7 and 8 were fully 
characterized as their corresponding hydrochlorides. 
 






Pharmacology and Structure-Activity Relationships. To evaluate if the new compounds were 
able to antagonize NMDARs, we measured their effect on the increase in intracellular Ca2+ evoked 
by application of NMDA (100 µM, in the presence of 10 µM of glycine) to cultured rat cerebellar 
granule neurons.51 Pleasingly, inspection of the results shown in Table 1 reveals that all the new 
compounds were clearly more potent than amantadine (IC50 = 92 M) with values of IC50 in the 
low micromolar range. Although differences are small, it seems that conformationally restricted 
secondary amines 9 (5.8  1.0 M) and 10 (5.1  1.0 M) are less potent than secondary amine 8 
(2.8  1.1 M), while directly joining the polar amino group to the polycyclic ring slightly reduces 
the potency (compare 7 vs 8). Overall, guanidine 11 and primary amine 8 were the more potent 
compounds, with IC50 values (2.7  0.4 and 2.8  1.1 M, respectively) only slightly higher than 
that of memantine (1.5  0.1 M). 
 





 NMDA (100 M) 
Compound IC50 (M) 
4 92  29 
5 1.5  0.1 
7 4.1  1.7 
8 2.8  1.1 
9 5.8  1.0 
10 5.1  1.0 
11  2.7  0.4 
aIC50 is the concentration of a compound that inhibits the measured response by 50%. Data were 
obtained from primary cultures of cerebellar granule neurons as described in Methods by 
measuring the intracellular Ca2+ concentration. Cells were exposed to 100 M NMDA plus 10 M 
glycine. Data shown are means ± SEM of at least three separate experiments carried out on three 
different batches of cultured cells.  
 
Functional block of NMDARs by polycyclic compounds 7-11. We next evaluated 
electrophysiologically the functional ability of compounds 7-11 to block NMDARs. To carry out 
these studies, we performed whole-cell experiments on tsA201 cells transfected with expression 
plasmids codifying rat GluN1 and GluN2A subunits to measure the properties of the newly 
synthesized polycyclic amines. We clamped the cells at -60 mV and then evoked NMDAR currents 
by applying 100 µM NMDA plus 10 µM glycine. After the NMDAR-evoked current reached a 
steady state, we rapidly applied a given blocking compound by means of piezoelectric translation 
of a double-barreled theta glass tubing (<1 ms exchange between solutions). By doing so, we could 
compare the percentage of block for each tested compound. Figure 3 shows a typical example of 
an experiment for the compounds tested (5 and 7-11). Compound 5 at 10 M blocked nearly 90% 
of the activated current while the percentage of block by the newly synthetized compounds varied 
amongst them. Compounds 7 and 8 at 10 M displayed degree of NMDAR block similar to 5, i.e., 
82.5 ± 3.2 % for 7 and 88.3 ± 3.7 % for 8 vs 89.2 ± 1.0 % for 5 (Figure 4A). Compounds 9 and 10 




1.0 % for 5; (Figure 4A). On the other hand, 10 M of compound 11 induced more inhibition than 
5, although the difference was not significant, i.e., 97.9 ± 1.9 % for 11 vs 89.2 ± 1.0 % for 5. Thus, 
compounds 7, 8 and 11 appeared to block NMDARs with potency similar to that of memantine. 
We also evaluated the ability of the newly synthesized blockers to unbind from the channel pore 
upon drug removal. Unbinding was measured by rapidly removing the blocker in the continuous 
presence of agonists (100 µM NMDA plus 10 µM glycine). Unblock (Fig. 4B) was calculated as 
the percentage of current recovery after a 30-s application of agonists without blocker, when the 
current was at or very near steady state. All tested compounds showed similar abilities to unbind 
from the pore compared with 5, i.e., 94.9 ± 2.2 %, 90.6 ± 3.5 %, 92.5 ± 5.9, 92.3 ± 3.0 % and 93.5 
± 3.4 % for compounds 7, 8, 9, 10 and 11, respectively, vs 94.2 ± 2.1 % for 5 (Figure 4B). 
Finally we assessed the voltage dependence of channel block by the compounds. During the 
recordings we applied two positive pulses to +60 mV for 0.5 s during the sustained NMDA- and 
glycine-evoked current. The first pulse was applied in the presence of the blocking compound at 
10 M and a second +60 mV pulse was applied in the absence of the blocker. Hence, we could 
extract the percentage block at +60 mV. Compound 11, which appeared to be the most potent 
compound when tested at -60 mV, also displayed the greatest inhibition at +60 mV, i.e., 73.0 ± 3.6 
% block for 11 vs 8.1 ± 4.0 % for 5 (Figure 4C). Compounds 7-10 had similar blocking percentages 
at +60 mV to 5, i.e., 2.4 ± 5.1 %, 14.7 ± 4.5 %, 9.0 ± 3.6 % and 10.4 ± 6.4 % for compounds 7, 8, 






Figure 3. Block, unblock and voltage dependence of compounds 5, 7-11. A. Example recording 
showing the protocol used to study the degree of channel block, the voltage dependence and the 
unblocking percentage of compound 5. Whole-cell currents were evoked in tsA201 cells 
expressing GluN1/2A NMDARs by bath application of 100 μM NMDA plus 10 μM glycine. 
Compound 5 was rapidly applied at 10 μM. B-F. Example traces in the same conditions as 







Figure 4. Quantification of block, unblock and percentage of block at +60mV of compounds 5, 7-
11. A. Summary of the blocking percentage at the holding potential of -60 mV for the different 
compounds tested. Asterisks identify mean values with statistically significant differences. The 
number of asterisks indicates the magnitude of the p-value, the probability of measuring by chance 
a difference equal to or greater than the observed difference between indicated mean values. 
**p<0.01 and ***p<0.001 vs compound 5; one-way ANOVA with Tukey post hoc analysis. 
Numbers inside bars denote the number of experiments. B. Degree of unblock, measured as the 
percentage of current recovery after removal of the blocker; no differences between compounds 
was observed (p>0.05 for all compounds compared with compound 5). Numbers inside bars denote 
the number of experiments. C. Percentage of block at +60 mV for the studied compounds. 
***p<0.0001 vs compounds 5, 7, 8, 9, and 10; one-way ANOVA with Tukey post hoc analysis; 
n=17, 7, 7, 8, 10 and 10 for compounds 5, 7, 8, 9, 10 and 11, respectively. 
 
Concentration and voltage dependence of NMDAR inhibition by 5, 7, 8, and 11. Whole-cell 
patch-clamp recordings from tsA201 cells expressing GluN1/2A receptors were used to further 
assess the pharmacological properties of three promising derivatives, primary amines 7, 8, and 11. 
Experiments measuring the IC50 and voltage-dependence of block by compound 5 were performed 
for comparison. In cells held at -65 mV, inhibition by each drug was measured at increasing drug 
concentrations (Figures 5–8, A) and used to calculate the IC50 and Hill coefficient (nH, which 
reflects the steepness of the concentration-inhibition curve; see Equation 2). The IC50 value and 
Hill coefficient measured for 5 (Fig. 5B) are similar to previously-reported values measured under 
the same conditions.42 Compounds 7, 8, and 11 were found to have moderate IC50 values (Figures 




lower than the IC50s of 5 (1.84 ± 0.39 μM) or 7 (2.78 ± 0.25 μM), and the IC50 of 5 was significantly 
lower than the IC50 of 7 (Fig. 9A). There were no significant differences between the nH of the 
drugs, i.e., 1.07 ± 0.27, 0.98 ± 0.08, 1.01 ± 0.11, and 1.00 ± 0.03 for compounds 5, 7, 8, and 11, 
respectively. Modest differences between IC50s measured using intracellular Ca
2+ measurements 
from cerebellar granule neurons (Table 1) and patch-clamp recordings from tsA201 cells 
expressing GluN1/2A receptors (Figs. 5 – 9) were observed. The differences may have resulted 
from expression of GluN2 subunits other than GluN2A in cerebellar granule neurons, and from 
differences in recording technique.   
To measure voltage dependence of inhibition by 5, 7, 8, and 11, inhibition elicited by roughly 
twice the IC50 of each drug was measured at 9 different voltages (examples from 5 voltages are 
shown in Figures 5–8, C). The inhibition produced by the drugs decreased as voltage was 
depolarized (Figures 5–8, C and D), as expected of positively charged channel blockers. Fitting of 
Equation 3 to current-voltage data was used to quantify V0, the change in voltage (in mV) that 
results in an e-fold change in the IC50 of a drug. Equation 4 was used to calculate δ, an estimate of 
the fraction of the total transmembrane voltage field felt by the blocker at its binding site.52 The 
value of δ is calculated from the value of V0 (Equation 4); strong voltage dependence is reflected 
by a large δ and a small V0. All compounds displayed strongly voltage-dependent block ,i.e., for 
5, V0 = 28.0 ± 2.2 mV and δ = 0.91 ± 0.08; for 7, V0 = 26.5 ± 1.8 mV and δ = 0.99 ± 0.05; for 8, 
V0 = 29.9 ± 1.9 mV and δ = 0.87 ± 0.05; for 11, V0 = 33.6 ± 1.5 mV and δ = 0.76 ± 0.03 (Figures 
5–8, D). The voltage dependence of inhibition was found to be significantly weaker for 11 than 





Figure 5. Concentration and voltage dependence of NMDAR inhibition by 5. A. Representative 
current traces from one cell depicting effect of 5 on GluN1/2A receptor currents. Application of 1 
mM Glu (black bars) elicited an inward current that was antagonized by application of 5 (red bars). 
B. Concentration-inhibition relation for 5. Line shows best fit of Equation 2 (IC50 = 1.84 ± 0.39 
μM, nH = 1.07 ± 0.27; n=5). C. Representative voltage (Vm; top) and current (bottom) traces 
depicting effect of membrane potential upon inhibition by 3 μM 5. Traces from 5 of the 9 
membrane potentials tested are displayed for clarity. D. Current-voltage relation of inhibition by 
5. Line shows best fit of Equation 3 (V0 = 28.0 ± 2.2; n=5).  Points in B and D represent mean 
fractional currents measured at each concentration (B) or voltage (D); error bars represent SEM 
and are sometimes smaller than symbols. Comparison of the concentration and voltage dependence 






Figure 6. Concentration and voltage dependence of NMDAR inhibition by 7. A, B. Same as Figure 
5A, B, except concentration-inhibition measurements made using 7. Line in B shows best fit of 
Equation 2 (IC50 = 2.78 ± 0.25 μM, nH = 0.98 ± 0.08; n=7). C, D. Same as Figure 5C, D, except 
measurements of voltage-dependence made using 5 μM 7. Line in D shows best fit of Equation 3 
(V0 = 26.5 ± 1.8; n=7). Comparison of the concentration and voltage dependence of NMDAR 





Figure 7. Concentration and voltage dependence of NMDAR inhibition by 8. A, B. Same as Figure 
5A, B, except concentration-inhibition measurements made using 8. Line in B shows best fit of 
Equation 2 (IC50 = 1.01 ± 0.13 μM, nH = 1.01 ± 0.11; n=7). C, D. Same as Figure 5C, D, except 
measurements of voltage-dependence made using 2 μM 8. Line in D shows best fit of Equation 3 
(V0 = 29.9 ± 1.9; n=8). Comparison of the concentration and voltage dependence of NMDAR 





Figure 8. Concentration and voltage dependence of NMDAR inhibition by 11. A, B. Same as 
Figure 5 A, B, except concentration-inhibition measurements made using 11. Line in B shows best 
fit of Equation 2 (IC50 = 0.48 ± 0.09 μM, nH = 1.00 ± 0.03; n=4). C, D. Same as Figures 5 C, D, 
except measurements of voltage-dependence made using 1 μM 11. Line in D shows best fit of 
Equation 3 (V0 = 33.6 ± 1.5; n=4). Comparison of the concentration and voltage dependence of 





Figure 9. Comparison of NMDAR channel blocker properties. Sample size denoted by number 
inside column. A. Comparison of blocker IC50 values measured at -65 mV. B. Comparison of 
voltage dependence of inhibition by the blockers. All comparisons made by one-way ANOVA 
with Tukey post hoc analysis; *p<0.01, **p<0.001, ***p<0.0001. 
 
CONCLUSIONS 
We have described the synthesis, pharmacological evaluation and electrophysiology of a novel 
family of N-methyl-D-aspartic acid receptor (NMDAR) channel blockers. Despite profound 
structural modifications, e.g., compare diene 9 with the other compounds, or different pKas, e.g., 
compare amine 10 with guanidine 11, all the inhibitors showed similar potency as NMDAR 
antagonists. However, more subtle changes in the chemical structure modulated both the degree 
of inhibition and voltage-dependence of inhibition by the inhibitors, e.g., compare primary amine 
8 with secondary amine 10 or amine 10 with guanidine 11 (Figures 3 and 4). Primary amines 7 






Chemistry. (3,4,8,9-Tetramethyltetracyclo[4.4.0.03,9.04,8]dec-1-yl)amine hydrochloride (7). A 
solution of the acid 15 (182 mg, 1.35 mmol) in DCM (5 mL) was prepared in a two-neck round-
bottom flask equipped with a condenser, a gas outlet and a magnetic stirring. Concentrated H2SO4 
(0.43 mL) was added and the reaction was heated to 50 °C. Then, NaN3 (189 mg, 2.90 mmol) was 
carefully added portionwise. The reaction was kept at 50 °C for 1.5 h. The resulting mixture was 
cooled with an ice bath. Crushed ice (2 g) was added to the reaction and the aqueous layer was 
basified with 2 N NaOH to basic pH. The layers were separated, and the aqueous layer was 
extracted with warmed CH2Cl2 due to the low solubility of the product (6 x 20 mL). The combined 
organics were dried over anhydrous Na2SO4 and filtered. An excess of HCl in 1,4-dioxane was 
added to the residue and the suspension was concentrated under reduced pressure to give the 7·HCl 
as a brown solid (182 mg, 95% yield). The analytical sample was obtained by crystallization from 
hot CH2Cl2, mp 200 °C (sublimation). IR (ATR) : 628, 685, 716, 1010, 1041, 1062, 1090, 1114, 
1147, 1163, 1188, 1232, 1294, 1310, 1341, 1369, 1385, 1452, 1460, 1483, 1501, 1524, 1547, 1620, 
1646, 2072, 2583, 2697, 2790, 2873, 2899, 2961, 3395, 3426 cm-1. 1H-NMR (400 MHz, CD3OD) 
δ: 0.90 [dd, J = 11.4 Hz, J’ = 2.4 Hz, 2H, 5(7)-Ha], 0.98-1.02 [d, J = 10.8 Hz, 2H, 2(10)-Ha], 1.01 
[s, 6H, 3(9)-CH3 or 4(8)-CH3], 1.03 [s, 6H, 4(8)-CH3 or 3(9)-CH3], 1.94 [dd, J = 11.4 Hz, J’ = 1.6 
Hz, 2H, 5(7)-Hb], 1.99 [d, J = 10.8 Hz, 2H, 2(10)-Hb], 2.25 (m, 1H, 6-H). 
13C-NMR (100.5 MHz, 
CD3OD) δ: 15.4 [CH3, C3(9)-CH3 or C4(8)-CH3], 15.6 [CH3, C4(8)-CH3 or C3(9)-CH3], 38.9 
[CH2, C5(7)], 40.8 (CH, C6), 42.0 [CH2, C2(10)], 45.8 [C, C3(9) or C4(8)], 46.2 [C, C3(9) or 
C4(8)], 58.1 (C, C1). HRMS-ESI+ m/z [M+H]+ calcd for [C14H23N+H]
+: 206.1903, found: 
206.1907. Anal. Calcd for C14H23N·HCl·0.66H2O: C 66.24, H 10.06, N 5.52. Found: C 66.07, H 




(3,4,8,9-Tetramethyltetracyclo[4.4.0.03,9.04,8]dec-1-yl)methylamine hydrochloride (8). A solution 
of 16 (96 mg, 0.41 mmol) in anhydrous toluene (10 mL) was cooled to 0 °C and Red-Al® (0.7 mL, 
2.05 mmol) was added dropwise. The reaction was heated to reflux overnight. The resulting 
mixture was cooled with an ice bath and aqueous 10 N NaOH solution was added dropwise to 
basic pH. Then, the reaction was stirred for 10 min. The layers were separated and the aqueous 
layer extracted with DCM (3 x 20 mL). The combined organics were dried over anhydrous 
Na2SO4, filtered and HCl/Et2O was added. After concentration under reduced pressure, 8·HCl was 
obtained as a white solid (92 mg, 88% yield). The analytical sample was obtained by washing the 
solid with cooled Et2O, mp 240 °C (sublimation). IR (ATR) ν: 715, 844, 933, 968, 986, 998, 1016, 
1031, 1064, 1097, 1117, 1130, 1163, 1178, 1223, 1297, 1350, 1367, 1383, 1451, 1461, 1479, 1501, 
1514, 1613, 2860, 2916, 2941, 3012 cm-1. 1H-NMR (400 MHz, CD3OD) δ: 0.63 [d, J = 11.2 Hz, 
2H, 2(10)-Ha], 0.79 [broad d, J = 11.2 Hz, 2H, 5(7)-Ha],  0.995 [s, 6H, 3(9)-CH3 or 4(8)-CH3], 
0.999 [s, 6H, 4(8)-CH3 or 3(9)-CH3], 1.76 [d, J = 11.2 Hz, 2H, 5(7)-Hb], 1.82 [d, J = 11.2 Hz, 2H, 
2(10)-Hb], 2.12 (m, 1H, 6-H), 3.01 (s, 2H, CH2NH2). 
13C-NMR (100.5 MHz, CD3OD) δ: 15.8 
[CH3, C3(9)-CH3 or C4(8)-CH3], 16.0 [CH3, C4(8)-CH3 or C3(9)-CH3], 38.2 (CH, C6), 39.3 [CH2, 
C5(7)], 42.1 [CH2, C2(10)], 42.5 (C, C1), 45.9 [C, C3(9) or C4(8)], 47.1 [C, C3(9) or C4(8)], 48.1 
(CH2, CH2NH2). HRMS-ESI+ m/z [M+H]
+ calcd for [C15H25N+H]
+: 220.2060, found: 220.2050. 
Anal. Calcd for C15H25N·HCl·0.25H2O: C 69.21, H 10.26, N 5.38. Found: C 69.15, H 10.01, N 
5.19. 
Intracellular Ca2+ measurements. The functional assay of antagonist activity at NMDA 
receptors was performed using primary cultures of rat cerebellar granule neurons that were 
prepared according to established protocols.51 Cells were grown on 10 mm poly-L-lysine coated 




6 M Fura-2 AM (Invitrogen-Molecular Probes) for 30 min. Afterwards a coverslip was mounted 
on a quartz cuvette containing a Mg2+-free Locke-HEPES buffer using a special holder. 
Measurements were performed using a PerkinElmer LS-55 fluorescence spectrometer equipped 
with a fast-filter accessory, under mild agitation and at 37 ºC. Analysis from each sample was 
recorded real-time during 1600 s. After stimulation with NMDA (100 M, in the presence of 10 
M glycine), increasing cumulative concentrations of the compound to be tested were added. The 
percentages of inhibition at every tested concentration were analyzed using a non-linear regression 
curve fitting (variable slope) using the software Prism 5.04 (GraphPad Software Inc.). 
Cell culture, transfection, and recordings for electrophysiology experiments. All 
electrophysiological experiments were performed at room temperature using the tsA201 cell line 
(European Collection of Authenticated Cell Cultures) transiently cotransfected with mammalian 
expression plasmids containing cDNAs encoding the rat GluN1-1a and GluN2A subunits.   
For Figures 3–4, cells were maintained as previously described53 in DMEM:F12 supplemented 
with 10% fetal bovine serum and 1% penicillin/streptomycin (Sigma). Cells were plated at 0.1- 
0.2 x 105 cells/dish in onto 10 mm glass coverslips treated with poly D-lysine. 12–24 hours after 
plating, the cells were transiently transfected using PEI transfection reagent (1 mg/ml) in a 3:1 
ratio (PEI:DNA). Culture medium was supplemented with the competitive NMDAR antagonist D, 
L-2-amino-5-phosphonopentanoate (dl-APV, Sigma, 500 μM) at the time of transfection to 
prevent NMDAR-mediated cell death. Whole-cell voltage-clamp recordings were performed 48 
hours after transfection. Pipettes were pulled from borosilicate capillary tubing (OD = 1.5 mm, ID 
= 0.86 mm) using a PC-10 vertical puller (Narishige Instruments) and subsequently fire-polished 
to a resistance of 3–5 MΩ using an MF-830 forge (Narishige). Intracellular pipette solution 




to 7.25 with CsOH. Extracellular recording solution contained (in mM): 140 NaCl, 5 KCl, 1 CaCl2, 
10 HEPES and 10 glucose, balanced to pH 7.2 ± 0.05 with NaOH. Drugs were diluted from 
concentrated stock solutions (5 stock = 10 mM in dH20; 7-11 stocks = 10 mM in 75% HEPES 
buffer and 25% ethanol) in extracellular solution each day of experiments. Whole-cell currents 
were recorded using an Axopatch 200B patch-clamp amplifier (Molecular Devices). Current signal 
was low-pass filtered at 1 kHz and sampled at 2 kHz in pClamp 10 (Molecular Devices). Series 
resistance was 10-15 MΩ. Solutions containing agonists (100 μM NMDA and 10 μM glycine) or 
agonists and 10 μM blocker were applied by piezoelectric translation (P-601.30; Physik 
Instrumente) of a theta-barrel application tool made from borosilicate glass (1.5 mm o.d.; Sutter 
Instruments).  
For Figures 5–9, cells were maintained as previously described54 in DMEM supplemented with 
10% fetal bovine serum, 1% GlutaMAX (Thermo Fisher Scientific), and for some experiments 1% 
penicillin/streptomycin (Sigma). Cells were plated at 1 x 105 cells/dish in 35 mm petri dishes with 
three 15 mm glass coverslips treated with poly D-lysine (0.1 mg/ml) and rat-tail collagen (0.1 
mg/ml, BD Biosciences). 12-24 hours after plating, the cells were transfected using FuGENE 6 
Transfection Reagent (Promega) as previously described.54 Culture medium was supplemented 
with 200 μM dl-APV at the time of transfection to prevent NMDAR-mediated cell death. Whole-
cell voltage-clamp recordings were performed 18-30 hours after transfection. Pipettes were pulled 
from borosilicate capillary tubing (OD = 1.5 mm, ID = 0.86 mm) using a Flaming Brown P-97 
electrode puller (Sutter Instruments) and subsequently fire-polished to a resistance of 2.5 – 4.5 
MΩ using an in-house fabricated microforge. Intracellular pipette solution contained (in mM): 130 
CsCl, 10 HEPES, 10 BAPTA, and 4 MgATP with pH balanced to 7.2 ± 0.05 with CsOH and an 




KCl, 1 CaCl2, 10 HEPES, 0.01 EDTA, and 0.1 glycine, and was balanced to pH 7.2 ± 0.05 with 
NaOH and to osmolality 290 ± 10 mOsm with sucrose. Drugs were diluted from concentrated 
stock solutions (5 stock = 10 mM in dH20; 7, 8, and 11 stocks = 40 mM in 100% DMSO) in 
extracellular solution each day of experiments. Whole-cell currents were recorded using either an 
Axopatch 1D or Axopatch 200A patch-clamp amplifier (Molecular Devices). The current signal 
was low-pass filtered at 5 kHz and sampled at 20 kHz in pClamp 10 (Molecular Devices). Series 
resistance was compensated 80-90% in all experiments. A –6 mV liquid junction potential between 
the intracellular pipette solution and extracellular solution was corrected in all experiments. 
Glutamate and drug solutions were delivered to the cell via an in-house fabricated ten-barreled 
gravity-fed fast perfusion system.40,54  
Data Analysis. The percentage of channel block, unblock and recovery shown in Figures 3 – 4 
were measured with the following protocol: at a holding potential of –60 mV, NMDA (100 μM) 
and glycine (10 μM) were applied until current reached a clear steady-state (about 90 s). Then 
compounds 5, 7, 8, 9, 10 or 11 were rapidly applied by piezo control (1 ms solution exchange) for 
30 seconds as described.55 During the application of the blocker, a 5-s voltage step to +60 mV was 
applied in order to study the voltage dependence of block. Blockers were then removed in the 
presence of agonists to allow recovery of the current. During this period (around 1 min) a second 
voltage step (5 s duration) to +60 mV was applied. Finally, agonists were removed. Percentage of 
block was calculated by dividing steady state current in the presence of the blocker by steady state 
current in the absence of the blocker. Percentage of unblock was calculated by dividing the steady 
state current after blocker removal by the steady state current before blocker application. Finally, 








where I+60(Drug) is the steady state current at the holding voltage of +60 mV in the presence of 
agonists and the blocker, and I+60(Agonist) is the steady state current at +60 mV in the presence of 
agonists but absence of the blocker.  
Concentration-inhibition relations were measured using the protocol shown in Figures 5–8, A and 
B. Glutamate (1 mM) was applied until current reached steady-state (20 s), then 5, 7, 8, or 11 at 
the plotted concentration was applied in the presence of glutamate until a new steady-state current 
level was reached (30 s). Glutamate in the absence of drug was then reapplied for 30 s to allow 
drug unbinding and recovery from inhibition. Cells in which recovery from inhibition did not reach 
90% of steady-state current during initial glutamate application were excluded from analysis. IC50 










where IDrug/IGlu was calculated as the mean current over the final 1 s of drug application (IDrug) 
divided by the average of the mean steady state currents (final 1 s) elicited by glutamate before 
and after drug application (IGlu). IC50 and nH were free parameters during fitting. 
Voltage dependence of block by 5, 7, 8, and 11 was measured using the protocol shown in Figures 
5–8, C and D. Cells were subjected to voltage jumps from -65 mV to nine voltages ranging from 
-105 to +55 mV. The protocol at each voltage consisted of: a 4-s wait in extracellular solution 
following the voltage step; application of 1 mM glutamate for 10 s; application of drug with 1 mM 
glutamate for 15 s; application of 1 mM glutamate for 15 s to allow drug unbinding; application 




jump was made. ~2 times the IC50 of each drug was used in voltage dependence experiments. 













where IC50 (–65 mV) is the IC50 at –65 mV calculated in concentration-inhibition experiments, and 
V0 represents the change in voltage (in mV) that results in an e-fold change in the IC50 of the drug. 
IDrug/IGlu was calculated as described for concentration-inhibition data. V0 was the only free 
parameter during fitting. An estimate of the fraction of the total membrane voltage field felt by the 







Where R, T, z and F have their usual meanings. Note that, although δ is useful for comparing 
voltage dependence of blockers, voltage dependence of NMDAR channel block is influenced by 
permeant ions.56 Therefore, δ should be used only as a rough estimate of binding site location in 
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